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SUMMARY 
Expression of accessory proteins during human immunodefiency virus-1 (HIV-1) life 
cycle is essential to ensure efficient viral replication and spread. Despite of being 
dispensable for HIV-1 infection of cell lines in vitro, use of primary target cells and in 
vivo experiments proved them to be critical key pathogenicity factors. Along with 
counteraction of restriction factors to facilitate immune response escape, they play an 
important role as manipulators of host cell fundamental biological processes to favor 
replication. This work focuses on the study of the accessory proteins. Both these 
proteins are known to strongly alter intracellular vesicular transport. As a consequence, 
the composition of the plasma membrane is modified upon their expression, a 
phenomenon studied in the first part of this thesis. Here, it has been demonstrated the 
specificity of the Nef- and Vpu-mediated downregulation of tetraspanins, the most 
drastically affected host receptors, and identification of molecular determinants of both 
proteins necessary for this activity was pursued. It was also studied the ability of Vpu to 
retarget the T lymphocyte master regulator Lck, a well described phenomenon induced 
by Nef. Another yet unstudied field for Vpu examined herein was the induction of 
extracellular vesicle release. This work revealed that Vpu, like Nef, enhances 
extracellular vesicle release when expressed by T lymphocytes with comparable or even 
higher efficiency. The second part of this thesis addressed the effect of these proteins on 
T cell polarity disruption in the context of T cell migration. Unlike Vpu, Nef has been 
reported to inhibit F-actin cytoskeleton rearrangements. This requires the interaction of 
Nef with PAK2 which facilitates a specificity switch of the host kinase resulting in 
hyperphosphorylation and thus inactivation of the actin severing factor cofilin. As a 
consequence, the motility of HIV-infected T lymphocytes is hampered. A previous 
report showed that in murine CD4+ T cells, the central Nef-mediated block in vivo and 
ex vivo is at the level of transendothelial and subendothelial migration. Whereas the 
latter is dependent on Nef-PAK2 on actin dynamics, the effect on transmigration 
involves other, yet uncharacterized protein interactions and is remarkably paralleled by 
a pronounced reduction of cell polarization. This thesis shows that Nef also hinders 
polarization of HIV-1 infected primary human CD4+ T lymphocytes. Vpu was entirely 
unrequired for this effect. Nef-expression in human T cell lines caused a marked 
polarization defect conserved among Nef proteins from HIV-1, -2 and simian 
immunodeficiency virus. The interaction surface of Nef with the Nef-associated kinase 
complex (NAKC) was found to be the essential molecular determinant for polarization 
disruption by Nef, both when overexpressed or in HIV-1 infection. Pharmacological 
inhibition of NAKC components evidenced the involvement of protein kinase C (PKC) 
in this Nef activity. This work also details setting up of experimental conditions to study 
the possible implication of this Nef amino acid stretch on transendothelial migration, 
that is on diapedesis ex vivo. Altogether, the results presented here underline the 
importance of the studied redundant functions between Nef and Vpu in HIV-1 infection 
and the relevance of these accessory proteins as pathogenicity factors. Also, they 
highlight the role of Nef as the main HIV-1 negative regulator of T lymphocyte 
migration.  
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ZUSSAMENFASSUNG 
Die Expression akzessorischer Proteine während des Humanes Immundefizienz-Virus-1 
(HIV-1) Replikationszyklus ist essenziell für die effiziente Replikation und Verbreitung 
des Virus. Obwohl akzessorische Proteine bei der Infektion von Zelllinien in vitro nicht 
notwendig sind, zeigten Experimente mit primären Zielzellen und in vivo Versuche, 
dass diese Proteine kritische Faktoren der Pathogenese darstellen. Neben der Abwehr 
von Restriktionsfaktoren, um dem Immunsystem auszuweichen, spielen akzessorische 
Proteine eine wichtige Rolle bei der Manipulation essentieller biologischer Prozesse des 
Wirts, um die Virusreplikation zu unterstützen. Diese Arbeit behandelte die Rolle der 
akzessorischen Proteine Nef und Vpu mit genauerer Betrachtung ihrer gegenseitig 
redundanten Funktionen. Beide Proteine sind dafür bekannt, den intrazelluläre 
Transport zu verändern. Als Folge, wird die Komposition der Plasmamembran bei ihrer 
Exprimierung modifiziert, ein Phenomen, das im ersten Teil dieser Arbeit untersucht 
wurde. In diesem Teil wurde gezeigt, dass das Herunterregulieren von Tetraspanine, die 
am stärksten herunterregulierten Wirtsrezeptoren während einer Infektion, spezifisch 
durch Nef und Vpu vermittelt wird. Zusätzlich es wurde versucht, die molekularen 
bestimmenden Faktoren beider Proteine, die für diesen Effekt verantwortlich sind, zu 
identifizieren. Weiterhin wurde Vpu auf die Fähigkeit hin untersucht, den T-Zell-
Hauptregulator Lck umzuleiten, ein Phänomen dass für Nef bereits ausführlich 
beschrieben ist. Zusätzlich wurde in dieser Arbeit der Einfluss von Vpu auf die 
Vesikelfreisetzung untersucht, welches ein bislang unerforschtes Gebiet darstellte. 
Diese Arbeit zeigte, dass wenn Vpu in T-Zellen exprimiert wird, die Vesikel 
Freisetzung im verglich zu Nef-Exprimierung genauso oder sogar effizienter verstärkt 
wird. Im zweiten Teil der Arbeit wurde der Einfluss beider Proteine auf den 
Zellpolaritätsdefekt und dessen Auswirkung auf die Zellmigration untersucht. Im 
Gegensatz zu Vpu, es wurde berichtet, dass Nef kann die Umlagerung des Aktin-
Zytoskeletts weitgehend beeinträchtigen. Dafür wird die Interaktion zwischen Nef und 
der Wirtskinase PAK2 benötigt, was eine Veränderung der Spezifität dieser Kinase 
einleitet und mit einer Hyperphosphorylierung und Inaktivierung des 
Aktindepolymerisierugsfaktors Cofilin einhergeht. Dies führt zu einer beschränkten 
Motilität von HIV-infizierten T-Zellen. In CD4+ Mauszellen ist diese Blockade in vivo 
und ex vivo auf der Ebene der transendothelialen und subendotelialen Migration 
bemerkbar. Letztere ist abhängig von der Nef-PAK2 Interaktion und der damit 
verbundenen Beeinträchtigung des Aktin-Zytoskeletts, jedoch ist der Effekt auf die 
transendotheliale Migration von anderen Faktoren abhängig und geht 
bemerkenswerteweise mit einer ausgeprägten Inhibierung der Zellpolarität einher. 
Weiterhin konnte gezeigt werden, dass der negative Einfluss auf die Zellpolarität auch 
in HIV-1-infizierten humanen primären CD4+ T Zellen auftritt, dieser jedoch 
unabhängig von Vpu ist. Die Expression von Nef in T-Zelllinien zeigte einen 
ausgeprägten Defekt auf Ebene der T-Zellpolarität, der von HIV-1 und HIV-2, bis hin 
zu Simianes Immundefizienz-Virus konserviert war. Die Interaktionsoberfläche von Nef 
mit dem Nef-assoziierten Kinase-Komplex (NAKK), wurde als essentielle molekulare 
Determinante identifiziert, die für die Störung der Zellpolarität verwantwortich war. 
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Dies konnte in HIV-1-Infektionsversuchen sowie durch die Überexpression von Nef 
bewiesen werden. Die pharmakologische Inhibierung von NAKK-Komponenten zeigte, 
dass Protein-Kinase C (PKC) bei diesem durch Nef hervorgerufenen Effekt beteiligt ist. 
Es wurde in dieser Arbeit zudem eingerichtet ein experimentelles System auf, welches 
den Einfluss der Aminosäurenabfolge der Interaktionsoberfläche von Nef mit NAKK 
auf die transendotheliale Migration ex vivo, vor allem während der Diapedese, testen 
lässt. Zusammengefasst zeigen die hier aufgeführten Ergebnisse die Bedeutung der 
redundanten Wirkweise der Proteine Vpu und Nef während der HIV-1-Infektion und 
der Relevanz dieser akzessorischen Proteine als pathogene Faktoren. Zusätzlich wird 
die Hauptrolle von Nef als wichtigster negativer Regulator der T-Lymphozyten-
Migration verdeutlicht.  
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1 INTRODUCTION 
1.1 Retroviruses 
1.1.1 General genomic features 
Retroviruses are a family of enveloped RNA viruses which share structural, 
composition and replication properties. They represent one the most broadly spread 
family of infectious factors in vertebrates, having been identified in all mammals’ 
species as well as some birds, reptiles and fish, and probably the most diverse (Coffin, 
1992). The retroviral virions are 80-100 nm in diameter and contain two identical copies 
of positive single-stranded, linear and non-segmented RNA genome which is 7-12 kb in 
size depending on complexity. The most exclusive characteristic of the retroviridae 
family of viruses is its replication strategy that comprises retrotranscription or 
conversion of the genomic RNA to double-stranded DNA and the subsequent 
integration of the synthesized DNA in the genome of the infected cell. The first one of 
these steps is possible thanks to a unique enzyme of this virus family after which they 
are named: the Reverse transcriptase (RT) or retrotrancriptase (retro, Latin for 
“backwards”) (Baltimore, 1970; Temin and Mizutani, 1970). The integrated DNA or 
provirus relies upon integration on the cellular machinery for its transcription and 
translation. All retroviruses contain common coding domains that encode for 
polyproteins: gag (for Group-specific antigen), encoding for the structural virion 
proteins matrix (MA), capsid (CA) and nucleocapsid (NC), pol, containing the 
expression sequence of the RT and integrase (IN) enzymes, and env, the transcription of 
which results in the expression of the viral envelope protein with its transmembrane 
(TM) and the surface (SU) components (Vogt, 1997). The latter represents the main 
differential feature of retroviruses from other retroelements (Kim et al., 2004) and is 
responsible of the recognition and initial interaction with the host cell. The expression 
of the viral protease (PR), necessary to cleave the polyproteins into mature proteins 
during the virion maturation process, follows a different scheme in different viruses.  
1.1.2 Classification of retroviruses 
Members of the family of retroviruses are categorized in two subfamilies according to 
their complexity: the orthoretrovirinae, including the genera alpha-, beta-, gamma-, 
delta- and epsilonviruses, as well as lentiviruses, and the spumavirinae, integrated by 
the single genus of spumaviruses (Table 1). The human and simian immunodeficiency 
viruses (HIV and SIV, respectively) are some of the most characteristic representatives 
of the lentiviruses genus which is characterized by their slow progression to disease 
(Lentus, Latin for “slow”).    
The integration of retroviral genomic sequences into the genome of cells of the germ 
line originated the so called endogenous retroviruses or inheritable retroviral elements 
(Escalera-Zamudio and Greenwood, 2016; Weiss, 2016). It is considered that 5-8 % of 
the genes in human genome derive from retroviral elements (Belshaw et al., 2004; 
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Lander et al., 2001; Seifarth et al., 2005). Retroviral element derived-genes are involved 
in important physiological processes not only in humans but also in most vertebrate 
species like placenta formation, brain cognitive functions, immunity against 
retroelements and some fundamental biological processes such as cell proliferation, 
apoptosis and cancer (Naville et al., 2016). Upon infection exogenous can recombine 
with endogenous retroviral elements resulting in the activation of the latter, as observed 
for murine and feline gammaretroviruses (Rosenberg and Jolicoeur, 1997) or HIV (van 
der Kuyl, 2012; Vincendeau et al., 2015). The same has been described for human 
herpesviruses (HHVs) such as human cytomegalovirus (HCMV) (Assinger et al., 2013) 
or Epstein-Barr virus (EBV) (Brudek et al., 2008; Sutkowski et al., 2001).  
Subfamily Genus Example 
Orthoretrovirinae Alpharetrovirus Avian Leukosis Virus (ALV); Rous Sarcoma Virus (RDV); 
Moloney Murine Leukaemia Virus (MMLV) 
Betaretrovirus Mouse Mammary Tumor Virus (MMTV); Mason-Pfizer 
Monkey Virus (MPMV) 
Gammaretrovirus Murine Leukaemia Virus (MLV); Feline Leukaemia Virus 
(FLV) 
Deltaretrovirus Human T-cell Lymphotrophic Virus-1 and 2 (HTLV-1, -2) 
Epsilonretrovirus Walleye Dermal Sarcoma Virus (WDSV) 
Lentivirus HIV; SIV; Feline Immunodeficiency Virus (FIV) 
Spumavirinae Spumavirus Simian Foamy Virus (SFV);  Human Foamy Virus (HFV) 
Table 1.1: Classification of exogenous retroviruses.  
1.2 HIV and Acquired Immunodeficiency Syndrome (AIDS)  
In the early 1980s a list of opportunistic infections was described for groups of 
homosexual and intravenous-drug user patients (CDC, 1981; Gottlieb et al., 1981; 
Masur et al., 1981). This included Pneumocystis Carinii pneumonia, mucosal 
candidiasis and Kaposi’s Sarkoma, a rare type of cancer caused by human herpesvirus-8 
(HHV-8), and it was coupled to diminished total lymphocyte counts or lymphopenia 
and a reversion in the ratio of helper and cytotoxic T cells. The term AIDS was used to 
refer to the newly characterized clinical picture. Soon after, blood transfusion recipients 
were defined as a third risk group. With epidemic spread, AIDS became a major public 
health problem and affected people beyond the initially defined risk groups. Two years 
were needed until the causative agent of AIDS, a retrovirus later designated HIV, was 
discovered (Barre-Sinoussi et al., 1983; Gallo et al., 1984; Popovic et al., 1984). The 
authorship of this discovery remained subjected to a very polemic discussion. The 
discovery was awarded with the Nobel Prize in 2008 to the French researchers F. Barre-
Sinoussi and L. Montagnier, first and last authors of the original article published in 
1983.      
HIV infection and AIDS represents one of the largest and most lethal pandemics in 
history having claimed more than 34 million lives so far (WHO, 2015). By the end of 
2014 there were 36.9 million people living with HIV around the globe. Among those, 2 
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million were newly infected in the course of that year. Access to antiretroviral therapy 
(ART) (See section 1.2.5) is increasing and 15.8 million people were under treatment as 
of June 2015, up from 13.6 million in June 2014 (UNAIDS, 2016). This resulted in a 
reduction in the number of people dying from AIDS-related illnesses from 2 million in 
2005 to 1.2 million in 2014, a 42% drop since the peak in 2004. Despite of the 
optimistic data, lack of access to ART is still a problem affecting millions of people 
especially in developing countries. The most affected area of the globe is Sub-Saharan 
Africa where 25.8 million people were living with HIV in 2014. This region also 
accounts for 70% of the total of new infection (WHO, 2015). Probably the most 
preoccupying piece of information is that worldwide only 54% of people infected by 
HIV know their status (UNAIDS, 2016; WHO, 2015). 
1.2.1 Classification 
HIV is the result of a zoonosis. It originated from simian immunodeficiency viruses 
(SIV) as a result of several cross-species transmissions (Sharp and Hahn, 2011). Most of 
those events resulted in viral strains that spread in humans to a certain limit. However, 
one of them occurring from chimpanzee subspecies Pan troglodytes troglodytes 
generated group M of HIV-1 (for “major”), which accounts for most of the infections 
worldwide (Gao et al., 1999; Keele et al., 2006; Sharp and Hahn, 2011; Van 
Heuverswyn and Peeters, 2007). Another two transmissions gave rise to the other two 
described groups of HIV-1: group N (for “no M, no O”) , transmitted from the same 
Chimpanzee subspecies as above (Gao et al., 1999; Keele et al., 2006; Sharp and Hahn, 
2011; Van Heuverswyn and Peeters, 2007), and group O (for “outlier”, transmitted from 
Gorilla (Sharp and Hahn, 2011; Takehisa et al., 2009; Van Heuverswyn et al., 2006; 
Van Heuverswyn and Peeters, 2007). Group M can be further subdivided in nine 
subtypes or clades (A-K). The genetic variability within clades ranges between 15-20% 
whereas between clades the range is >30% (Hemelaar et al., 2006; Korber et al., 2001; 
Luft et al., 2011). The most prevalent clade is C which accounts for 52% of the 
infections and is predominant in Southern and Eastern Africa and India. 12% prevalence 
corresponds to clade A which is mostly found in West Africa and Eastern Europe. Clade 
B with 10% prevalence is mainly distributed in Central and Western Europe, America 
and Australia (Hemelaar et al., 2006; Killian and Levy, 2011; Luft et al., 2011). 
Furthermore, over 45 circulating recombinant forms of HIV-1 have also been described 
to date (Luft et al., 2011). A second type of HIV, HIV-2, resulted from eight 
independent transmission events from monkey of the species sooty mangabey 
(Cercocebus atys) that generated the described groups A-H (Gao et al., 1992; Hirsch et 
al., 1989; Lemey et al., 2003). 
1.2.2 HIV-1 Genome and structure 
The HIV-1 genome spans approximately 10 Kbp and an infectious virion consists of 
two copies of positive single-stranded RNA comprising 9 open reading frames (ORFs) 
flanked by long terminal repetitions (LTRs). The ORFs encode 9 different proteins 
including the 3 characteristic retroviral polyproteins: Gag, Pol and Env (Figure 1.1A). 
Proteolysis of the latter 3 generates a total of 15 viral proteins, most of which form the 
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125 nm-sized HIV-1 particles (Figure 1.1B and C) (Briggs et al., 2006). Viral assembly 
is largely driven by Gag and its isolated expression results in the release of 
noninfectious virus-like particles (VLPs) (Ganser-Pornillos et al., 2008; Schur et al., 
2015). PR-mediated cleavage of the multi-domain polyprotein Gag generates the 
structural HIV proteins MA, CA, NC and the small p6 protein (Sundquist and 
Krausslich, 2012). MA interacts with phospholipids to form a layer underneath the viral 
envelope, an essential phenomenon for the recruitment of Gag to budding sites (Briggs 
et al., 2009). The mature cone-shaped HIV-1 core is formed by roughly 250 CA 
hexamers and 12 pentamers distributed at each end of the cone, required for closure of 
the curved hexagonal lattice (Figure 1.1D) (Briggs and Krausslich, 2011; Ganser et al., 
1999; Li et al., 2000). This structure contains NC-coated genome (Briggs and 
Krausslich, 2011). P6 is required for the correct budding process and release of nascent 
virions facilitating the recruitment members of the endosomal sorting complexes 
required for transport (ESCRT) (Friedrich et al., 2016; Gottlinger et al., 1991). As a 
consequence of a ribosomal frame-shift with a frequency of ~5% the fusion protein 
Gag-Pol is synthesized (Biswas et al., 2004), PR-mediated processing of which results 
in the 3 viral enzymes PR, RT and IN. The first of them mediate proteolytic maturation 
of the Gag and Pol polyproteins. RT and IN are required for conversion of the viral 
RNA into double-stranded DNA and its integration in the host cell genome, respectively 
(Craigie and Bushman, 2012; Hu and Hughes, 2012). Finally, the Env polyprotein is 
cleaved by the host protease furin at the Golgi apparatus to originate glycoprotein (gp) 
120 and gp41 (Hallenberger et al., 1992). Both proteins form heterodimers which are 
located at the viral envelope, being gp120 exposed at its surface and gp41 spaning the 
lipid bilayer. This heterodimers in turn trimerize to form the so called HIV spikes. 
Besides the structural proteins, the HIV-1 genome encodes also 2 regulatory proteins, 
Tat and Rev (Cullen, 1991), and four accessory proteins, Vif, Vpr, Vpu and Nef (Figure 
1.1A) (for detailed information see 1.2.3 and 1.3, respectively). The expression of 
accessory proteins is characteristic of the complex retroviruses HIV and SIV that 
distinguishes them from other viruses of the same family. Initially thought to be 
dispensable for viral replication, as concluded from in vitro observations, they have 
been proven necessary for efficient infection in vivo. Critical roles have been described 
for these proteins not only as counteractors of host innate and adaptive antiviral 
responses but are also thought to favor viral pathogenesis by targeting bystander cells 
(see also 1.3) (Malim and Emerman, 2008; Seelamgari et al., 2004).    
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Figure 1.1 HIV‐1 Genome and structure.  (A) Representation of  the HIV‐1 genome. The  two copies of plus single‐
stranded RNA comprise the typical retroviral structural genes (gag, pol, env), four accessory genes (vif, vpr, vpu, nef) 
and two regulatory genes (tat, rev) organized  in 9 ORFs and flanked by the LTRs. Processing of the gene products 
results in a total of 15 different proteins. (B) Electron microgram (left) and schematic cartoon (right) of an immature 
virion structure. (C) Electron microgram (left) and schematic cartoon (right) of a mature virion structure. Maturation 
implies virion protein reorganization within the viral particle following proteolysis. Protease activation is therefore 
essential for maturation. (D) Schematic cartoon of the conical capsid core of a mature virion. (A) (Fackler and Geyer, 
2002) (B),(C) (Konvalinka et al., 2015) (D) (Freed, 2015). 
 
1.2.3 Replication cycle of HIV-1 
The first phase of viral replication cycle is the entry, which begins with the adhesion of 
the virion to the host cell and ends with the fusion of the cellular and viral membranes 
with the release of the virion content into the host cell (Figure 1.2). A first contact 
between the virion and the host cell can result from unspecific interactions like that of 
Env with negatively-charged heparan sulphates proteoglycans (Saphire et al., 2001) or 
be the consequence of more specific interactions like that of Env with α4β7 integrin 
(Arthos et al., 2008; Cicala et al., 2009) or with pathogen associated molecular patterns 
(PAMP) receptors such as dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN) (Geijtenbeek et al., 2000). All these interactions 
mediated by attachment factors which are not indispensable for HIV-1 pathogenesis 
increase infection efficiency by bringing Env to the vicinity of the primary viral 
receptor CD4 and coreceptor (Orloff et al., 1991). The close proximity favors the 
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interaction of both proteins in which the variable loop V3 of Env plays a critical role 
and it leads to several conformational changes in Env needed for the subsequent binding 
to the coreceptor (Chen et al., 2005; Hartley et al., 2005; Kwong et al., 1998). CCR5 
and CXCR4 are the two coreceptors of HIV-1 and the viral strains can be classified 
according to their coreceptor usage as R5 or X4 tropic viruses. There are viral strains 
which can use both correceptors and are therefore designed as dual or X4R5 tropic 
(Berger, 1998; Berger et al., 1998). Upon interacting with the coreceptor, the 
hydrophobic gp41 subunit of Env is exposed and gets inserted in the cell host 
membrane. After a series of conformational changes, this leads eventually to the 
formation of a fusion pore through which the viral conical core is delivered into the host 
cell cytoplasm (Melikyan, 2008). Despite the lack of dependence on low pH (Stein et 
al., 1987), it is still a matter of discussion whether internalization of the virion-receptor 
complexes is needed for fusion to occur as opposite to fusion at the cell surface (Daecke 
et al., 2005; Fackler and Peterlin, 2000; Herold et al., 2014; Miyauchi et al., 2009). It is 
becoming increasingly clear that both take place and that it depends on the cell type and 
virus type as well as the disease stage. 
Following fusion, the CA conical core structure of HIV-1 is released into the cytoplasm 
and subsequently disassembled releasing its content, a process known as uncoating 
(Figure 1.2). The mechanism as well as the precise location or timing of uncoating is 
not clear yet but it is thought to be a progressive multistep process and to be critical for 
further post-entry steps, i.e. reverse transcription and nuclear import (Dismuke and 
Aiken, 2006; Forshey et al., 2002). A partial disassembly of the viral core is enough for 
RT to start reverse transcribing the viral RNA into DNA (Peng et al., 2014). RT 
synthesizes dsDNA using the viral RNA genome as a template with an error rate of 1 x 
105, which account for one error per replication cycle (Abram et al., 2010)  The protein 
complex formed by the disassembling core, the viral RNA genome, RT, the nascent 
DNA and other viral as well as cellular factors is known as the reverse transcription 
complex (RTC) (Peng et al., 2014). This complex evolves into the preintegration 
complex (PIC) as reverse transcription is completed and it is translocated into the 
nucleus through the nuclear pore. This process is dependent on the viral CA and 
involves also proteins of the nuclear pore complex such as NUP358 (Schaller et al., 
2011). 
Once in the nucleus, the DNA is integrated in the cell host genome by the IN, a 
hallmark of retroviral infection. Integration takes place at the periphery of the nucleus 
and in the vicinity of a nuclear pore preferentially within actively transcribed chromatin 
(Marini et al., 2015; Schroder et al., 2002). In addition to IN, members of the NPC and 
other host factors such as LEDGF/p75 are required for this process (Koh et al., 2013; 
Marshall et al., 2007; Matreyek et al., 2013; Ocwieja et al., 2011; Shun et al., 2007). 
Unsuccessful integration results in the formation of defective LTR circles (Farnet and 
Haseltine, 1991). Two critical aminoacid residues involved in binding to the target 
DNA have been described for IN and mutations of those have been correlated to disease 
progression (Demeulemeester et al., 2014).  
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After integration the provirus can enter latency (see 1.2.5) or undergo gene expression. 
The latter relies on the cellular transcription machinery and it is regulated by the viral 
factor Tat, which is expressed early. Activation-dependent host cell transcription factors 
NF-κB and NFAT are translocated into the nucleus and recruited to the viral promoter 
at the LTR (Nabel and Baltimore, 1987). The regulatory protein Tat binds to the TAR 
(transactivation responsive region) RNA element present at the HIV-1 leader sequence. 
This interaction leads to the recruitment of P-TEFb and other cellular elongation factor 
to the transcription complex increasing the efficiency of the process (Karn and 
Stoltzfus, 2012; Laspia et al., 1989). Viral genome transcription follows a complex gene 
expression pattern. Early completely spliced mRNAs encoding Tat, Rev and Nef are 
expressed in a short time interval following infection. Larger, incompletely spliced 
mRNAs which encode for Env and the accessory proteins Vif, Vpr and Vpu and full-
length, unspliced encoding for the polyprotein Gag-Pol also acting as the virion 
genomic RNA are transcribed only late after that (Karn and Stoltzfus, 2012). The 
unspliced mRNA which will constitute the virion genome and the incompletely spliced 
mRNA which encodes for the structural proteins is transported out of the nucleus in a 
Rev-dependent manner, to avoid the otherwise typical degradation of intron-containing 
transcripts (Sodroski et al., 1986). This requires a threshold level of the Rev protein 
(Pomerantz et al., 1992). Rev interacts with an elongated stem-loop RNA structure of 
the env gene termed Rev-responsive element (RRE) (Malim et al., 1989). 
Once in the cytoplasm, the viral transcripts are translated by the cellular machinery 
generating the viral proteins (Figure 1.2). The newly synthesized proteins localize then 
to specialized microdomains at the plasma membrane where assembly of the new virion 
progeny occurs (Sundquist and Krausslich, 2012). The Gag protein itself is able to 
mediate all steps of the virion assembly process. Its molecules arrange themselves 
underneath the plasma membrane inducing its curvature (Gottlinger, 2001). The amino-
terminal domain MA is responsible of binding to the plasma membrane and to recruit 
the Env protein, trimers of which form HIV-1spikes (Tang et al., 2004). The central 
domain CA mediates protein-protein interactions that stabilize the immature Gag lattice 
during assembly. Gag-Pol molecules are also recruited to the assembly site. The basic 
NC domain of Gag interacts with the genomic RNA via its two zinc finger motifs 
recruiting it to the assembly site (Sundquist and Krausslich, 2012). Finally the carboxy-
terminal domain p6 recruits several other viral factors. It also interacts with proteins 
from the ESCRT pathway namely Tsg101 and ALIX, which the virus hijacks to achieve 
budding of the viral particles (Bieniasz, 2006; Pornillos et al., 2003). During the 
budding process the viral PR gets activated, a key event for the subsequent maturation 
of the immature, non infectious released virions. Cleavage of Gag and Gag-Pol results 
in a reorganization of the internal protein structure and the formation of the conical core 
typical of fully mature, infectious virions (Briggs and Krausslich, 2011; Briggs et al., 
2009; Schur et al., 2015). 
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Figure 1.2 HIV replication cycle. The scheme represents the main steps of viral replication and the stages at which 
antiretroviral drugs block it.  (Laskey and Siliciano, 2014). 
 
The dynamics of the early steps of HIV-1 replication are cell type dependent and the 
differences in the published estimations may be due to variation in receptor and 
intracellular dNTP pool. Viral entry takes place <1-3 hours after exposure of cells to the 
virus (Fernandez-Larsson et al., 1992; Platt et al., 2005; Reeves et al., 2002), reverse 
transcription occurs in the following 6-48 hour (Collin and Gordon, 1994; Donahue et 
al., 2010; Kim et al., 2012; Murray et al., 2011; O'Brien et al., 1994) and integration 
takes place 5 hours after completion of reverse transcription (Donahue et al., 2010; 
Murray et al., 2011). Data derived from time-of-addition experiments show resistance to 
transcription inhibitors is acquired ~35 hours after infection (Lalonde et al., 2011; 
Tomaras et al., 2000). The kinetics of the late stages of HIV-1 replication cycle are 
poorly understood as compared to those of the early stages. This is mostly due to the 
inherent asynchrony in populations of infected cells. However, published data suggest a 
temporal gap of ~11 hours between integration and transcription of early genes, a 
smaller delay between early and late gene expression (~3h) and the need for another 6-
12h between late gene expression and new virions release (Holmes et al., 2015). The 
time required for a complete viral life cycle is estimated to be 48 hours and it 
interestingly matches to the lifespan of an infected cell in vivo (Dixit et al., 2004). 
1.2.4 Means of transmission and pathogenesis 
HIV is transmitted by sexual, percutaneous and perinatal routes (Cohen et al., 2011; 
Hladik and McElrath, 2008). The infection is nevertheless predominantly acquired via 
sexual exposure. This type of transmission accounts for 80% of the infections among 
adult people (Cohen et al., 2011; Sharp and Hahn, 2011). The squamous stratified 
epithelium of the vagina, ectocervix, male foreskin and the columnar epithelium of the 
endocervix and rectum constitute the entry path of HIV. Despite of a lower probability 
of effective HIV transmission than anal intercourse, vaginal sex accounts globally for 
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most of the new HIV infections (Figure 1.3) (Hladik and McElrath, 2008). 
Nevertheless, the mucosa represents a high selective barrier to HIV transmission that 
results in an infection established by one single virus, the so called founder virus. CD4+ 
T cells are the main targets of infection by HIV. To a lesser extent the virus also infects 
cells involved in antigen presentation, including dendritic cells (DCs), monocytes and 
macrophages (Patterson et al., 1995; Stevenson, 2003; Vremec et al., 2000). All these 
cells express the virus receptor CD4 (Dalgleish et al., 1984; Klatzmann et al., 1984) and 
CC-Chemokine receptor-5 (CCR5) or CXC-Chemokine receptor-4 (CXCR4), that act as 
entry co-receptors for HIV-1 (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; 
Dragic et al., 1996; Feng et al., 1996; Lee et al., 1999; Patterson et al., 1995; Vremec et 
al., 2000). Interestingly, the founder virus presents R5 or X4R5 tropism in the great 
majority of the cases (Keele et al., 2008). There are mainly two differentiated 
mechanisms for viral spread: cell-free and cell-cell. Direct cell to cell spread takes place 
via the formation of intercellular contacts known as virological synapses and it has been 
shown to have a higher efficiency in vitro (Chen et al., 2007). Eventually and making 
use probably of both these mechanisms, the virus disseminates through the blood stream 
causing a systemic infection.   
Figure 1.3 HIV‐1 early transmission events and spread. In women, vaginal sex transmission requires crossing of the 
squamous stratified epithelium of  the vagina or  the ectocervix or of  the columnar epithelium of  the endocervix. 
After establishing the first infection in a yet undetermined cell type, the virus reaches the draining lymph node from 
which  it disseminates via  the bloodstream  to  the  rest of  the organism. CNS,  central nervous  system; GALT, gut‐
associated lymphoid tissue.  (Fackler et al., 2014). 
 
Many aspects about the first transmission events remain yet unclear however. It is not 
yet known how the virus crosses the genital or rectal mucosal tract to reach the first 
target cell. It also remains unclear which target cell is infected by HIV in the first place 
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and how. Another unanswered question in HIV pathogenesis is how the virus reaches 
the draining lymph node after local expansion at the mucosal tissue. DCs can also 
capture HIV virions and release them upon contact with CD4+ T cells resulting in the 
infection of the latter (Geijtenbeek et al., 2000; Izquierdo-Useros et al., 2014; Izquierdo-
Useros et al., 2012; Kwon et al., 2002; McDonald et al., 2003). This phenomenon is 
termed trans-infection and relies on the interaction of the virions with the sialic acid 
binding molecule Siglec-1 (Izquierdo-Useros et al., 2014; Izquierdo-Useros et al., 
2012). Whether it is a DC carrier cell or a migrating infected CD4+ T cell or 
macrophage that brings the virus to the lymphoid tissue, the outcome of this event is the 
efficient amplification of the infection due to the high target cell concentration. 
The course of HIV infection presents three stages (Figure 1.4). The first of them known 
as acute phase spans approximately 2 to 4 weeks after a person acquires the virus. 
Following transmission of the founder virus, HIV replication rapidly increases. Flu-like 
clinical manifestations are frequent during this phase including fever, headache and rash 
as a consequence of the innate immune response mounted with prominent induction of 
proinflammatory cytokines and chemokines. Viral load is high since viruses are 
spreading throughout the body and massive CD4+ T cell depletion occurs. Transmission 
of HIV can take place at any stage but the risk peaks at the acute infection phase. 
Typically between 1 and 3 weeks later the asymptomatic or chronic phase begins. As a 
response of the antiviral immune response, viral load decreases and the extent in this 
drop constitutes an important predictor factor for disease progression (Figure 1.4). 
During this stage HIV replication continues albeit at low levels. In parallel, immune 
activation drops although not reaching pre-exposure levels. This is maintained during 
the course of infection, establishing chronic immune activation. Simultaneously, a slow 
and progressive loss of CD4+ T cells takes place (Figure 1.4). In the absence of 
treatment, progression to the final phase, AIDS, occurs after 10 years in average. 
Diagnosis of AIDS is made when a person has CD4+ T lymphocyte counts lower than 
200 cell/mm3 and/or development of one or more AIDS defining illnesses. The latter 
include opportunistic infections and rare malignancies such as candidiasis, 
cytomegalovirus infections, Kaposi sarcoma, lymphomas, neuro-AIDS (a form of 
dementia in which HIV-infected microglia is dysfunctional), pneumocystis pneumonia 
and tuberculosis. Without treatment an AIDS-diagnosed person typically survives 
around 2 years. In some exceptional cases the progression rate to AIDS varies from the 
characteristic disease course exposed above. This is the case of rapid progressors, for 
which the chronic phase lasts about 2 to 3 years, and the long-term-non-progressors 
(LTNP), which are able to control viremia and maintain CD4+ T cell levels high in the 
absence of ART (Kumar, 2013). 
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Figure 1.4 Clinical course of HIV‐1  infection  in  the absence of antiretroviral  treatment. Following  transmission 
and during the acute phase, the viral load, or viral RNA copies in plasma, increase rapidly and then drop as a result 
of the patient’s immune response to the so called set point. From then on and lasting years, viral load increases in 
parallel  to  the  loss  of  CD4+  T  cells  during  the  asymptomatic  phase,  a  phenomenon  specially marked  in  the 
gastrointestinal tract (GIT), until CD4+ T cell counts reach 200 which is the onset of AIDS. (Maartens et al., 2014). 
    
1.2.5 Immune response against HIV-1 
The immune system establishes responses against HIV-1 early after transmission which 
are maintained and develop during the course of the disease. The following provides 
some information of an investigation field of increasing relevance for HIV researchers 
and retrovirologists in general. 
1.2.5.1 Innate immunity 
The innate immunity accounts for the early, unspecific response to HIV-1 when 
adaptive immunity has not been mounted yet. Within minutes, the immune system is 
able to sense viral components and from other pathogens through pattern recognition 
receptors (PRRs), such as Toll like-receptors (TLRs), and PAMP receptors (Altfeld and 
Gale, 2015). Additionally, DNA sensors like gamma-interferon-inducible protein-16 
(IFI16) and cyclic GMP-AMP synthase (cGAS) contribute to HIV recognition at early 
stages (Gao et al., 2013; Jakobsen et al., 2013a; Sauter and Kirchhoff, 2016). These 
sensors generally activate signaling cascades leading to induction of interferon and 
proinflammatory cytokines and chemokines release, which in the HIV-1 infection 
scenario is termed “cytokine storm” due to the magnitude it reaches (Stacey et al., 
2009). As a consequence, an antiviral state is established by the expression of interferon 
induced genes (ISDs) and innate immune cells are recruited, respectively. The cytokine 
storm is secreted by natural killer (NK) cells, NKT cells, plasmacytoid dendritic cells 
(pDCs), monocytes, macrophages and CD4+ T cells.   
1.2.5.2 Intrinsic immunity 
HIV-1 specific restriction factors were typically categorized as part of the innate 
immunity. Unlike the prototypical innate immune players which induce an antiviral 
state through indirect mechanisms, restriction factors rather limit replication and spread 
in a direct, efficient way. For that reason they are now suggested to form an independent 
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immune strategy against infection, the intrinsic immunity (Simon et al., 2015). The 
mediated block occurs throughout the HIV-1 replication cycle (Fackler, 2015). 
Individual steps restricted include early post-entry, where TRIM5α and Mx10 recognize 
and destabilize capsid cores (Kane et al., 2013; Stremlau et al., 2004), reverse 
transcription, interfered by apolipoprotein B mRNA editing enzyme, catalytic peptide-
like 3G (APOBEC3G) and SAM domain- and HD domain- containing protein 
(SAMHD-1) (Baldauf et al., 2012; Bishop et al., 2008; Hrecka et al., 2011; Laguette et 
al., 2011; Mangeat et al., 2003), virion production, where Schlaffen 11 restricts 
translation of viral mRNA (Jakobsen et al., 2013b; Li et al., 2012), virion release, 
blocked by tetherin (see ) (Neil et al., 2008; Perez-Caballero et al., 2009) and infectivity 
of release viral particles, affected by serine incorporator 3/5 (SERINC3/5) (see ) (Rosa 
et al., 2015; Usami et al., 2015). To overcome these host cell barriers, the virus has 
developed antagonists which establish a dose-dependent response against them. The 
accessory proteins of HIV-1 often act as counteractors of the restriction imposed by 
these molecules which typically involves direct interaction. In some cases, no 
counteraction has been yet found despite of extensive investigation. This is the case of 
TRIM5α, which is able to bind to incoming viral capsids and hamper the uncoating 
process and for which no antagonism by an accessory protein has been described to date 
and only mutations in the Capsid protein induce escape (Stremlau et al., 2004).       
1.2.5.3 Adaptive immunity 
After the initial unspecific response, a more specific and efficient one based on antigen-
recognition is established. This type of immunity presents the advantage of memory 
acquisition what makes it able to mount faster and stronger responses to the same 
antigen in the future. Memory development constitutes the foundation for vaccine 
development. The adaptive immune response comprises two interrelated strategies: the 
humoral response, or antibody production, and the cellular response. CD4+ T cells are 
necessary for the correct functioning of both components of the adaptive immunity and 
therefore the systematic depletion and impaired functionality of these cells developed 
upon HIV-1 infection results in a compromised performance (Iyasere et al., 2003; 
Kaufmann et al., 2007).  
Cytotoxic T lymphocytes (CTLs) are the major mediators of the adaptive cellular 
response and HIV-1-specific subsets are involved in the decline of viremia in plasma 
observed at the acute phase of infection (Koup et al., 1994). The selection pressure 
imposed by the CTL response leads at this stage to the establishment of a population of 
viruses known as the quasispecies, leading to escape to founder virus-specific CTLs 
(Keele et al., 2008; Koup, 1994). A proof of the relevance of CTL response in HIV-1 
infection is provided by the viral control observed for LNTP presenting some particular 
MHC-I alleles (Allen et al., 2005). HIV-1 has developed evasion mechanisms against 
recognition and lysis consequence of the CTL response which include the accessory 
proteins Nef and Vpu (Collins et al., 1998; Matusali et al., 2012; Schwartz et al., 1996; 
Shah et al., 2010). 
   Introduction 
 
13 
 
The humoral response is mediated by antibody producer cells or B cells. Despite of not 
being natural targets of HIV-1, these cells are dysfunctional in infected individuals and 
only small subpopulations are HIV-1-specific (Eriksson et al., 1995; Moir et al., 2001). 
While these subjects show increased antibody production or 
hypergammaglobulinaemia, the produced antibodies are polyclonal and present low 
affinity (Shirai et al., 1992). Broadly neutralizing antibodies (bNAbs) targeting several 
HIV-1 strains and quasispecies can be found in about 20% of the HIV-1 infected 
patients (Mikell et al., 2011); however they are effective only in 1% of them, the so 
called elite controllers (Mouquet, 2014).              
1.2.6 Therapy and challenges towards the cure of HIV-1 infection 
Treatment of HIV infection with antiretroviral therapy (ART) can reduce HIV-
associated morbidity, prolong survival and prevent HIV transmission 
(Antiretroviral_Therapy_Cohort_Collaboration, 2008; Palella et al., 1998; Vittinghoff et 
al., 1999). Sustained suppression of plasma viremia mediated by ART restores and 
preserves immune function with a certain recovery in CD4 T cell levels and may reduce 
also the chronic immune activation observed in HIV infected patients. Furthermore, it 
delays or prevents the development of drug-resistance mutations (O'Brien et al., 1996; 
Yamashita et al., 2001). Monitoring CD4 T cell counts and viral load in plasma is 
critical to identify ART response.  
Since the approval in 1987 of zidovudin (AZT), the first anti-HIV drug, more than 25 
antiretroviral agents belonging to six different mechanistic classes or families have been 
approved for the treatment of HIV infection (Table 1.2). The first drugs developed and 
approved targeted the viral RT. Due to the lack of proofreading activity of this enzyme 
and the subsequent high mutation rate but also to HIV’s high viral turnover and 
frequency of recombination, selective pressure is established among the viral 
populations present in a patient to escape the effect of the therapy (Santoro and Perno, 
2013). Drug resistance was the main cause of treatment failure until medicaments from 
two new families of antiretroviral drugs targeting the viral protease were approved in 
1995 and 1996. Since then, ART has been administered as a combination of drugs of 
different families including typically two nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTI) and a third drug from one of the other families: non-
nucleoside/nucleotide reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), 
fusion inhibitors, entry inhibitors or integrase strand transfer inhibitors (INSTI). This 
combination ART (cART) is also known as high activity antiretroviral therapy 
(HAART) (Table 1.2). The list of antiretroviral approved drugs has not stopped 
growing. This constant development of new drugs is essential to maximize safety and 
tolerability while maintaining or improving clinical efficacy. Thanks to this, typically 
associated ART side effects in the 1980s and 1990s such as lipodystrophy, strongly 
linked to the social stigma, are now a problem of the past. The current international (e.g. 
WHO, 2016; URL: http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/) and 
regional guides (e.g. federally approved HIV/AIDS medical practice guidelines 2016; 
URL: https://aidsinfo.nih.gov/guidelines) recommend starting treatment following HIV 
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infection diagnosis regardless of the CD4 counts. This very recent update responds to 
the results obtained from the international study START (short for “Strategic Timing of 
Antiretroviral Treatment”) (Lundgren et al., 2015) and the study TEMPRANO 
conducted in Ivory Coast (Danel et al., 2015). Both studies provide the highest levels of 
evidence that early HIV treatment is associated with reduced frequency of primary 
outcomes (any serious adverse event -AIDS related or non-AIDS related- or dead). Still 
today, access to ART remains an important issue affecting ~56% of HIV infected 
population, especially in low-and middle-income countries.  
Drug Family Mechanism of Action FDA Approved Drugs 
Nucleoside/nucleotide 
RT inhibitors (NRTI) 
Nucleoside/nucleotide analogues lacking a 3'OH 
group incorporated into the viral DNA. Reverse 
transcription stops the impossibility of further 
addition of nucleotides 
abacavir, didanosine, 
emtricitabine, lamivudine, 
stavudine, zidovudine 
(AZT), tenofovir 
Non-nucleoside 
RT inhibitors (NNRTI) 
Despite structurally diverse, they bind to the 
same, unique site of RT close to active center 
inhibiting it 
efavirenz, etravirine, 
nevirapine, rilpivirine 
Protease inhibitors Prevent cleavage of polyproteins atazanavir, darunavir, 
fosamprenavir, indinavir, 
nelfinavir, ritonavir, 
tipranavir, saquinavir 
Fusion inhibitors Directly bind to gp41 and preventing 
conformational changes needed for fusion of 
cellular and viral membranes 
enfuvirtide (T-20) 
Entry inhibitors Interaction between gp120 and CCR5 is blocked maraviroc 
Integrase inhibitors Viral integrase is inhibited (3' processing of 
viral 
DNA and/or strand transfer), thereby preventing 
integration of viral DNA into the host cell 
genome 
raltegravir, dolutegravir, 
elvitegravir 
Table 1.2 Classification and pharmacological mechanism of antiretroviral drugs.  
Despite of the efficacy of HAART to control HIV infection, discontinuation of it results 
in a rebound of the viral load. The reason is the generation of a pool of latently infected 
cells or reservoir which cannot be targeted by ART due to lack of replication.  
Similarly, these latently integrated viruses remain invisible to the immune system. The 
site of integration, interaction with cellular factors and, epigenetics play a pivotal role in the 
establishment of latency (Lusic and Giacca, 2015; Siliciano et al., 2003). Post-integration 
latency occurs in resting (central or translational) memory CD4 T cells (Chomont et al., 
2009). The reservoir is established early during acute infection, likely within days 
following initial exposure (Chun et al., 1998a). Therefore, early initiation of HAART 
might contribute limiting reservoir size. These cells bearing the transcriptionally silent 
provirus are fully capable of generating infectious virions once they are reactivated by 
recall antigen or cytokines (Chun et al., 1998b). The frequency of latently infected 
resting CD4 T cells is 1 in 106 cells (Chun et al., 1997; Finzi et al., 1997; Wong et al., 
1997). However, the decay rate of the reservoir is so slow (half-life of latently infected 
cells is 43.9 months) that it was estimated it would take 73 years for ART to clear it 
(Siliciano et al., 2003). It has been later reported the existence of latent, replication-
competent proviruses in the reservoir not responding to PHA induction in viral 
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outgrowth assays. Based on this, eradication of the reservoir would be much more 
challenging than initially thought (Ho et al., 2013). Evidence for the contribution to the 
residual plasma viremia by other source than resting CD4 T cells in patients under ART 
has been provided (Nickle et al., 2003; Ruff et al., 2002). However, no conclusive data 
about the identity of it could be obtained so far. 
Given the great obstacle latency represents towards HIV infection cure, eradicating the 
viral reservoir is now one of the priorities in this field (Katlama et al., 2013; Richman et 
al., 2009). The main strategy is to find a way to reactivate cells from the reservoir in 
patients under HAART. It is assumed that reversion of latency in these cells will lead to 
dead by the viral cytopathyc effects or due to recognition and killing by the patient’s 
CTLs (Hoxie and June, 2012). Cytokines such as IL-2 and anti-CD3 antibodies have 
been tested with no success (Chun et al., 2015; Davey et al., 1999). Agonists of PKC for 
downstream activation of NF-κB (Brooks et al., 2003; Jiang and Dandekar, 2015) or 
inhibitors of histone deacetylase (HDAC), shown to interact with 5’ LTR and induce 
latency (Jiang et al., 2007; Williams et al., 2006), have arose promising results in in 
vitro studies (Archin et al., 2009; Korin et al., 2002; Kulkosky et al., 2001; Lehrman et 
al., 2005; Williams et al., 2004; Ylisastigui et al., 2004). Interestingly, antigen-
stimulation of patient cytotoxic lymphocytes (CTL) prior to viral reactivation from the 
latent reservoir is essential for efficient killing of HIV-1 infected cells in vitro (Shan et 
al., 2012). This suggests a potential need for boosting patient CTL response in order to 
deplete the HIV reservoir. Targeting latent provirus in cells from the reservoir for 
excision has also been attempted. Delivery specificity represents the main limitation in 
this case (Ebina et al., 2013; Hu et al., 2014).  
The only case reported of HIV healing in history was that in 2009 of a patient with 
acute myeloid leukemia, the so called “Berlin patient” (Hutter et al., 2009). This patient 
received an allogeneic hematopoietic progenitor/stem cells transplant from a donor who 
was homozygotic for a 32 bp deletion in the CCR5 allele which confers immunity 
against HIV infection (Dean et al., 1996; Liu et al., 1996).  The CD4 counts of the 
patient recovered and the viral load remained undetectable following the transplant 
leading to discontinuation of HAART. No viral load rebound in plasma or in tissues was 
detected ever since and the size of the reservoir got reduced until becoming 
undetectable (Allers et al., 2011; Yukl et al., 2013). This case however has remained as 
unique. Similar attempts did not succeed due to viral tropism shift to X4 strain 
(Kordelas et al., 2014) or the patients died after the transplant (Passaes and Saez-Cirion, 
2014). As opposing to a sterilizing cure as that of the “Berlin patient”, a functional cure 
was reported for 14 patients from the so called VISCONTI cohort (for “VIrologic 
Sustained CONTrol after Treatment Interruption”). After a limited time of early 
treatment, they displayed undetectable viremia in plasma while still bearing latent 
provirus in their reservoir (Saez-Cirion et al., 2013). Other efforts included repression of 
viral gene expression by engineered zinc-finger transcription factors (Reynolds et al., 
2003), genetic manipulation of CD4 T cells to achieve resistance to infection, mostly by 
modification or knock-down of CCR5 (Didigu et al., 2014) or by transplantation of 
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autologous cells redirected to target HIV or manipulated genetically to express antiviral 
molecules such as bNAbs or nucleic acids (Focosi et al., 2015).    
Development of a preventive vaccine is the main goal to achieve eradication given that, 
despite of the existence of effective therapies, more than half of the HIV-infected 
population worldwide does not have access to them. The discovery of HIV-1 specific 
bNAbs in LNTPs provided faith in the possibility of developing a vaccine which could 
induce its production. Before that all attempts to elicit protecting antibodies against 
Env, the only accessible protein on the viral surface, did not succeed due to the lack of 
broadly neutralizing capacity (Wang et al., 2015). Recent promising results derived 
form in vivo work on protection acquired upon passive transmission of bNAbs keep the 
hope on the potential of this strategy (Hessell et al., 2009; Pietzsch et al., 2012). A 
second direction towards the development of a vaccine aims at stimulating HIV-specific 
CTL response. A report showing this type of response in uninfected women highly 
exposed to HIV serves as a proof of principle supporting this idea (Rowland-Jones et 
al., 1995). Life-attenuated vaccines like MMR (measles, mumps, rubeola) are not 
pursued anymore due to safety concerns, despite of the induction of a potent immune 
cellular responses. As an alternative vaccines based on vectors such as canarypox or 
adenoassociated virus have and are currently being developed and they are able to elicit 
both cellular and humoral responses. The most promising results were obtained in a 
phase III clinical trial that combined two of these vaccines to achieve efficient delivery 
of gag, protease and env followed by two boost immunizations including env from 
another subtype. As a result, the HIV infection risk was reduced in a 31%. Interestingly, 
the successful results correlated with antibody-dependent cellular cytotoxicity rather 
than induction of neutralization. 
1.3 Accessory proteins of HIV-1 
Besides the prototypical lentiviral structural proteins Gag, Pol and Env and the 
regulatory proteins Tat and Rev, complex primate lentiviruses express so called 
accessory proteins with essential functions to ensure efficient viral replication, despite 
the misleading of their name. The terms accessory genes and proteins derive from initial 
reports describing that inactivation of these gene products in vitro had little or no impact 
on virus replication in continuous cell lines (Fan and Peden, 1992; Strebel et al., 1988). 
However, further research focusing on primary cells susceptible to HIV infection or on 
in vivo models dispelled the doubts concerning unneglectable relevance of the accessory 
proteins during the course of infection (Bour and Strebel, 2000). Primate lentiviral 
accessory proteins are Vif, Vpr, Nef and Vpu. While the first three are expressed by 
most HIV-1, HIV-2 and SIV strains, Vpu is only expressed by HIV-1 with the 
exception of SIVcpz and SIVgsn (Courgnaud et al., 2002; Huet et al., 1990). At each 
step of the viral cycle certain accessory proteins are expressed and, through the multiple 
functions exerted by them, these proteins contribute to achieve efficient viral infectivity 
(Nef and Vif), viral gene expression (Vpr) and optimal virion production (Vpu). Among 
others, one of the main functions attributed to lentiviral accessory proteins is to fine 
tune the interactions between the infected cells and the immune system facilitating 
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escape to innate and adaptive immune responses. Often, that is driven by the 
counteraction of host cell barriers known as restriction factors which trigger those innate 
responses (Simon et al., 2015). One of the first restriction factors described was 
APOBEC3G, a cytidine deaminase which elevates the mutation rate during reverse 
transcription hampering viral replication (Bishop et al., 2004; Sheehy et al., 2002). HIV-
1 Vif promotes degradation of APOBEC3G and prevents its inclusion into nascent 
virions (Simon et al., 2015). Via counteraction of one or more unknown restriction 
factors, Vpr antagonizes restriction of Env expression in a macrophage-dependent 
manner (Collins et al., 2015; Mashiba et al., 2014). In the same cellular system, Vpr 
arrest cell cycle in G2 phase (Re and Luban, 1997). In addition, it activates the SLX4 
endonuclease complex with subsequent clearance of exogenous DNA resulting in the 
suppression of IFN type I production and hampering antiviral response (Laguette et al., 
2014). The following describes in more detail the accessory viral gene products Nef and 
Vpu as well as some of the cellular processes in which they interfere to enable optimal 
viral replication.        
1.3.1 HIV-1 pathogenesis factor Nef 
HIV-1 Nef is a 27-35 kDa myristoylated accessory protein synthesized early in the viral 
cycle by HIV-1, HIV-2 and SIV. The nef coding sequence appears at the 3’ end of the 
viral genome where it overlaps partially with the 3’ LTR. Despite of its low 
concentration and inactivation by the viral PR within the virions (Pandori et al., 1996; 
Welker et al., 1996), Nef is active at early infection stages and it has been shown to be 
transcribed and expressed even prior to integration of the provirus (Sloan et al., 2011; 
Wu and Marsh, 2003). Nef was initially described to have a negative impact on viral 
replication and transcription and thereby to be involved in establishment of latency, 
hence its name which stands for “negative factor” (Ahmad and Venkatesan, 1988; 
Cheng-Mayer et al., 1989; Luciw et al., 1987; Terwilliger et al., 1986). Results from 
other researchers however refuted these findings soon thereafter (Hammes et al., 1989; 
Kim et al., 1989). Also, in vivo studies showed how macaques infected with SIV 
harboring insertions or deletions in the nef gene abolishing expression of the protein led 
to a reduction in the viral pathogenicity and slower or no progression to 
immunodeficiency (Kestler et al., 1991; Whatmore et al., 1995). Furthermore, selective 
pressure established in the infected monkeys resulted in the reversion of the introduced 
mutations underlining the importance of the viral product Nef. There are also evidences 
of the importance of Nef for HIV pathogenesis and progression to AIDS in humans. The 
study of a cohort of LTNP patients who received blood or blood products transfusion 
from the same LTNP donor infected by an HIV-1 bearing deletions in the nef ORF and 
absence of other changes in the viral genome is one example of it (Deacon et al., 1995; 
Kirchhoff et al., 1995). Despite of having all remained asymptomatic during 10 to 14 
years after sero-conversion, some of these patients have eventually developed AIDS 20 
years after sero-conversion (Gorry et al., 2007), linking expression of the viral factor to 
high virulence and rapid disease progression while no absolute requirement of an intact 
nef ORF for the development of AIDS can be concluded. Adding up to these 
observations, studies using a transgenic mice model showed AIDS-like disease 
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development and CD4 T lymphocyte depletion upon isolated Nef expression by CD4 T 
cells and cells of the macrophage/dendritic lineages (Hanna et al., 1998). Altogether, the 
previous studies demonstrate the critical role Nef plays as a pathogenicity factor during 
infection. While the direct mechanistic fundaments for that remain unclear, multiple Nef 
functions have been described in vitro which might contribute to the pathogenic 
outcome mediated by the accessory protein, namely interference with host cell vesicular 
transport, signal transduction and enhancement of virion infectivity (explained more in 
detail below). In the absence of enzymatic activity, Nef exerts all the above functions 
via specific protein-protein interactions with a large array of host cell factors. Motifs 
involved in many of these interactions have been described and they are present 
throughout the molecule. However, which of those motifs are relevant in vivo remains a 
conundrum. Crystal (Arold et al., 1997; Grzesiek et al., 1997; Lee et al., 1996) and 
NMR (Grzesiek et al., 1996a; Grzesiek et al., 1997) studies showed that Nef’s structure 
consists of a membrane anchor, a globular core and two highly flexible loops (Figure 
1.5). The N-terminal domain of Nef contains an SH4 domain (Geyer et al., 2001). This 
domain consists of a glycine in position 2 as part of the N-myristoylation consensus 
sequence MGxxx(S/T) with a tendency to find a lysine or arginine at positions 7 and/or 
8 (Resh, 1999). Nef myristoylation and subsequent interaction with cellular membranes 
is critical for all Nef described activities (Fackler et al., 2006; Giese et al., 2006; Guy et 
al., 1990; Kaminchik et al., 1994; Yu and Felsted, 1992). Residues from the two flexible 
loops are involved in transient interactions with proteins of the trafficking machinery 
relevant for downregulation of cell surface receptors such as CD4 and MHC-I (Atkins et 
al., 2008; Craig et al., 1998; Dikeakos et al., 2012; Greenberg et al., 1998; Lindwasser 
et al., 2007; Piguet et al., 2000; Ren et al., 2014; Rhee and Marsh, 1994). Interactions 
between Nef and signaling proteins containing SH3 domains or with p21-activated 
kinase (PAK) rely on residues of the central core (Geyer et al., 2001; Lee et al., 1996; 
Nunn and Marsh, 1996; Renkema et al., 1999; Sawai et al., 1994). 
 
Figure 1.5 Structure of HIV‐1 Nef.   Structural  representation of  full‐length Nef  is derived  from a NMR structure 
assemble. Three main domains can be distinguished (N‐t membrane anchoring domain, central core domain and C‐
t disordered loop) and functional motifs and interaction partners are indicated. Adapted from (Geyer et al., 2001). 
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1.3.1.1 Enhancement of viral infectivity and replication 
Nef has been shown to induce a 3- to 10-fold increase in single-round infectivity assays 
when viruses containing the intact nef gene sequence were compared to viruses with 
disrupted nef genes including a Nef-deficient virus (ΔNef virus). This activity is 
dependent on Nef’s correct association with cellular membranes and its presence in the 
virus producer but not in the target cells, and due to enhancement of the intrinsic 
infectivity of the virions rather than an increase in the number of particles released 
(Aiken and Trono, 1995; Chowers et al., 1994; Miller et al., 1994; Pizzato, 2010; 
Schwartz et al., 1995b; Spina et al., 1994). Furthermore, it is evolutionarily conserved 
and maintained through high selective pressure during disease progression (Carl et al., 
2001; Munch et al., 2007). The identification of a Jurkat clone (Jurkat E6.1) for which, 
when used as virus producer cells, the Nef-mediated fold-change in infectivity rose up 
to 100 shed some light on our understanding of the molecular basis of Nef-induced 
boost of lentiviral infectivity (Pizzato et al., 2007; Pizzato et al., 2008). In this system, 
Nef effect on infectivity depended on the GTPase dynamin 2, clathrin and the adaptor 
complex AP-2, suggesting that Nef exploits the endocytic machinery of the host cell for 
this activity (Pizzato et al., 2007; Usami et al., 2015). Together with the requirement for 
functional clathrin-mediated endocytosis, the fact that this activity has been mapped to 
the PxxP, EEEE66-69 and Δ12-39 motifs, all of them relevant for vesicular trafficking, 
(Chowers et al., 1994; Fackler et al., 2006; Goldsmith et al., 1995; Pizzato et al., 2007) 
suggested that the observed effects of Nef on viral infectivity are exerted by 
counteracting a yet unknown restriction factor. Through two different experimental 
approaches (proteomics of virions produced in presence or absence of Nef or expression 
profiling of Nef-sensitive and Nef-insensitive producer cells (Fackler, 2015)), the 
Pizzato and Göttlinger laboratories identified two members of the SERINC protein 
family, SERINC3 and 5, as the responsible host cell restriction factors implicated (Rosa 
et al., 2015; Usami et al., 2015). Both these proteins are incorporated in significant 
amounts in released HIV-1 particles and the presence of Nef strongly reduced their 
incorporation. Parallel observations by the same authors regarding the cell surface 
expression levels and subcellular localization of SERINC3/5 in the presence of Nef 
indicate that the viral factor retargets them from the plasma membrane to a Rab-7 
positive compartment. Also, SERINC5 hinders virion fusion. The current model 
therefore is that the presence of SERINC3/5 on HIV virions impairs fusion to target 
cells and Nef counteracts this restriction by redirecting the host factors to an endocytic 
intracellular compartment reducing thereby their incorporation into budding viral 
particles (Fackler, 2015) 
1.3.1.2 Nef-mediated receptor downregulation: CD4 and MHC-I 
The best described in vitro Nef function is the modulation of the levels of cell surface 
receptors. This is thought to have a beneficial impact on infection by avoiding 
superinfection, mediate evasion of the immune response, or enhance virus release, thus 
generating the optimal scenario for viral replication (Landi et al., 2011). The main HIV 
receptor CD4 is found among the surface proteins downmodulated by Nef (Garcia and 
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Miller, 1991). Nef causes a reduction in CD4 surface levels by mediating its 
internalization from the plasma membrane via clathrin-mediated endocytosis (Aiken et 
al., 1994; Chowers et al., 1994; Piguet et al., 1998). CD4 downregulation results in the 
reduction of superinfection, a phenomenon which may drive to premature cell death due 
to aggregation of non-integrated proviral DNA, as well as in the optimization of viral 
spread by preventing redundant infection (Benson et al., 1993; Michel et al., 2005; 
Wildum et al., 2006). Furthermore, it is thought to promote viral egress by avoiding 
interaction between newly synthesized gp120 and CD4 within the vesicular system prior 
to assembly of new virions (Willey et al., 1992b) or at the cell membrane where CD4 
can act as a “tether” for the budding virion progeny (Ross et al., 1999). However, this 
has only been shown for unphysiologically high levels of CD4. The molecular 
determinants defining this Nef activity are the myristoylation site needed for the 
interaction with cellular membranes (glycine in position 2) (Aiken et al., 1994; Peng 
and Robert-Guroff, 2001), the W61-62 motif necessary for the direct interaction with 
the cytoplasmic tail of CD4 (Grzesiek et al., 1996b) and the dileucin motif in the C-
terminal flexible loop (LL168/169) involved in the interaction with the clathrin adaptor 
AP2 required for CD4 targeting to lysosomal degradation (Craig et al., 1998; Ren et al., 
2014; Rhee and Marsh, 1994). The transport pathway that CD4-containing vesicles 
follow to encounter lysosomes is still unclear but it seems to follow the endosomal 
sorting complexes required for transport (ESCRT) pathway and to require interaction of 
Nef with TSG101 and Alix (Amorim et al., 2014; daSilva et al., 2009). Unlike in the 
case of CD4 where Nef mediates its internalization, Nef modulates the levels of most of 
the other targeted receptors by altering their anterograde transport. This is the way how 
Nef reduces the levels of major histocompatibility complex (MHC)-I what is needed to 
escape adaptive CTL responses (Collins et al., 1998; Schwartz et al., 1996). The 
absence of MHC-I at the plasma membrane is also sensed by the innate immune system 
through NK cells. To avoid NK cell-mediated killing, HIV-1 Nef specifically 
downregulates two of the isoforms of MHC-I, human leukocyte antigen (HLA)-A and -
B, but not HLA-C and -E (Cohen et al., 1999). The molecular mechanism of Nef-
mediated MHC-I downregulation relies on the interaction of the viral protein with the 
cytoplasmic tail of the cellular protein and the subsequent formation of a complex with 
the sorting molecules PACS-1 and -2 and the clathrin adaptor AP-1. All these 
interactions and complex formation lead to an interference with the anterograde 
transport of newly synthesized MHC-I molecules and their retargeting from the TGN to 
lysosomal degradation (Roeth et al., 2004; Williams et al., 2002). A second model 
suggests that mature MHC-I molecules are internalized from the plasma membrane and 
targeted to lysosomal degradation through an unclear mechanism (Pawlak and 
Dikeakos, 2015). The molecular determinants of Nef involved on MHC-I 
downmodulation are defined and include EEEE66-69 needed for the interaction with the 
PACS sorting adaptors (Atkins et al., 2008; Piguet et al., 2000), PxxP (80-83) and M20 
both involved in the interaction with AP-1 (Greenberg et al., 1998; Hung et al., 2007) 
(Dikeakos et al., 2012; Jia et al., 2012) as well as the myristoylation site G2 (Peng and 
Robert-Guroff, 2001). The HIV coreceptor CXCR4 is also downregulated from the cell 
surface by Nef and the motifs involved on this process are the ones involved on MHC-I 
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downregulation. Therefore a similar mechanism has been proposed (Venzke et al., 
2006). Nef also mediates downmodulation of the other HIV coreceptor, CCR5, as well 
as other members of the family of the chemokine receptors (Michel et al., 2005; Michel 
et al., 2006). Downregulation of the correceptors CXCR4 and CCR5 takes place even 
before proviral integration (Sloan et al., 2010). The reduction in the expression of the 
HIV correceptors may contribute to prevent superinfection as well as to the impairment 
on T cell motility mediated by Nef (Venzke et al., 2006). The number of surface 
receptors and molecules described to be targeted by Nef for downregulation does not 
stop to grow (Haller et al., 2014). Also, the fact that whole protein families are 
susceptible to Nef effects and common motifs are responsible for this effect show that 
the effect of Nef is on general transport platforms rather than on single molecules.  
1.3.1.3 Modulation of T cell signaling by Nef 
T lymphocytes form transient interactions in which their TCR complexes recognize the 
antigens bound to MHC-II molecules on the surface of APCs. This leads to the 
formation of the so called immunological synapse (IS), a complex structure formed by 
signaling and intercellular adhesion molecules associated to a polymerized F-actin 
structure, which optimizes TCR signaling and leads to T cell activation (Alarcon et al., 
2011). Nef profoundly alters the signaling cascade downstream of the TCR in infected 
T lymphocytes as well as in cells expressing the viral factor alone. This is mediated via 
the interaction with several proteins of the TCR signaling cascade (Haller et al., 2006; 
Iafrate et al., 1997; Schindler et al., 2006; Schrager and Marsh, 1999). This way, Nef 
fine-tunes the degree of T cell activation favoring viral spread and replication. It has 
been reported that Nef induces T cell activation prior to proviral DNA integration by 
lowering the threshold for the TCR signaling cascade leading to efficient viral 
transcription (Abraham and Fackler, 2012; Baur et al., 1994; Wu and Marsh, 2001). On 
the other hand, TCR overstimulation can result in cell death (Arnold et al., 2006; 
Bourgeois and Stockinger, 2006). This phenomenon known as activation induced cell 
death (AICD) can also be prevented by Nef by interfering with IS formation. To study 
this in vitro, some of the features of IS formation can be reproduced by seeding T 
lymphocytes on anti-CD3 or anti-CD3/anti-CD28 antibody-coated surfaces (Fackler et 
al., 2007). On this artificial system, cells spread and form the characteristic actin ring 
and proximal TCR signaling can be detected by the formation of distinct signaling 
complexes or microclusters (MCs). On one hand, Nef inhibits formation of MCs 
positive for the signaling adaptor Src homology-2 domain-containing leukocyte protein 
of 76 kDa (SLP-76) to reduce the density of MC (Abraham et al., 2012). This results in 
a potent inhibition of the early TCR signaling events. Nef’s negative effects on the actin 
cytoskeleton organization are necessary but not sufficient to mediate the observed 
disruption. On the other hand, Nef retargets members of the TCR signaling cascade 
such as LAT or Lck to intracellular compartments (Abraham et al., 2012; Haller et al., 
2007; Haller et al., 2006; Pan et al., 2012). Unlike in the case of retargeting of LAT, 
which is consistent with disruption of early TCR signaling events, rerouting of Lck has 
been associated to the enhancement of distal TCR  signaling events. Lck is redirected 
and accumulated at early and recycling endosomes (RE) as well as at the trans-Golgi 
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network (TGN) in a catalytically active, signaling competent conformation (Haller et 
al., 2007; Haller et al., 2006; Pan et al., 2013b; Pan et al., 2012; Thoulouze et al., 2006). 
The enrichment of active Lck at this compartments lead to activation of the RAS 
GTPase and ultimately to the activation of Erk kinase and production of IL-2 upon 
exogenous stimulation (Abraham et al., 2012; Haller et al., 2007; Haller et al., 2006; 
Keppler et al., 2006; Rudolph et al., 2009). Thereby, Nef induces paradoxal effects on 
TCR signaling potently inhibiting the early steps and enhancing downstream events. 
Furthermore, Nef from the non-pathogenic viruses HIV-2 and SIV are able to 
downregulate TCR-CD3. The lack of this activity in Nef from HIV-1 and HIVcpz has 
been linked high T cell activation levels and display of a virulent outcome of the 
infection with this viruses with (faster) progression towards AIDS (Munch et al., 2002; 
Rudolph et al., 2009; Schindler et al., 2006).  
1.3.1.4 Inhibition of actin dynamics by Nef 
1.3.1.4.1 The actin cytoskeleton 
The actin cytoskeleton consists of a highly flexible filament meshwork in constant 
remodeling that defines the inner structure and the outer shape of the cells. Regulated 
actin rearrangements ensure fundamental cellular processes such as cell migration, 
endocytosis and intracellular vesicle trafficking or cell division. Particularly, 
cytoskeletal reorganization plays a crucial role in multiple aspects of T cell function 
where it is involved in cell signaling, differentiation, adhesion, membrane reshaping and 
protrusion formation, molecular and morphological polarization, motility, immune 
synapse formation and activation, and execution of effector functions (Burkhardt et al., 
2008; Dupre et al., 2015; Samstag et al., 2003). Actin polymerization and 
depolymerization is tightly regulated by actin-binding proteins which act as nucleators 
as well as upstream promoting factors and regulators. The building block is the actin 
monomer or globular actin (G-actin). Double-stranded helical actin filaments are 
assembled when a critical concentration of ATP-bound G-actin is reached. Actin 
filaments are polar, meaning they have two differentiated ends: the fast-growing barbed 
ends (plus ends), where actin polymerization takes places, and the pointed ends (minus 
ends) where actin disassembly occurs (Dupre et al., 2015). Actin nucleators such as 
formins or the actin related proteins 2/3 (Arp2/3) complex are responsible of initiating 
polymerization, a thermodynamically disfavored process not taking place otherwise 
(Devreotes and Horwitz, 2015). While formins are able to promote de novo linear actin 
assembly or the elongation of existing filaments, Arp2/3 complex binds to preexisting 
filaments and induces formations of branches with an angle of 70º (Figure 1.6) (Insall 
and Machesky, 2009). Branching is crucial to achieve an elaborated actin filament 
network. Arp2/3 activity is regulated by proteins of the Wiskott-Aldrich syndrome 
protein (WASP) family and the WAVE family (Padrick and Rosen, 2010; Pollitt and 
Insall, 2009). Together with formins, the latter are regulated by small GTPases of the 
Rho family, including Rho, Rac and Cdc42 (Parsons et al., 2010). These proteins are 
active when bound to GTP and become inactive when the nucleotide is hydrolyzed to 
GDP. This inactivation process is catalyzed by GTPase activating proteins (GAPs) 
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whereas activation by exchange of GDP for free GTP is mediated by guanine nucleotide 
exchange factors (GEFs) (Bos et al., 2007). Guanosine nucleotide dissociation inhibitors 
(GDIs) stabilize the inactive form of small GTPases. By being switched on and off, 
these proteins are able to modulate actin cytoskeleton spatially and temporally 
according to extracellular triggers. These proteins also regulate kinases such as p21-
activated kinase (Pak) or Rho kinase (ROCK) which are necessary for contractility and 
controlled severance of existing actin filaments (Bokoch, 2003). The latter process is 
absolutely necessary for rearrangements in the actin cytoskeleton upon a certain 
stimulus since de novo filament synthesis is a slow process which does not account for 
the required rapid responses. Fragmentation of existing filaments is mediated by the 
actin severing factor cofilin and provides new barbed ends for further polymerization 
and nucleation by Arp2/3 complex (Carlier et al., 1997; Ichetovkin et al., 2002; 
Ichetovkin et al., 2000; Lappalainen and Drubin, 1997). Cofilin induces also 
disassembly at the pointed end of actin filaments by targeting ADP-bound actin 
molecules. Profilin induces nucleotide exchange and regenerates ATP-bound actin 
monomers that can be used for polymerization at the barbed end (Dupre et al., 2015; 
Wolven et al., 2000). Both cofilin and profilin are then essential to ensure rapid actin 
dynamics. Phosphorylation of cofilin at a serine residue at position 3 mainly by Lim 
Kinase (LIMK) downstream of PAK and ROCK leads to its reversible inactivation 
(Bernstein and Bamburg, 2010). Capping proteins prevent actin monomer association or 
dissociation at the barbed ends stabilizing the filament (Bear and Gertler, 2009).  
Figure 1.6 Main actors involved in the actin polymerization/depolymerization process. Actin dynamics is a tightly 
regulated process. Arp2/3 and Cofilin are the central players in polymerization/depolymerization of branched actin 
filaments. The activity of this two proteins is modulated by a number of effectors regulated in turn by small GTPases 
of the Rho family, including Rho, Rac and Cdc42 families. (Devreotes and Horwitz, 2015). 
 
   Introduction 
 
24 
 
1.3.1.4.2 Nef interferes with actin dynamics 
HIV manipulates the actin cytoskeleton of the host cell to its own benefit during several 
steps of the viral cycle including entry into, trafficking within and egress from infected 
cells (Fackler and Krausslich, 2006). In this context, many viral factors have been 
shown to interact with components of the actin cytoskeleton. Among them Nef plays a 
central role as a master inhibitor of actin rearrangements (Fackler and Krausslich, 2006; 
Stolp and Fackler, 2011). HIV-1 Nef is long known to associate with actin (Fackler et 
al., 1997; Niederman et al., 1993). Nef was reported to interact with the GEF Vav 
leading to its activation and ultimately to F-actin depolymerization (Fackler et al., 
1999). Further investigations showed that Nef-mediated effects on actin dynamics were 
dependent on its interaction with the cellular kinase Pak 2 in the context of a labile 
multiprotein complex together with the GEF Vav and the small GTPases Rac and 
Cdc42 (Haller et al., 2006; Nunn and Marsh, 1996; Rauch et al., 2008; Renkema et al., 
1999; Stolp and Fackler, 2011). Despite of being transient and of very low affinity, the 
interaction between both proteins reprograms the substrate specificity of the kinase 
towards the non natural substrate cofilin. Following dissociation of the complex, Pak 2 
phosphorylates cofilin what renders the actin severing factor inactive resulting 
ultimately in a reduction of actin turnover (Stolp et al., 2009). Nef and Pak 2 interact via 
a hydrophobic patch in Nef consisting of several aminoacids but mutation of one single 
residue, F195 in SF2 Nef (F191 in NL4-3 and NA7 Nef), has proven to disrupt 
association of the protein (O'Neill et al., 2006; Rauch et al., 2008).   Nef-Pak 2 
interaction as well as the effects on actin dynamics are conserved among SIV, HIV-1 
and HIV-2 Nef proteins (Rudolph et al., 2009; Stolp et al., 2010). Besides F195/191, 
additional motifs involved in other functions of Nef are also important for Nef-Pak 2 
association. Membrane association via G2 myristoylation and targeting to lipid rafts 
where Pak 2is recruited via K4K7 are both needed for the interaction (Krautkramer et 
al., 2004). Integrity of the acidic stretch EEEE66-69 is also required (Baugh et al., 2008; 
Haller et al., 2007; Stolp et al., 2010; Stolp et al., 2009). The PxxP motif is also 
involved in the outcome of the interaction between Nef and Pak 2 since it is necessary 
for the recruitment of Vav, upstream activator of the kinase via Rac and Cdc42 (Fackler 
et al., 1999; Rauch et al., 2008). The PAK 2 interaction surface of Nef was thought to 
be exclusively involved in the interaction between both proteins until recently. The 
exocyst complex (EXOC), an octameric protein complex implicated in vesicular 
trafficking and actin remodeling, has been shown to interact with Nef via the Pak 2 
interacting domain (Mukerji et al., 2012). Mutational, biochemical and functional 
analysis of its interaction with Nef proved that interaction of Nef and Pak2 is essential 
to induce the recruitment of EXOC which, after dissociation of Pak 2 from the complex, 
remain stably associated to the viral factor. Despite of being dispensable for other 
activities like Nef-Pak 2 downstream functions and interference of intracellular 
trafficking, Nef-EXOC complex is necessary for TCR-induced actin remodeling 
inhibition by Nef in the context of IS formation (Imle et al., 2015). This adaptor 
function of PAK2 for the recruitment of EXOC is independent of the other described 
PAK2 activities.              
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1.3.2 Viral protein U of HIV-1 (Vpu)      
HIV-1 Vpu is a 16 kDa, integral type I transmembrane (TM) protein encoded by the 
pathogenic viruses HIV-1 and some related SIV strains, but absent in the less or non 
pathogenic viruses HIV-2 and other SIVs (Cohen et al., 1988; Courgnaud et al., 2002; 
Gonzalez, 2015; Huet et al., 1990; Maldarelli et al., 1993; Strebel et al., 1988). As 
observed for Nef, macaques infected with Vpu deficient hybrid HIV-SIV viruses 
(SHIV) displayed a 10- to 100-fold reduction in viral titers in plasma as compared to wt 
SHIV (Hout et al., 2005). Also, recent studies have proven the relevance of Vpu during 
early HIV-1 spread during acute infection in humanized mice models (Dave et al., 2013; 
Sato et al., 2012). Vpu is expressed from a bicistronic mRNA that encodes as well for 
the Env protein. As a result both proteins are produced late in the viral life cycle in a 
coordinated manner (Schwartz et al., 1990).  The translated product has about 81 amino 
acids (aa) and consists of a short luminal domain and unknown function, a single α-
helical TM domain and cytoplasmic tail (Figure 1.7) (Sugden et al., 2016). The TM 
domain with 23 aa enables the viral protein to form supramolecular complexes by 
homooligomerization or by interaction with other proteins (Gonzalez, 2015). The 
cytoplasmic domain is 56 aa long and comprises a flexible hinge region proximal to the 
plasma membrane followed by two α-helices (H1 and H2) flanking a linker region 
containing a highly conserved double-serine motif (positions 52 and 56). The 
subcellular localization of HIV-1 Vpu varies with the different clades. Vpu from clade 
B localizes preferentially at the TGN while Vpu from clade C is also present at the 
plasma membrane (Pacyniak et al., 2005). 
Figure 1.7 Structure of HIV‐1 Vpu. The Vpu protein presents a short N‐t tail facing the ER lumen, a TM domain and a 
cytoplasmic  C‐t  domain.  The  latter  consists  of  a  short  C‐t  tail  and  two  helices  separated  by  a  flexible  hinge 
containing two constitutively phosphorylated serine residues. The aa positions correspond to the NL4.3 Vpu allele. 
(Dube et al., 2010a) 
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1.3.2.1 CD4 downregulation by HIV-1 Vpu        
CD4 downregulation by HIV is a relevant phenomenon for virus replication and spread. 
An evidence for it is that several viral proteins contribute to this activity this activity: 
Nef, Vpu and Env (Wildum et al., 2006). The strongest downregulation effect is 
mediated by Nef which is capable of inducing CD4 internalization and degradation 
(Aiken et al., 1994; Chowers et al., 1994; Piguet et al., 1998). On the other hand, Vpu 
and Env block transport of newly synthesized CD4 molecules to the plasma membrane 
(Willey et al., 1992a). Vpu targets molecules of the receptor at the endoplasmic 
reticulum (ER) to the ER-associated degradation (ERAD) pathway (Binette et al., 2007; 
Magadan et al., 2010; Schubert et al., 1998; Willey et al., 1992a). Following the 
interaction of both proteins through their cytoplasmic tails (Bour et al., 1995), the SCF 
E3 ubiquitin ligase adaptors beta-transducin repeats-containing proteins (β-TrCP) -1 and 
-2 are recruited to the complex leading to subsequent recruitment of SCF complex. 
Interaction between Vpu and β-TrCP requires integrity of the canonical sequence 
DSGXXS of Vpu and phosphorylation of its two serine residues at positions 52 and 56 
(Margottin et al., 1998; Schubert et al., 1994). This ultimately results in the 
serine/threonine-dependent polyubiquitination of the cytoplasmic tail CD4 (Binette et 
al., 2007; Magadan et al., 2010; Schubert et al., 1998), but not Vpu (Schubert and 
Strebel, 1994), promoting recruitment of the VCP-UFD1L-NPL4 dislocase complex, a 
late stage component of the ERAD pathway, and relocalization of CD4 from the ER to 
the cytoplasm where they are finally delivered to the proteasome for efficient 
degradation (Binette et al., 2007; Magadan et al., 2010; Schubert et al., 1998). 
1.3.2.2 Counteraction of BST-2/tetherin/CD317 by Vpu 
Another well described effect of HIV-1 Vpu is the mediation of efficient virion release 
from infected cells (Klimkait et al., 1990; Strebel et al., 1989; Terwilliger et al., 1989). 
It was observed that following infection with a Vpu deficient virus the newly produced, 
budding viral particles remain associated to the surface of infected cells and 
accumulated at endosomal compartments (Neil et al., 2006). Previous reports showed 
that this impairment was cell specific (Geraghty et al., 1994; Sakai et al., 1995). 
Furthermore, it was later described that this restriction could be induced in permissive 
cells by Interferon (IFN)-I treatment (Neil et al., 2007). These findings suggested the 
presence of a cell-type specific restriction factor responsible for the observed 
“tethering” of new virions on the surface of infected cells. The search led to the 
discovery of tetherin (also known as bone marrow stromal cell antigen 2 (BST2) or 
CD317) as the IFN-I-inducible molecule mediating virion retention (Neil et al., 2008; 
Van Damme et al., 2008). Tetherin is a type II integral transmembrane protein which is 
present at the plasma membrane and also at the TGN and recycling compartments. From 
the structural perspective, it consists of a short cytoplasmic tail with a conserved 
dityrosine trafficking motif (YDYCRV), a membrane spaning α-helix and a 
predominantly α-helical luminal domain with a glycosylphosphatidylinositol (GPI) 
membrane anchor at the C-terminal end (Arias et al., 2011; Kupzig et al., 2003). This 
peculiar topology enables tetherin to perform its virion retaining function as part of the 
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innate antiviral immune response. This occurs through the incorporation of one its 
membrane anchors into the membrane of the virion, with a preference to be this the GPI 
anchor (Venkatesh and Bieniasz, 2013), while maintaining the other membrane anchor 
into the plasma membrane of the producer cell (Lehmann et al., 2011; Perez-Caballero 
et al., 2009). HIV-1 Vpu was thought to counteract tetherin by interfering with its 
anterograde transport to the plasma membrane (Dube et al., 2009; Schmidt et al., 2011). 
For this, both proteins directly interact at the TGN through their respective TM domains 
(Dube et al., 2010b; McNatt et al., 2013) with the subsequent sequestration of tetherin at 
this level. This interaction is essential for counteraction and relies on the A10, A14, A18 
and W22 residues of Vpu, which form a hydrophobic rim within the membrane spaning 
region (Skasko et al., 2012; Vigan and Neil, 2010). Subsequently, Vpu mediates 
targeting of tetherin to proteasomal degradation through the endosomal sorting complex 
required for transport (ESCRT) pathway (Janvier et al., 2011). This requires recruitment 
of the β-transducin repeats-containing protein (β-TrCP)-2 subunit of the SCFβ-TrCP-1/2E3 
ubiquitin ligase and therefore the integrity of the conserved diserine β-TrCP-binding 
motif (S52,56) (Douglas et al., 2009; Mitchell et al., 2009). SCFβ-TrCP-1/2E3 ubiquitin 
ligase ultimately mediates direct ubiquitination of tetherin and degradation in the 
lysosomes (Gustin et al., 2012; Tokarev et al., 2011). Vpu-mediated tetherin 
counteraction has been linked to its downregulation form the host cell surface. 
However, tetherin antagonism has been observed in the absence of downregulation 
(Miyagi et al., 2009). Furthermore, β-TrCP recruitment and tetherin degradation can be 
decoupled from the antagonism of tetherin by Vpu (Dube et al., 2010b; Mitchell et al., 
2009; Schmidt et al., 2011; Tervo et al., 2011). The facts that Vpu blocks anterograde 
transport of newly-synthesized tetherin as well as the transport of recycling tetherin 
molecules to the plasma membrane (Dube et al., 2011; Schmidt et al., 2011), that Vpu 
antagonism of tetherin strongly depend on clathrin (Kueck and Neil, 2012; Lau et al., 
2011) and that Vpu can interact with adaptor proteins AP-1 and AP-2 (Jia et al., 2014; 
Kueck et al., 2015), have led to a new mistrafficking model. In this new model Vpu 
mediates sequestration of tetherin at clathrin-rich areas of endosomes at the TGN by 
hijacking AP-1-dependent membrane trafficking where the cellular protein is eventually 
targeted to β-TrCP-dependent degradation. Consistently with this model, it has been 
also reported that Vpu displaces tetherin from virion assembly sites (McNatt et al., 
2013). Recently Pujol et al. have shown that interference with recycling or anterograde 
transport is not sufficient for counteraction of tetherin-mediated restriction by Vpu and 
tetherin displacement from assembly sites is strictly dependent on the tetherin- and AP-
1-binding motifs and correlates to viral particle release antagonism (Pujol et al., 2016). 
Inhibition of AP-1 or a reduction in its expression confirmed these results. In sum, Vpu 
blocks tetherin-mediated viral release restriction by preventing its recruitment to the 
assembly sites of nascent viral particle in an AP-1-dependent manner. 
Besides its virion “trapping” function, tetherin also acts as an innate viral sensor by 
mediating activation of nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) resulting in antiviral gene expression by the host cell (Galao et al., 2012; 
Tokarev et al., 2013). Mechanistically, the sequestration of virions on the surface of the 
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infected cell leads to the formation of tetherin dimer clusters and tyrosine-dependent 
phosphorylation at the cytoplasmic tails. This is the trigger for intracellular signaling 
that proceeds by the recruitment of spleen tyrosine kinase (Syk) and ultimately causes 
activation of NF-κB which is translocated into the nucleus where it induces 
proinflammatory gene expression (Galao et al., 2014). By counteracting virus retention 
on the plasma membrane Vpu avoids tetherin-triggered signaling and immune 
recognition of the infected cells. In addition, it has also been reported that Vpu is able to 
stabilize IκB, the NF-κB regulator which interferes with its translocation, resulting in 
the sequestration of the p65 subunit of NF-κB in the cytoplasm (Sauter et al., 2015). 
HIV however depends on NF-κB activation for viral gene expression and its genome 
contains two NF-κB binding sites at the 5’LTR (Nabel and Baltimore, 1987). Given the 
ability of Nef to induce activation of the transcription factor, it has been proposed that 
Nef acts on NF-κB activity early in the replication cycle promoting its activation and 
viral gene transcription and Vpu inactivates it at late stages to prevent immune detection 
of infected cells (Sauter et al., 2015). 
1.3.2.3 Other Vpu functions: ion channel and proapoptotic factor   
Given the structural similarities between Vpu and the M2 ion channel protein of 
influenza virus, it was hypothesized that homooligomerization of Vpu could result in 
the formation of membrane pores (Maldarelli et al., 1993). Further in vitro 
experimentation with artificial lipid bilayers confirmed that Vpu indeed forms selective 
ion channels for monovalent cations like sodium and potassium (Ewart et al., 1996; 
Schubert et al., 1996). It was thereby suggested that this activity could be required for 
its effects on viral release. Despite a discrete number of in vitro and in vivo studies were 
consistent with this hypothesis (Herrero et al., 2013; Hout et al., 2005; Hsu et al., 2010), 
more recent studies argue against this based on the fact that mutations which disrupt ion 
channel activity (e.g. S23A or S23L) do not affect virus release enhancing and 
mutations that affect virus release (e.g. A14N or A18N) retained ion channel activity 
(Bolduan et al., 2011; Kuhl et al., 2011; Mehnert et al., 2008; Skasko et al., 2011). 
Thus, HIV-1 Vpu possesses a viroporin activity for which a clear biological function 
has yet to be revealed.  
As discussed above, HIV-1 Vpu is able to deregulate NF-κB by preventing 
phosphorylation at serine residues and β-TrCP-dependent subsequent proteasomal 
degradation of its natural inhibitor IκB (Sauter et al., 2015). The consequences of 
inhibiting a central transcription factor such as NF-κB can be very important since it has 
been shown to be involved in the expression of key cellular genes for cell proliferation, 
cytokine induction and apoptosis (Barkett and Gilmore, 1999; Pahl, 1999). 
Consequently, Vpu-mediated inhibition of NF-κB in HIV-1 infected cells potentially 
can play a role in the induction of apoptosis in these cells (Badley et al., 2000; Casella 
et al., 1999). This idea was strongly supported by a study in Jurkat T cells which 
displayed two-fold increase in apoptosis levels when infected with a Vpu-deficient virus 
as compared to wt HIV-1-infected control cells. This effect was dependent on the 
inhibition of NF-κB-dependent expression of antiapoptotic genes such as the Bcl2 
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family proteins resulting in an increase in the levels of the apoptosis-inducer caspase-3               
(Akari et al., 2001).  
1.3.3 Overlap in functions exerted by Nef and Vpu 
Despite of the fact that HIV-1 both factors are very distinct in regard to their sequence, 
structure, organization of their domains and membrane topology, the accessory proteins 
Nef and Vpu carry out redundant functions. As mentioned above, the downmodulation 
of CD4 levels from the plasma membrane is the best example. By doing so, they 
prevent superinfection and premature death of infected cells and optimize viral egress 
and spread (Benson et al., 1993; Michel et al., 2005; Wildum et al., 2006; Willey et al., 
1992b). Both proteins downmodulate other surface receptors and molecules from the 
plasma membrane of infected cells such as MHC-I, CD1d and poliovirus receptor 
(PVR) (Chen et al., 2006; Kerkau et al., 1997; Matusali et al., 2012; Moll et al., 2010; 
Schwartz et al., 1996). A particular case is that of the restriction factor 
tetherin/CD317/BST-2. As described previously, counteraction of the antiviral effect of 
this molecule is a well-described activity of Vpu and it is thought to be the result of the 
displacement form the virion assembly sites (McNatt et al., 2013; Pujol et al., 2016) 
and, at least in part, of a block in the anterograde transport of newly synthesized as well 
as recycling tetherin molecules leading eventually to proteasomal degradation (Douglas 
et al., 2009; Mangeat et al., 2009; Neil et al., 2008). However, recent studies showed 
that in viruses lacking the vpu gene Nef was able to perform such activity (Zhang et al., 
2009). In vpu-deficient viruses tetherin is counteracted by Nef and this activity was 
overtaken by Vpu in those viruses that incorporated the vpu gene. Exceptions to this are 
the HIV-1 precursors SIVcpz and SIVgor which, despite of encoding the Vpu protein, 
express Nef proteins able to counteract tetherin albeit with poor activity (Sauter et al., 
2009). In humans, tetherin is insensitive to Nef due to a 5-aminoacid deletion which 
represents an interspecies transmission barrier (Sauter et al., 2009). Nevertheless, 
likewise SIVcpz and SIVgor Nef proteins, the HIV-1 group O Nefs are able to 
counteract tetherin despite of the expression Vpu by these viruses (Kluge et al., 2014).  
Another function in which both Nef and Vpu play key roles and is also partially linked 
to their ability to downregulate proteins from the cell surface is the evasion of innate 
immune response mediated by natural killer (NK) cells. NK cells as well as other cells 
of the lymphoid lineage namely monocytes and neutrophils posses so called Fc 
receptors on their surface (FcγRIIIa; CD16) which recognize and bind the crystallizable 
(Fc) region of antibodies coating the surface of APCs. Recognition leads to the 
activation of their cytolitic activity and the killing of the antibody-coated APCs. This 
process is commonly known as antibody-dependent cell-mediated cytotoxicity (ADCC) 
(Scully and Alter, 2016). The extent of the ADCC response depends on the antigen 
being recognized by the antibodies coating the APCs (Rolland et al., 2012). Recently, 
gp120-CD4 interactions have been linked to anti-HIV mediated ADCC by NK cells 
(Smalls-Mantey et al., 2013). The interaction facilitates exposure of an epitope in gp120 
which is preferentially recognized by non-neutralizing antibodies which mediate ADCC 
(Bonsignori et al., 2012; Ferrari et al., 2011; Veillette et al., 2014; Wyatt et al., 1995). 
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By downregulating CD4 from the plasma membrane of infected cells, Nef and Vpu 
promote escape from ADCC by NK cells (Pham et al., 2014; Veillette et al., 2014). 
Furthermore, the retention of viral particles on the surface of infected cells mediated by 
tetherin increases the pool of viral antigens exposed to immune recognition favoring 
ADCC. Consistently, Vpu-induced decrease in virion tethering results in a significant 
reduction in Env epitopes exposure and lower NK cell-driven ADCC (Alvarez et al., 
2014; Arias et al., 2014; Pham et al., 2014). Altogether, in the context of HIV-1 
infection ADCC is prevented by two synergistic strategies: CD4 downregulation by Nef 
and Vpu, and tetherin counteraction by Vpu. In addition, Nef and Vpu contribute to NK 
cell-mediated innate response by specifically downregulating NK cell ligands such as 
NK T and B cell antigen (NTBa), PVR and UL16-binding protein involved in the 
activation of these cells (Galaski et al., 2015; Matusali et al., 2012; Shah et al., 2010). 
All in all, HIV-1 Nef and Vpu perform a number of redundant functions directed to 
escape host immune responses. These functions are strongly linked to the ability of both 
accessory proteins to modulate the exposure of a long and largely overlapping list of 
receptors and surface molecules by the infected cells. 
1.4 Tetraspanins (TSPANs)  
The members of the TSPAN superfamily of proteins are present at the plasma 
membrane and intracellular vesicles of virtually all mammalian cells. TSPANs contain 
4 transmembrane domains and have small and large extracellular loops (SEL and LEL, 
respectively) and short N- and C- terminal cytoplasmic tails. The LEL is involved in 
specific protein-protein interactions and the cytoplasmic regions act as linkers to 
cytoskeletal and signaling molecules (Tarrant et al., 2003). TSPANs form 
microstructures at the plasma membrane known as tetraspanin-enriched microdomains 
(TeMs). These structures act as protein scaffolds similar to but biochemically 
distinguishable from lipid rafts (Tarrant et al., 2003). Selective sorting of proteins into 
these microdomains appears to be important for a number of membrane-dependent 
processes to take place such as cell-cell fusion, cell adhesion, cell motility and sorting 
of exosomal proteins, among many others (Hemler, 2003; Levy and Shoham, 2005a, b; 
Perez-Hernandez et al., 2013; Wright et al., 2004; Zoller, 2009). Notably, assembly sites 
of HIV-1 at the plasma membrane of host infected cells selectively localize at TeMs 
(Jolly et al., 2007; Nydegger et al., 2006), likely a consequence of Gag-TSPANs 
interactions (Hogue et al., 2011). Consistently, TeMs also form part of the virological 
synapses (Nydegger et al., 2006; Welsch et al., 2007). As a result of that, TSPANs are 
included in viral particles (Orentas and Hildreth, 1993; Ott, 2008). Other human 
pathogens rely on TSPANs for their replication, i.e. hepatitis C virus (HCV) whose 
main entry cellular receptor is known to be CD81 (Feneant et al., 2014; Pileri et al., 
1998). 
1.5 T cell biology: migration and extracellular vesicle release 
As central players of the immune system, T cells need to communicate with a vast 
spectrum of cells to carry out their defensive function. Direct contact with other cells 
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efficiently help them feel and sense activatory clues and need for immune synergy. 
Thereby, there is a continuous requirement form active migration and covering of long 
distances. Another way to send and receive signals is via a more paracrine, or even 
endocrine, manner which can involve single molecules such as cytokines, hormones or 
growth factors or complex structures like extracellular vesicles. Now the focus falls on 
migration and its main molecular and temporal components and on extracellular vesicle 
release. 
1.5.1 T cell migration   
Continuous migration is a hallmark of T cell function and immune surveillance (Dupre 
et al., 2015; Samstag et al., 2003; Serrador et al., 1999). Already at the earliest phase of 
their life following haematopoiesis, immature T cells or thymocytes need to travel from 
the bone marrow to the thymus where they mature into naïve T cells. During 
maturation, TCR-mediated antigen specificity is achieved and cells with intermediate 
affinity are selected. Once out of the primary lymphoid organs (PLO), naïve T cells are 
constantly migrating between the bloodstream and the secondary lymphoid organs 
(SLO, lymph nodes, spleen, tonsils and Payers patches). The so called T cell homing 
process or migration from the blood to SLO allows for cognate MHC II-antigen 
complex recognition from the surface of APCs by these cells (Figure 1.8C). The 
resulting effector T cells migrate then to the inflammation sites where adaptive immune 
responses are initiated. T cells migrate with high speed reaching 7-10 μm/min, 10 times 
faster than fibroblasts (0.3-1.3 μm/min) (Gudima et al., 1988). The whole process is 
tightly regulated and directed by chemokines sensed through chemokine receptors and 
adhesion molecules on other cells or by the extracellular matrix (ECM) interacting with 
those present on the surface of T lymphocytes. Migrating T cells have morphological 
and functional characteristics reminiscent of amoeba. This migration mode requires 
continuous changes in cell shape and relies on the ability of the cell to polarize which 
subsequently depends on a highly dynamic cytoskeleton (Figure 1.8) (see 1.5.2). 
Amoeboid migration is a multistep process comprising four consecutive events: actin-
driven protrusion, adhesion to the substrate, myosin-based contraction and disassembly 
of adhesive contacts (Ridley et al., 2003; Serrador et al., 1999). T cells can adapt the 
migration mode to the environmental context and stimulus such as chemoattractants, 
share flow and the cellular/matrix density and composition in the tissue as well as to 
their own functional status. These adaptations result in two different types of amoeboid 
migration: a slow migration mode involving strong focal adhesion contacts to the 
substrate observed in 2D ligand-coated surfaces, a model for T cell migration on 
endothelial cell monolayers, or a fast migration mode in which contacts with the 
substrate are more diffuse, used during 3D migration within solid tissues. 2D migration 
is largely integrin-dependent whereas 3D migration involves multiple cell-cell and/or 
cell matrix interactions (Dustin, 1997; Dustin et al., 1992; Friedl and Brocker, 2000; 
Lammermann et al., 2008). T cell can also use a mesenchymal mode of migration 
associated with matrix degradation in which their cell body acquires an elongated 
spindle-like shape showing one or more leading pseudopods at the front.  
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Figure  1.8  Polarization  of  migrating  T  cells.  (A)  Molecular  and  morphological  organization  of  a  polarized  T 
lymphocyte.  (B) Cytoskeletal  fundamental differences are present  in  the actin  cytoskeleton of a polarized T  cell. 
Actin polymerization takes place mainly at the leading edge resulting in a largely branched actin filament network. 
Actin filaments at the uropod are linear and form bundles to which myosin associates to promote rear contraction. 
(C) Lymphocytes scan APCs within the  lymph nodes relying on their migration capacity  in a “stop and go” fashion. 
Polarization is a prerequisite for T cell migration and allows for directed migration leading to sequential encounters 
with APCs. These contacts can last a few minutes in the context of immature IS or be extended in time as in the case 
of a mature IS resulting from cognate antigen recognition. (A) (Vicente‐Manzanares and Sanchez‐Madrid, 2004); (B) 
and (C) (Dupre et al., 2015).  
 
1.5.2 Polarization of migrating T cells 
Acquisition of spatial asymmetry or cellular polarization is a fundamental property of 
most eukaryotic cells and can be permanent, as in the case of an epithelial cell, or 
transitory, as in migrating lymphocytes or fibroblasts). By acquiring a polarized 
morphology, the cell establishes and keeps physically separated and functionally 
differentiated membrane domains (Figure 1.8A). The spatial organization and distinct 
composition of these domains are essential for a number of basic cellular and 
physiological processes such as diverse as cell-cell interaction, vesicle secretion, 
cellular immunity, cell migration, differentiation, development, tissue function and 
morphogenesis.   
In order to migrate, T lymphocytes have to acquire a polarized shape described as a 
“hand-mirror” which permits conversion of mechanical forces into net cell locomotion 
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(Figure 1.8) (Stossel, 1993). Polarization is a complex process in which several 
regulatory pathways integrating spatial and temporal actin cytoskeleton components are 
involved (Gomez-Mouton et al., 2001; Ridley et al., 2003). Two highly specialized 
compartments can be distinguished in a polarized T cell: a leading edge at the front and 
the uropod at the rear (Figure 1.8A) (Friedl and Brocker, 2000; Sanchez-Madrid and del 
Pozo, 1999; Serrador et al., 1999). The formation of two differentiated compartments 
leads to an asymmetrical spatial organization optimal for the establishment of net 
movement associated with the onset of migratory induction. This includes binding to 
and crawling on the endothelium, migration within the ECM, and response to 
chemotactic factors.  
 The leading edge (LE) 
It localizes at the front of the cell (Figure 1.8A). Plasma membrane protrusions 
namely lamellipodia and filopodia emerge here due to high actin polymerization rates 
defining the direction of migration (Figure 1.8B). This compartment is thereby enriched 
in F-actin and actin-binding proteins such as talin, vinculin or α-actinin. Chemokine 
receptors are also concentrated at this end and they direct cell migration by sensing the 
chemotactic gradient (Gomez-Mouton et al., 2001; Nieto et al., 1997). Molecules 
involved in the formation of adhesion contacts such as LFA-1 (αLβ2 integrin) and the 
focal adhesion (FAK) localize to this area of the cell and mediate adhesion of the 
protruded membrane to the substrate (Campanero et al., 1994; Friedl and Brocker, 2000; 
Nieto et al., 1997). 
The proteins N-WASP and WAVE regulate the formation of protrusions at the 
front of a migrating cell. As reviewed above, they act as effectors of small GTPases and 
this subsequently regulate Arp2/3, which ultimately mediates branched actin 
polymerization. However, different small GTPases are involved in generating different 
types of protrusions. Lamellipodia require Rac activity whereas Filopodia are dependent 
on Rho and Cdc42. The supramolecular design of these two types of structures enable 
the cell to perform different functions in relation to migration: by forming lamellipodia 
the cell elongates increases vastly the length of its plasma membrane, while filopodia, 
with paralleled actin bundles starting at the plasma membrane, serve as “sensors” to 
explore the extracellular environment (Figure 1.8A) (Borisy and Svitkina, 2000; Dupre 
et al., 2015; Samstag et al., 2003). Furthermore, focal adhesions contribute to the 
stabilization of actin filaments and require activation of integrins which are recruited to 
the nascent adhesions. Other proteins regulated by Rac like Talin, PKC, Rap1 and PI3K 
are also involved in actin-driven formation of protrusions (Webb et al., 2002).           
 The uropod       
It is a narrow cytoplasmic projection at the trailing edge of the cell (Figure 
1.8A). The motor protein myosin II concentrates here (Campanero et al., 1994; Serrador 
et al., 1997). Dimers of this protein form bipolar filaments which associate with actin 
filaments and generate ATP-dependent motion by pulling two actin filaments against 
each other (Jay et al., 1995; Korn and Hammer, 1988). The intracellular adhesion 
   Introduction 
 
34 
 
molecules (ICAM)-1, -2 and -3, CD43, CD44 and β1 integrins are also polarized to this 
part of the cell (del Pozo et al., 1995; Friedl and Brocker, 2000; Serrador et al., 1997). 
The actin-binding proteins of the ezrin radixin moesin (ERM) family link physically the 
plasma membrane and F-actin (Tsukita and Yonemura, 1999). These proteins activity is 
dependent on phosphorylation at a threonine residue at the C-terminal by Rho as well as 
on PIP2 binding to the N-terminus. When inactivated by dephosphorylation and PIP2 
dissociation, N- and C-termini of proteins of the ERM family interact intramollecularlly 
preventing binding between the plasma membrane and F-actin. As a result, the actin 
cytoskeleton disorganizes what is a pre-requisite for adhesive interactions disassembly 
(Samstag et al., 2003; Tsukita and Yonemura, 1999). In that regard, myosin II has also 
been suggested to be important by promoting break-down of adhesion contacts with the 
substrate by direct application of physical stress which results in disruption of the 
intracellular interaction between integrins and the actin cytoskeleton and/or with their 
extracellular ligands (Cox and Huttenlocher, 1998). 
Thus, polarization enables T cells to acquire the structural organization required to 
perform amoeboid motility. A fundamental characteristic of this migration mode is the 
ability to form protrusions at the leading edge of the cell and not at the uropod (Figure 
1.8B). To spatially coordinate this, small GTPases are essential. Rac largely controls 
leading edge protrusion whereas Rho induces lack of them at the uropod. Cdc42 serves 
as guide to control the overall cellular polarity acquisition process (Bardi et al., 2003; 
Bustelo, 2002; del Pozo et al., 1999; Lee et al., 2004; Ratner et al., 2003). 
1.5.3 Transendothelial migration (TEM) 
As discussed above, migration of T cells throughout the body is essential for 
immunosurveillance and repair of peripheral tissues as well as for efficient immune 
responses against pathogens and tumor cells. This implies frequent crossing of 
endothelial barriers limiting blood vessel walls, a complex multistep process known as 
transendothelial migration (TEM) (Figure 1.9). This is the case for naïve T cells 
migrating from the bloodstream into the lymph nodes across the high endothelial 
venules (HEV) or for effector T cells after recognition of cognate antigen when they 
travel into sites of inflammation. Initially, T cells circulating in the bloodstream 
establish weak, transient interactions with the endothelial cells of the walls of HEV or 
postacapillary venules in the vicinity of an inflamed tissue. These weak interactions 
trigger a process called the leukocyte-adhesion cascade which consists of selectin-
mediated tethering and rolling on the endothelium, integrin activation, subsequent firm 
arrest and crawling and, finally, TEM (Ley et al., 2007; Nourshargh et al., 2010). These 
sequential but overlapping steps are controlled by the integration of chemotactic and 
exit cues, mainly chemokines displayed on the luminal and basolateral sides of the 
endothelium as well as the underlying extravascular tissue and lipid chemoattractants 
(Alon and Shulman, 2011; Rot and von Andrian, 2004). A crucial step for these events 
to take place is the activation of the endothelial cells. There are two modes of 
endothelial activation: a rapid (within minutes) and protein-synthesis-independent 
leading to expression of preformed adhesion molecules on the plasma membrane (e.g. 
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P-selectin), and a slow (within hours) and protein-synthesis-dependent mode which 
involves transcription of trafficking molecules, namely selectins, integrin ligands and 
chemoattractants. This occurs as a result of inflammatory stimuli such as histamine and 
PAF in the case of rapid activation and cytokines in the case of slow activation (e.g. 
interleukin-1β (IL-1β) and tumor necrosis factor (TNF)) (Pober and Sessa, 2007). 
Circulating T cells in the blood are covered with short microvilli. These structures 
contain parallel bundles of highly dynamic actin filaments (Majstoravich et al., 2004). 
The tips of these microvilli is rich in low-affinity adhesion molecules such as L-selectin 
and α4β7 integrin (Stein et al., 1999), whereas molecules that mediate firm arrest, e.g. 
LFA-1, are distributed randomly or excluded from microvilli (Berlin et al., 1995; Bruehl 
et al., 1996). Interaction between lymphocyte glycoproteins (e.g. P-selectin glycoprotein 
ligand (PSGL-1)) on microvilli with P-selectin and E-selectin molecules on the surface 
of endothelial cells results in the formation of reversible interactions mediating not only 
tetherin of lymphocytes on the endothelium (Ley et al., 2007; Zarbock et al., 2011) in 
the collapse of microvilli (Alon and Feigelson, 2002). PSGL-1 on free lymphocytes in 
the bloodstream can bind to L-selectin on attached lymphocytes leading to secondary 
lymphocyte tetherin (Eriksson et al., 2001; Sperandio et al., 2003). Flattening slows 
down rolling and facilitates topographical availability of chemokine receptors and 
integrins. The former recognize endothelium-displayed chemokines which mediates the 
stimulation of GEFs or JAK protein tyrosine kinases and in turn different members of 
the Rho GTPase family leading to inside-out and the activation of integrins on the 
surface of the lymphocyte (Alon and Dustin, 2007; Alon and Feigelson, 2009; Carman 
and Springer, 2003; Ley et al., 2007; Montresor et al., 2013).  Activated lymphocyte 
integrins such as LFA-1, VLA-4 and α4β7 bind to their ligands, e.g. ICAM-1 and 
vascular adhesion molecule (VCAM)-1, inducing lymphocyte arrest (Figure 1.9) 
(Nourshargh and Alon, 2014). Upon arrest, lymphocytes protrude and directly 
translocate their body through the endothelium or crawl in search for exit cues 
(Phillipson et al., 2009). Crawling requires lymphocyte polarization, relies on the 
actomyosin machinery and is chemokine-directed and integrin-dependent (Hyun et al., 
2012; Shulman et al., 2009). TEM can occur through junctions between adjacent 
endothelial cells (paracellular TEM) or through the body of these cells (transcellular 
TEM), being the former the preferred route (Muller, 2011; Nourshargh et al., 2010). 
Both modes are the result of lymphocyte-driven changes in the endothelium such as the 
formation of adhesion platforms including ICAM-1, VCAM-1 and different tetraspanins 
and pentaspanins (e.g. CD9, CD151 or CD47, respectively) (Azcutia et al., 2012). 
Ligation of these molecules by their ligands on lymphocytes induce signaling in the 
endothelial cells leading to reduced endothelial barrier properties such as an increase in 
intracellular Ca2+ (Huang et al., 1993; Pfau et al., 1995), reactive oxygen species 
(ROS) generation (Deem et al., 2007; Martinelli et al., 2009), activation of Src 
(Allingham et al., 2007) or activation of p38 mitogen-activated protein kinase (MAPK) 
(Hu et al., 2000). These events result in the modulation of a number of endothelial 
targets and the reorganization of the cytoskeleton promoting junction opening and 
lymphocyte crossing of the endothelial barrier. VE-cadherin internalization and 
recycling has also been shown to be needed for successful lymphocyte diapedesis 
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(Weber et al., 2007). In the context of effector T cells migrating into inflamed tissues, 
TEM is related to enhanced survival and increased effector functions (Nourshargh et al., 
2010; Stark et al., 2013). Therefore, TEM not only represents a regulated process for 
lymphocytes to home to access damaged or infected tissues but also contributes to 
priming of the extravasated lymphocytes to an efficient immune response performance.   
Figure  1.9  Transendothelial  migration  process.  The  scheme  shows  the most  important  steps  of  this  complex 
process. Most relevant molecules mediating T cell‐endothelial cell interactions are indicated as well as the influence 
of  Nef  on  the  individual  steps  and  the  dependency  on  its  ability  to  disrupt  actin  dynamics.  (von  Andrian  and 
Mempel, 2003) 
 
1.5.4 Extracellular vesicle release 
Cell communication is essential in multicellular organisms. It can take place by direct 
cell-cell contact or via transfer of secreted molecules or more complex cell-derived 
structures such as extracellular vesicles (EV) (Gyorgy et al., 2011). These vesicles are 
produced by most cell types and are present in the extracellular space. According to 
their endosomal or plasma membrane origin, they can be classified as exosomes or 
microvesicles (MVs) (also known as shedding vesicles or ectosomes), respectively 
(Raposo and Stoorvogel, 2013). MVs are very variable in size ranging between 100 and 
1,000 nm in diameter and they are formed by outward budding of the plasma membrane 
upon activation and crosslinking of cell surface receptors or apoptosis and the 
correspondent intracellular Ca2+ increase (Ratajczak et al., 2006b). The release rate of 
MVs in steady state is typically low except for tumor cells which release them 
constantly (Muralidharan-Chari et al., 2010; Raposo and Stoorvogel, 2013). Exosomes, 
on the other hand, are smaller with sizes comparable to those of viruses ranging 
between 50 and 120 nm in diameter. These vesicles are formed by inward budding of 
the membrane of late endosomes resulting in the formation of multivesicular bodies 
(MVBs). MVBs can then follow two different pathways: either they fuse to lysosomes 
for degradation, or they fuse to the plasma membrane to release their content to the 
extracellular space, the so called exosomes (Mittelbrunn and Sanchez-Madrid, 2012; 
Yanez-Mo et al., 2015). Despite of their important role in intercellular communication, 
the overall function of exosomes remains unclear. Though, multiple functions of 
exosomes in immune modulation, tumorigenesis and the propagation of 
neurodegenerative diseases have been described. Nowadays exosomes raise 
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indisputable interest as biomarkers and therapeutic targets (Yanez-Mo et al., 2015). Of 
note, the membrane of both types of EVs displays an array of proteins which are not 
randomly included. Unknown protein sorting mechanisms play a role in the formation 
of these vesicles. However, a difference between them is the fact that MVs contain 
sorted plasma membrane proteins (Cocucci et al., 2007; Moskovich and Fishelson, 
2007), while exosomes contain proteins original form the plasma membrane, the 
endocytic pathway and the cytoplasm (Raposo and Stoorvogel, 2013; Thery et al., 2002; 
Vlassov et al., 2012). The composition of exosomes reflects their endosomal origin 
including proteins involved in the formation of MVBs including ESCRT proteins, 
apoptosis-linked gene 2-interactin protein X (Alix), tumor susceptibility gene 101 
(tsg101), Rab GTPases or tetraspanins such as CD9, CD63 and CD81. In the context of 
T cell biology, exosomes released by these cells have been described to be directed 
specifically to IS-engaged APCs in a polarized fashion and to contain microRNAs 
(miRNA) different from the repertoire present in their producer cells (Choudhuri et al., 
2014; Gutierrez-Vazquez et al., 2013; Mittelbrunn et al., 2011). Immune cell and T cell-
specific proteins have been identified to be enriched in exosomes derived from T cells 
such as TCR/CD3/ζ, MHC-I and –II, LFA-1, CXCR4 or Lck (Blanchard et al., 2002; 
Miguet et al., 2006). Additionally, a new type of vesicles derived from a T cell line was 
described. The so called microvesicle clusters (MCs) differ in the generation mechanism 
with other EVs which consists in the accumulation of small vesicles underneath the 
plasma membrane and the subsequent formation of a large ball-like structure containing 
the small vesicles with the eventual rupture of the plasma membrane limiting this 
structure and release of the small vesicle to the extracellular space (Muratori et al., 
2009).  
1.6 Effects of HIV-1 Nef on T cell biology 
HIV modulates several aspects of T cell biology to its own benefit. Nef seems to be the 
master manipulator leading to such modulation. The following provides a review on 
how Nef affects capital T cell functions such as migration or EV secretion.  
1.6.1 Nef interferes with T cell migration  
Nef potently interferes with T cell migration (Choe et al., 2002; Hrecka et al., 2005; 
Janardhan et al., 2004; Lee et al., 2008; Nobile et al., 2010; Park and He, 2009; Stolp et 
al., 2010; Stolp et al., 2009). As in most other Nef-mediated effects, T cell migration 
impairment has been linked to Nef-mediated downregulation of membrane receptors 
and adhesion molecules. Nef reduces surface expression levels of several chemokine 
receptors including CCR1, CCR2, CCR3, CCR4, CCR5, CXCR1, CXCR2 and CXCR4 
(Chandrasekaran et al., 2014; Hrecka et al., 2005; Michel et al., 2005; Michel et al., 
2006; Zaitseva et al., 2003). Despite marginal Nef-mediated downregulation of CCR7, a 
receptor involved in sensing of the chemokines CCL19 and CCL21 expressed by 
reticular stromal cells in lymphoid organs and required to direct T cell migration within 
them, it has been reported that Vpu reduces surface levels of this molecule contributing 
to Nef-induced overall migration defect (Ramirez et al., 2014). The effects of Nef on T 
cell migration however do not depend on CCR downregulation. Nef inhibits T cell 
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chemotaxis in vitro as reflected from transwell assays in which Nef-expressing cells 
migrate with significantly reduced frequency through filter pores towards a 
chemoattractant such as SDF-1α (Choe et al., 2002; Park and He, 2009; Stolp et al., 
2010; Stolp et al., 2009). From a molecular point of view, Nef effects on chemotaxis 
and migration rely on its ability to disrupt actin cytoskeleton by interacting with PAK-2 
and inducing substrate specificity change towards cofilin. Dependency on this 
molecular mechanism has been shown not only in vitro but also in complex in vivo 
experimental settings, such as migration of Nef-expressing primordial germ cells in 
zebra fish (Stolp and Fackler, 2011; Stolp et al., 2009) or homing of Nef-expressing T 
lymphocytes in mice models (Fujii et al., 2011; Stolp et al., 2012). Nef has been shown 
to impair T cell homing by strongly reducing the capacity of Nef-expressing T 
lymphocytes to migrate across HEVs in vivo using intravital 2-photon microscopy 
(Stolp et al., 2012). Influence of Nef on TEM was then assessed in vitro using an 
experimental system that incorporated primary endothelial murine cells as well as 
controlled shear flow. Transmigration across the endothelium of murine T cells 
expressing Nef was notably reduced when compared to control cells. In addition, 
dependency on the PAK-2 binding motif of Nef and, thereby, on impairment of actin 
cytoskeleton rearrangements by Nef was required for all TEM steps affected except 
diapedesis (Stolp et al., 2012). Nef-mediated block of TEM thereby relies on other, 
uncharacterized interaction motif of Nef. Furthermore, Nef as well as Vpu have been 
also described to induce downmodulation of L-selectin (CD62L), a molecule involved 
in T lymphocyte tethering and rolling leading to TEM by interacting to its ligands of 
endothelial cells at HEVs (e.g. GlyCAM-1 or CD34) or other lymphocytes (e.g. PSGL-
1) (Haller et al., 2014; Stolp et al., 2012; Vassena et al., 2015). The Nef-mediated 
interference with T cell migration was observed already at the early stage of 
polarization. Park and He described a defect polarization in Jurkat T cells on a 2D 
system consisting of anti-LFA-1-coated surfaces linked to expression of Nef which 
correlated to impaired chemotaxis and impaired migration through primary endothelial 
cells towards a chemoattractant (Park and He, 2009). Consistently, Stolp et al. observed 
a block in polarization of Nef-expressing murine T cells upon adherence to a primary 
endothelial cell monolayer under shear flow, a system which resembles better a 
physiologically relevant environment for T lymphocytes (Stolp et al., 2012). In this 
context, the inability of Nef-expressing cells to polarize correlated to the lack of 
locomotion on the endothelium and absence of diapedesis events. Of note, the block in 
polarization was also observed upon plating these cells on fibronectin-coated surfaces 
and stimulation with Sdf-1α (Stolp et al., 2012). Remarkably, Nef also inhibits the 
amoeboid motility of macrophages while it enhances the mesenchymal migration of 
these cells, a migration mode that relies on matrix degradation (Verollet et al., 2015).    
1.6.2 Nef induces EV secretion in T cells  
Across evolution EV biogenesis and release pathways have been modulated and 
exploited by various pathogens like viruses providing a potential escape mechanism 
from the host immune response. Studies with retroviruses showed that viruses are able 
to hijack the cellular machinery involved in EV generation for the budding of the viral 
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progeny (Schorey and Bhatnagar, 2008). HIV-1 Nef has been reported to induce 
alterations within the endosomal compartment and to increase endosome, lysosome and 
late endosome/MVB formation (Campbell et al., 2008; Sandrin and Cosset, 2006; 
Schwartz et al., 1995a). Muratori et al. described a Nef-mediated induction of EV 
release and the self-incorporation of the viral factor in these vesicles with the 
subsequent delivery to bystander cells (Muratori et al., 2009). These authors postulate 
the evolutionary advantage of Nef-delivered on exosomes to potentially increase 
detrimental bystander effects on non-infected cells as well as the induction of viral 
particle release. Lenassi et al. could also observe Nef incorporation into EVs derived 
from infected or Nef-expressing immortalized and primary T cells reported and that 
these Nef-containing EVs promoted apoptotic death of bystander cells (Lenassi et al., 
2010). Consistently, Nef-containing exosomes were detected in the cultures of HIV-1 
infected cells and the plasma of infected patients (Ali et al., 2010; Campbell et al., 2008; 
Raymond et al., 2011). Further investigation showed that Nef induces the release of 
TACE (ADAM-17)/ADAM-10 containing EVs through an intricate mechanism 
regulated by paxillin which leads to secretion of TNF-α in cells taking up those 
exosomes. Ultimately, TNF-α secretion is supposed to promote HIV-1 replication in 
infected cells (Lee et al., 2013).  Extensive mutagenesis analysis revealed a conserved 
motif (VGFPV 66-70) whose integrity is required for Nef-induced EV secretion in 
immortalized T cell lines transfected for expression of Nef, namely the secretion 
modification region (SMR) (Ali et al., 2010). This motif forms a binding pocket that 
facilitates interaction with mortalin, an event suggested to be part of the molecular 
mechanism underlying Nef-induced EV secretion (Shelton et al., 2012). Unlike what 
was observed for isolated expression of Nef, mutation in the SMR did not abrogate Nef-
induced EV secretion in infected T cell line cultures or humanized mice. However, 
apoptosis and CD4 T cell depletion were reduced, respectively (Konadu et al., 2015). In 
addition, humanized mice infected with the virus bearing the SMR Nef mutant 
displayed decreased cytokine production as compared to those infected with wt Nef 
encoding virus. Nef-containing exosomes also contain several endogenous retroviral 
RNA sequences, e.g. transactivation response element miRNA (Narayanan et al., 2013). 
Finally, the biological relevance of Nef-induced EV release has been highlighted by 
studies that found not only that these vesicles can render resting CD4 T cells permissive 
to HIV-1 infection (Arenaccio et al., 2014) but also that they are able to reactivate the 
latent provirus in a TACE-dependent manner (Arenaccio et al., 2015). 
1.7 Aims of the study 
The work presented in this thesis is divided in two parts. A minor project focuses on the 
study of HIV-1 Nef and Vpu redundant functions. The second part corresponds to the 
main PhD project and investigates the effects of these two proteins on T cell polarity in 
the context of T cell migration. 
1.7.1 Overlapping functions of Nef and Vpu 
Proteins of the TSPANs superfamily have been described to be involved in the 
replication cycle of HIV, conforming platforms for virion assembly and budding 
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(Nydegger et al., 2006). Recent work of our lab has identified members of the TSPAN 
family of proteins as specific targets for cell surface downregulation by Nef and Vpu 
(Haller et al., 2014). The mechanism by which this process takes place remains largely 
unidentified. Interestingly, Nef and Vpu share a number of redundant functions, many 
of them related to downregulation of host cell receptors and surface molecules. Of note, 
no comparative studies have been performed on the interference in host cell trafficking 
by these two viral factors, e.g. the transport of the host kinase Lck. In addition, it has 
been described that HIV-1 Nef stimulates the secretion of exosomes in Nef-expressing 
cells and in infected primary T cells (Lenassi et al., 2010; Muratori et al., 2009). 
Importantly, nothing was known regarding the effects of Vpu on exosome release at the 
time this project started. This minor thesis project aimed to provide an answer to the 
following questions: 
 Which are the determinants involved in the mechanism of downregulation of 
TSPANS by Nef and Vpu?  
 Are there other not yet defined shared functions between Nef and Vpu? More 
specifically: 
o Is Vpu able to block anterograde transport of the host kinase Lck? 
o Is Vpu able to enhance EV release and to induce its own incorporation 
into EVs? 
 Does the effect of Nef on EV release account for the mechanism of TSPAN 
downregulation from the cell surface? Could this be the case for Vpu as well?   
1.7.2 Effects of Nef on T cell polarization and TEM 
In the most recent work of our laboratory concerning Nef-mediated T cell migration 
impairment, Stolp et al. described that in vivo and ex vivo the predominant inhibition of 
murine CD4+ T lymphocytes by Nef is at the level of transmigration through endothelial 
monolayers as well as subsequent subendothelial migration (Stolp et al., 2012). While 
the inhibition of subendothelial migration is mediated via the effects of Nef on actin 
dynamics, Nef effects on transmigration involve other, yet uncharacterized protein 
interactions. Notably, the inability to transmigrate of Nef-expressing cells was 
paralleled by a marked reduction of cell polarization. This results however have not 
been yet confirmed for human cells. In this context, we hypothesize that the impairment 
of T cell polarity mediated by Nef determines the observed defect in TEM, more 
specifically in diapedesis. This main thesis project aims at testing this hypothesis and, 
more concretely, at finding an answer to these questions: 
 Does the Nef-mediated loss of polarity seen on transduced murine T cells also 
occur in primary human T cells in the context of infection? 
 Is this effect conserved among lentiviral Nef proteins? 
 Which are the molecular determinants of Nef involved in this activity, others 
than those responsible for actin rearrangements disruption? 
 Which is the mechanism by which Nef disrupts T cell polarity and the relevance 
of it in the frame of HIV-1 infection? 
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 What is the contribution of the disruption in polarity on the ability of T cells to 
migrate through the endothelium? 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals and reagents 
Name  Company 
Acrylamide Rothipherese Gel 40 Roth 
Agarose NEEO Roth 
Ampicillin Roth 
Anti-CD3 containing OKT3 hybridoma supernatant Kindly provided by Andrea Imle 
BEZ235 Synkinase 
BSA 100x NEB 
Calcium Chloride Sigma Aldrich 
CCL-21 Peprotech 
Cell Tracker Blue CMAC Thermo Fisher 
Cell Tracker Green CMFDA Thermo Fisher 
Cell Tracker Orange CMRA Thermo Fisher 
ColorPlus Prestained Protein Marker (7–175 kDa) New England Biolabs 
Compensation beads BD 
ConcavalinA Sigma Aldrich 
Dabrafenib SelleckChem 
DNA ladder 1kb Plus Life Technologies 
dNTP Set Fermentas 
ECL (supersignal west pico/femto) Pierce Biotechologies 
Gelatin Merck  
GFP-trap beads chromotek 
Glutamin Gibco 
Gö6983 Santa Cruz 
HBSS Sigma Aldrich 
High concentration rat Collagen I BD/Corning 
Hoechst 33258 Life Technologies 
Imatinib/Gleevec SelleckChem 
IL-2 Biomol 
IPA3 Sigma 
JetPei Peqlab 
Kanamycin Roth 
Linmount Linearis 
Luciferase Assay Substrate Promega 
Lysisbuffer for cell culture for Luciferase assay 5x Promega 
LY294002 (SF1126) Synkinase 
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Matrigel BD Biosciences/Corning 
Magnesium Chloride Hexahydrate  Merck Millipore 
MK-2206 Synkinase 
Mowiol 4-88 reagent Merck Millipore 
Midori Green Advance Nippon genetics 
Pei Sigma Aldrich 
Penicillin, Streptomycin Sigma Aldrich 
Phalloidin-TRITC Sigma Aldrich 
PIR3.5 Santa Cruz 
PKH 26 Sigma Aldrich 
PMSF Sigma Aldrich 
Polybrene Sigma Aldrich 
Poly-L-Lysine (0.01% solution) Sigma Aldrich 
Powdered milk Roth 
PP2 SelleckChem 
Protease inhibitor cocktail Sigma Aldrich 
Puromycin Sigma Aldrich 
RNAse Inhibitor, Ribolock Fermentas 
RiboLock RNase Inhibitor Thermo Scientific 
Rottlerin Santa Cruz 
SDF-1α, human (CXCL12) Peprotech 
Sorafenib Synkinase 
Sunitinib Synkinase 
SYBR Green Invitrogen 
TEMED Roth 
TMB Serva 
TNF-a  R&D 
Total Exosome Isolation (from cell culture) Reagent Invitrogen 
Trametinib (GSK1120212) Synkinase 
Tris Roth 
Triton x-100 Merck Millipore 
Trytan Blue Life Technologies 
Vemurafenib Synkinase 
β-Mercaptoethanol Sigma Aldrich 
X-Gal Thermo Scientific 
1 Kb plus DNA ladder  Life technologies 
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2.1.2 Buffers and solutions 
Name  Component  Concentration 
Blotting buffer  TrisHCl, pH 8.8 19 mM 
 SDS 0.1% (w/v) 
 Glycine 192 mM 
 Methanol 20% (v/v) 
Carbonate solution Na2CO3 0.2 M (2.2 g) 
 destilled H20 100ml 
Bicarbonate solution NaHCO3 0.2 M (1.68 g) 
 destilled H20 100 ml 
Carbonate/bicarbonate tampon buffer (pH 9.2) Carbonate solution 4 ml 
 Bicarbonate solution 46 ml 
 destilled H20 up to 200 ml 
DNA loading buffer TrisHCl, pH 7.5 50 mM 
 EDTA 50 mM 
 Glyerol 50% (v/v) 
 Bromophenol blue 0.25% (w/v) 
KEB lysis buffer  EDTA 2 mM 
 Glycerol 10% (v/v) 
 NP-40 0,5% (v/v) 
 NaCl 137 mM 
 TrisHCl, pH 8 50 mM 
MACS Buffer PBS 1x 
 EDTA 2 mM 
 inact. FBS 0.5% (v/v) 
3x Non-reducing sample buffer (SDS-PAGE) TrisHCL, pH 6.8 125 mM 
 SDS 2% (w/v) 
 Glycerin 10% (w/v)  
 Bromophenol blue 2% (w/v) 
10x PBS PBS Dulbecco (Biochrom), pH 7.4  1 pkg/l 
1x PBST Tween 20 in 1x PBS  0.1% (v/v) 
3% PFA paraformaldehyde in 1x PBS 3% (w/v) 
Ponceau Acetic Acid 5% (v/v) 
 Ponceau S Red 0.2% (w/v) 
RIPA Buffer Tris-HCl, pH 8 50 mM 
 NaCl 150 mM 
 SDS 0.1% (w/v) 
 Natrium deoxycholate 0.5% (w/v) 
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 Triton-X 100 1% (v/v) 
 Protease inhibitors cocktail 1:1000 
Running buffer (SDS-PAGE) TrisHCl 19 mM 
 SDS 0.1% (w/v) 
 Glycine 192 mM 
6x Sample buffer (SDS-PAGE) TrisHCl, pH 6.8 390 mM 
 SDS 10% (w/v) 
 β-Mercaptoethanol 30% (v/v) 
 Glycerol 30% (v/v) 
 Bromophenol blue tip of spatula 
4x Separating gel stock solution, pH 8.8 Tris 1.5 M 
 SDS 0.4% (w/v) 
Stacking gel stock solution, pH 6.8 Tris 0.6 M 
 SDS 0.4% (w/v) 
20% sucrose solution sucrose in 1x PBS  20% (w/v) 
   
SG-PERT 10x PCR buffer Tris-HCl, pH 8.0 50 mM 
 KCl 200 mM 
 (NH4)2SO4 200 mM 
SG-PERT 2x lysis buffer   Tris-HCL, pH 7.4 100 mM 
 KCl  50 mM 
 Glycerol  40% 
 Triton-X100  0.25% 
SG-PERT 2x reaction buffer 1x PCR buffer MgCl2  10 mM 
 2x BSA  
 dNTP  400 μM 
 Forward primer  1:00 PM 
 Reverse primer  1 pM 
 MS2 RNA  8 ng 
 SYBR Green  1:10000 
50x TAE buffer, pH 8.3  Tris 2 M 
 EDTA 0.1 M 
 NaAc 1 M 
β-Gal solution Ferrocyanide 3 mM 
 MgCl2 1 mM 
 PBS 1x 
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2.1.3 SDS-PAGE gel 
 10% Separating gel  Stacking gel  
SDS Seperating Gel stock  1 ml  -  
SDS Stacking Gel stock  -  0.3 ml  
H2O  1.7 ml  0.8 ml  
30% Acrylamide  1.3 ml  200 μl  
10% APS  13 μl  8 μl  
TEMED  6 μl  3 μl  
 
2.1.4 Antibodies 
Antibody Company/Source Technique Dilution 
APC mouse anti-human CD317  Biolegend  FACS 1:40 
APC mouse anti-human CD4   BD Biosciences FACS 1:30 
APC mouse anti-human HLA-ABC  BD Biosciences  FACS 1:20 
APC Mouse anti-human PECAM-1, CD31 eBiosciences FACS 1:20 
FITC Mouse anti-human E-Selectin, 
CD62E   
eBiosciences FACS 1:20 
FITC Mouse anti-human ICAM-1, CD54 Immunotools FACS 1:20 
FITC Mouse anti-human VCAM-1, 
CD106 
eBiosciences FACS 1:20 
Goat anti-Ezrin Santa Cruz IF 1:500 
Goat anti-mouse IgG, Fc Fragment Jackson 
ImmunoResearch  
(Dianova) 
Activating Surface 
(Coat) 
1:1000 
Goat anti-Talin Santa Cruz IF 1:1000 
mouse-anti-CA (183) kindly provided by  
Hans-Georg Kräusslich 
ELISA 1:1000 
Mouse anti-Calnexin Santa Cruz WB 1:2000 
Mouse anti-HIV-1 p24CA  Kindly provided by  
Hans-Georg Kräusslich 
ELISA 1:1000 
Mouse anti-HLA-DR-Brilliant Violet 510 
(L243) 
Biolegend FACS 1:20 
Mouse anti-Hsc70 Santa Cruz WB 1:4000 
Mouse anti-human CD37 BD Biosciences FACS 1:5 
Mouse anti-human CD53 BD Biosciences FACS 1:5 
Mouse anti-human CD63 BD Biosciences WB 1:1000 
  FACS 1:5 
Mouse anti-human CD81 BD Biosciences WB 1:1000 
  FACS 1:5 
Mouse anti-human E-Cadherin Invitrogen IF 1:24 
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Mouse anti-human Occludin Invitrogen IF 1:24 
Mouse anti-human-CD28 BD Biosciences Activating Surface 
(Coat) 
1:1000 
Mouse anti-human-CD3  BD Biosciences Activating Surface 
(Coat) 
1:1000 
Mouse anti-human Lck  Santa Cruz IF 1:50 
Mouse α-TfR (monoclonal)  ZYMED Laboratories IF 1:1000 
Rabbit anti-HIV-1 CA Kindly provided by  
Hans-Georg Kräusslich 
IF 1:200 
Rabbit anti-human Claudin-1 Invitrogen IF 1:24 
Rabbit anti-human ZO-1 Invitrogen IF 1:12 
Rabbit anti-PKCδ  Santa Cruz IF 1:20 
Rabbit anti-Vpu (polyclonal)   FabGennix Inc. WB 1:1000 
Rat anti-CD44  Biolegend IF 1:800 
Rat anti-GFP (monoclonal)  Chromotek WB 1:1000 
Secondary antibodies fluorophore-coupled 
(Alexa Fluor dyes) 
Molecular Probes 
(Invitrogen) 
IF 1:2000 
Secondary antibodies horseradish 
peroxidase-coupled 
Jackson 
ImmunoResearch  
(Dianova) 
WB 1:5000 
  FACS 1:200 
Sheep anti-HIV-1 p24CA   Kindly provided by  
Barbara Müller 
WB 1:5000 
Sheep anti-Nef (polyclonal)  NIBSC Center for AIDS WB 1:2000 
 
2.1.5 Enzymes 
Name  Company 
Alkaline Phosphatase, Calf Intestinal (CIP) New England Biolabs 
GoTaq Hot Start DNA Polymerase Promega 
Pfu Polymerase Promega 
Phusion High Fidelity DNA Polymerase New England Biolabs 
Restriction Endonucleases New England Biolabs 
T4 DNA Ligase New England Biolabs 
T4 Polynucleotide Kinase  New England Biolabs 
 
2.1.6 Plasmids 
Plasmid Description Source 
GFP (pEGFP-N1) CMV driven GFP expression, used for cloning of 
GFP fusion proteins 
Clontech 
pAdVAntage Expression enhancer plasmid Promega 
pDisplay.YFP yfp was cloned into pDisplay via BglII+Klenow and Kindly provided 
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SalI (pDisplay) or  
NcoI+Klenow and SalI (yfp insert); YFP is 
expressed on the cell surface 
by Barbara Müller 
pNL4.3 IRES.pDisplay.YFP XhoI site and NcoI site were removed in 
pDisplay.YFP by Quik-Change PCR, amplified 
fragment was interted into pNL4.3 IRES.GFP by 
NcoI and XmaI 
Kindly provided 
by Andrea Imle 
pNL4.3 HIV-1 SF2 Nef wt 
IRES.pDisplay.YFP 
Insertion a Mlu I site at 3' of nef from pNL4.3 SF2 
Nef, amplified  
fragment was interted into pNL4.3 
IRES.pDisplay.YFP by HpaI and MluI 
This work 
pNL4.3 HIV-1 ΔNef 
IRES.pDisplay.YFP 
XhoI site and NcoI site were removed in 
Display.YFP by Quik-Change PCR, amplified  
fragment was interted into pNL4.3 ΔNef IRES.GFP 
by NcoI and XmaI 
Kindly provided 
by Andrea Imle 
pNL4.3 HIV-1 SF2 Nef 
Δ12-39.wt 
IRES.pDisplay.YFP 
Sewing PCR Using Hpa-I and Mlu-I on a pNL4.3 
HIV-1 SF2 Nef.wt IRES.pDisplay.YFP to insert  
SF2 Δ12-39 Nef 
This work 
pNL4.3 HIV-1 SF2 Nef 
AXXA IRES.pDisplay.YFP 
Insertion a Mlu I site at 3' of nef from pNL4.3 SF2 
Nef AXXA, amplified  
fragment was interted into pNL4.3 
IRES.pDisplay.YFP by HpaI and MluI 
This work 
pNL4.3 HIV-1 SF2 Nef 
F195I IRES.pDisplay.YFP 
Insertion a Mlu I site at 3' of nef from pNL4.3 SF2 
Nef F195I, amplified  
fragment was interted into pNL4.3 
IRES.pDisplay.YFP by HpaI and MluI 
This work 
pNL4.3 SF2 Nef proviral vector expressing SF2 Nef. Standard 
proviral vector for HIV-1 infections 
Fackler lab, 
(Fackler et al., 
2006) 
pNL4.3 SF2 ΔNef proviral vector not expressing Nef due to the 
presence of two stop codons at the Nef ORF 
Kindly provided 
by Frank Kirchoff 
pNL4.3 SF2 Δvpu proviral vector not expressing Nef due to the 
presence of two stop codons at the Vpu ORF 
Kindly provided 
by Frank Kirchoff 
pNL4.3 SF2 ΔNefΔVpu  proviral vector neither expressing Nef nor Vpu due 
to the presence of stop codons at the  
respective ORFs 
Kindly provided 
by Frank Kirchoff 
pNL4.3 SF2 Δ12-39 Nef  proviral vector expressing SF2 Nef mutant Fackler lab, 
(Fackler et al., 
2006) 
pNL4.3 SF2 F195A Nef proviral vector expressing SF2 Nef mutant Fackler lab, 
(Fackler et al., 
2006) 
SF2 Nef.GFP (wt) Standard Nef allele used, expression of Nef fusion 
proteins by cloning HIV-1 SF2 nef into  
pEGFP-N1 via BglII and EcoRI 
Fackler lab, 
(Fackler et al., 
1999) 
SF2 Nef.GFP Δ12-39 SF2 Nef mutant fused to GFP Fackler lab, 
(Michel et al., 
2005) 
SF2 Nef.GFP AxxA SF2 Nef mutant fused to GFP Fackler lab, 
(Michel et al., 
2005) 
SF2 Nef.GFP E4A4 SF2 Nef mutant fused to GFP Fackler lab, 
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(Michel et al., 
2005) 
SF2 Nef.GFP EDAA SF2 Nef mutant fused to GFP Fackler lab, 
(Michel et al., 
2005) 
SF2 Nef.GFP Δ12-
39.F195A  
SF2 Nef double mutant fused to GFP This work 
SF2 Nef.GFP F195A SF2 Nef mutant fused to GFP Fackler lab, 
(Michel et al., 
2005) 
SF2 Nef.GFP G2A SF2 Nef mutant fused to GFP Fackler lab, 
(Michel et al., 
2005) 
SF2 Nef.GFP LLAA SF2 Nef mutant fused to GFP Fackler lab, 
(Michel et al., 
2005) 
SF2 Nef.GFP VGFAAA SF2 Nef mutant fused to GFP Fackler lab, 
(Michel et al., 
2005) 
SF2 Nef.GFP S6A SF2 Nef mutant fused to GFP (Wolf et al., 2008) 
SF2 Nef.GFP M20A SF2 Nef mutant fused to GFP (Chaudhry et al., 
2005) 
HIV-1 NL4.3.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
HIV-1 NA7.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
HIV-1 8161K9.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
HIV-1 YBF30.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
HIV-2 Ben.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
HIV-2 Cbl23.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV cpz Gab2 Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV cpz Tan3 Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV mac239 Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV gsn Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
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al., 2006) 
SIV mon Val Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV Ben Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV blue Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV blue Nef.YFP RRAA SIV blue Nef mutant fused to YFP (Rudolph et al., 
2009) 
SIV blue Nef.YFP R129A SIV blue Nef mutant fused to YFP (Rudolph et al., 
2009) 
SIV blue Nef.YFP ELAA SIV blue Nef mutant fused to YFP (Rudolph et al., 
2009) 
SIV smm Fwr 1 Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV smm Ffm 1 Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV agm Sab Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV agm Tan 1 Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SIV sykes 51 Nef.YFP Expression of Nef.YFP fusion protein (Rudolph et al., 
2009; Schindler et 
al., 2006) 
SrcN18.GFP Expression of N-terminal 18 aa of Src fused to GFP 
protein  
Fackler Lab (Pan 
et al., 2013) 
syn Vpu.GFP (wt) Standard Vpu allele used, expression of Vpu fusion 
proteins by cloning syn vpu into  
pEGFP-N1 via EcoRI and BamHI 
(Tervo et al., 
2011) 
syn Vpu.GFP S52/56A syn Vpu mutant fused to GFP Fackler Lab 
syn Vpu.GFP A14LW22A syn Vpu mutant fused to GFP Fackler Lab 
syn Vpu.GFP V25Y29G syn Vpu mutant fused to GFP Fackler Lab 
syn Vpu.GFP R30K31A syn Vpu mutant fused to GFP Fackler Lab 
syn Vpu.GFP TM VSV-G syn Vpu mutant fused to GFP This work, (Haller 
et al., 2014) 
Lck.GFP Expression of Lck fusion protein by cloning lck into 
pEGFP-N1  
Fackler Lab (Pan 
et al., 2012) 
 
2.1.7 Primers 
Description Primer Sequence 5'->3' 
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Cloning SF2 Nef and Δ12-39, AXXA and F195I mutants 
into pNL4.3 IRES.pDisplay.YFP 
Fwd ctaaagaatagtgctgttaacttgctcaatgcc 
 Rev gtactacaaagactgctgaacgcgtcggatc 
 
2.1.8 Kits 
Name Source 
μMACS GFP Isolation Kit Miltenyi Biotec 
CD4 isolation kit Miltenyi Biotec 
CD8 isolation kit Miltenyi Biotec 
Detach Kit for Endothelial Cells  PromoCell 
NucleoBond PC 500 Macherey-Nagel 
NucleoSpin Gel and PCR Clean-up Macherey-Nagel 
NucleoSpin Plasmid Macherey-Nagel 
Pierce BCA protein assay  Thermo Scientific 
Pierce microBCA protein assay  Thermo Scientific 
QIAfilter Plasmid Midi Kit Qiagen 
 
2.1.9 Bacterial culture media 
Name Component Concentration/Quantity Comments 
LB NaCl 86 mM add H2O and adjust to pH 7.2, autoclave 
 Tryptone 0.5% (w/v)  
 Yeast 
extract 
1% (w/v)  
LB agar 
plates 
agar 1.25% add when warm into plastic petri dishes 
 LB   
TB    
Solution A glycerine 4 ml autoclave solutions separately and then mix 
when <60°C 
 H2O 900 ml  
 Trypton 12 g  
 Yeast 
extract 
24 g  
Solution B H2O 100 ml  
 K2HPO4 12.5 g  
 KH2PO4 2.3 g  
 
2.1.10 Bacterial strains 
E. coli Genotype Company 
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strain 
Stble2 F– mcrA Δ(mcrBC-hsdRMS-mrr) recA1 endA1 lon gyrA96 thi supE44 
relA1 λ– Δ(lac-proAB) 
Life 
technologies 
DH5-α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
Life 
technologies 
 
2.1.11 Cell culture media 
Cell line/type Components 
Adherent cell lines  DMEM (Gibco) 
 FCS 10% (v/v) (Biochrom) 
 Penicillin (100 U/ml) 
 Streptomycin (100 μg/ml) 
Suspension cell lines (except CCR7)  RPMI 1640 (Gibco) 
 FBS 10% (v/v) 
 Penicillin (100 U/ml) 
 Streptomycin (100 μg/ml) 
CCR7  DMEM  
 FBS 10% (v/v) 
 Penicillin (100 U/ml) 
 Streptomycin (100 μg/ml) 
 2 mM glutamine 
 10 mM HEPES (pH 7.4) 
 1 mM sodium pyruvate 
 1x NEAA (Life Technologies) 
 45.76 μM β-Mercaptoethanol 
Cell freezing medium 90% (v/v) FBS  
 10% (v/v) DMSO 
HUVECs Basal Endothelial Cell Growth Medium (PromoCell) 
 EGCM supplement mix 1 or 2 (PromoCell) 
Cryo-SFM Medium (for endothelial cells) PromoCell 
 
2.1.12 Eukaryotic cell lines 
Cell line  Description Reference 
Jurkat TAg  Acute T cell leukemia-derived 
cell line expressing the SV40 
large T antigen 
(Northrop et al., 1993) 
Jurkat CCR7  Acute T cell leukemia-derived 
cell line stably transfected with 
CCR7 
(Ott et al., 2004) 
Jurkat E6.1  Acute T cell leukemia-derived (Weiss et al., 1984) 
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cell line, IL-2 producing  
A3.01  Acute lymphoblastic leukemia-
derived  
(Folks et al., 1985) 
HeLa TZM-bl  Human cervical epithelial cancer 
cell line, HeLa derivative; 
contains HIV-1 Tat-regulated 
luciferase and ß-galactosidase 
reporter genes 
(Wei et al., 2002) 
HEK 293T  Human embryonic kidney cells 
expressing the SV40 large T 
antigen  
(Pear et al., 1993) 
 
2.1.13 Primary cells 
Name  Source/Company 
Human Peripheral Blood Mononuclear 
Cells (PBMCs) 
Buffy Coats obtained form the Heidelberg University 
Hospital Blood Bank 
Human Lymphocytes 
Buffy Coats obtained form the Heidelberg University 
Hospital Blood Bank 
Human Umbilical Vein Endothelial Cells PromoCell 
 
2.1.14 Cell migration media 
Medium Components 
MAM HEPES 
 FCS 
 Glutamin 
Binding Medium HBSS cation free  
 HEPES 
 BSA 
 Ca2+ 
 Mg2+ 
 
2.1.15 Consumables 
Name Company 
μ-dish 50 mm, low (uncoated) Ibidi 
6-, 12-, 48-, 96-well plates (tissue culture)  BD Biosciences 
24-well plate Orange Scientific 
96-well U bottom Orange Scientific 
96-well V bottom BD 
Falcon Conical Tubes 15 and 50 ml  BD Biosciences  
Cellview Cell Culture Dishes, Glass Bottom 
(4 compartments) Greiner bio-one 
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Conical Tubes 50 ml Orange Scientific 
Counting chamber  Neubauer-improved Marienfeld-Superior 
Cover glasses  Thermo Scientific 
Cryotubes 1.5 and 2 ml  Greiner bio-one 
Electroporation cuvettes 0.4 cm  Life Technologies 
F 96 Maxisorb plate Nunc 
LS column Miltenyi Biotec 
LucentBlue X-ray film  Advansta 
Microscope slides  Marienfeld-Superior 
PCR tubes 0.2 ml Sarstedt 
PCR 8er SoftStrips 0.2 ml  Biozym Scientific GmbH 
Protran BA85 Nitrocellulose Membrane GE Healthcare Life Science 
Reaction tubes 1.5ml  Sarstedt 
Syringe Driven Filter unit 0.22, 0.45 μm  Merck Millipore 
Tissue culture dishes 15 cm Orange Scientific 
Tissue culture flasks T25, T75, T175  BD Biosciences 
Transwell filter 3 μm Corning 
Transwell filter 5 μm Corning 
Tubes for Micro-Rack-System 1.2 ml (FACS) Steinbrenner Laborsysteme 
Whatman blotting paper  GE Healthcare Life Sciences 
White plates 96 well Costar 
 
2.1.16 Equipment  
Name Company 
AutoMACS Pro Seperator Miltenyi Biotec 
Balance (Explorer) Ohaus 
Biofuge Fresco Table top centrifuge Heraeus 
CFX 96 Real Time PCR detector BioRad 
Climatisation control for Nikon microscope PerkinElmer 
Climatisation control for Spinning disc and Zeiss 
microscope EMBL 
Electrophoresis system 2-D Hoefer 
Flow cytometer FACS Calibur BD Biosciences 
Flow cytometer FACS Verse BD Biosciences 
Gel iX Imager INTAS Science Imaging 
Gene Pulser Xcell Bio-Rad 
Gliseal Borer Chemie 
Infors HT bacterial shaker Infors 
IX81 S1F-3 microscope Olympus 
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J2-Hc Centrifuge with JA-20  or F10-6x500/JA-10 
rotor Beckman Coulter 
L8-70M and XL-70 Ultracentrifuge with SW28 
and SW32 rotor Beckman Coulter 
Luer-Lok 1, 2, 10, 20 and 50 ml syringes  BD Biosciences 
Luminoscan Ascent Thermo Scientific 
Megafuge 1.0R Heraeus 
Migration chamber for flow movies (handmade) 
Kindly provided by  
Ruth Lyck 
Multiskan EX ELISA reader Thermo Scientific 
NanoPhotometer Implen 
Nanosight NS300 Malvern 
Nikon microscope Ti-E Nikon 
OctoMACS Magnet Miltenyi Biotec 
Open-top polyallomer centrifuge tubes 25 x 89 
mm  Seton 
pH Meter 761 Calimatic Knick 
Semidry blotter Cti 
Stericup Filterng Devices  Millipore 
Syringe Pump Harvard Apparatus 
Thermocycler Biometra, Eppendorf 
Ultra-View ERS-6 spinning disc confocal 
microscope PerkinElmer 
 
2.1.17 Software 
Name Source 
ApE Wayne Davis 
Cell M Olympus 
Cell Quest Pro BD Biosciences 
CFX Manager BioRad 
Cyflogic CyFlo Ltd 
Endnote Thomson Reuters 
Excel Microsoft 
FACSuite BD Biosciences 
FlowJo V10 FlowJo 
Graph Pad Prism 5 GraphPad software 
Illustrator CS5 Adobe Systems Inc. 
ImageJ NIH 
NIS Elements Nikon 
Photoshop CS5  Adobe Systems Inc. 
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Powerpoint  Microsoft 
Quantity One BioRad 
SnapGene Viewer  GSL Biotech 
UCSF Chimera 1.10.1 UCSF 
Velocity Perkin Elmer 
Word  Microsoft 
 
2.2 Molecular biology methods  
2.2.1 Transformation and culture of bacteria 
50 μl of StblII or DH5a bacteria were thawn on ice. Bacteria were added onto 1 μg of 
plasmidic DNA or a ligation reaction. The mix was incubated for 5 min on ice and then 
transferred to the heat block to undergo heat shock for 90 seconds at 42ºC. Bacteria 
were immediately taken onto ice and incubated for 10 minutes. 1 ml of LB medium was 
added and bacterial culture was shaken at 37ºC for one hour. Cultures were then 
centrifuged, supernatant was discarded and the pellet was resuspended in 50-100 μl LB 
medium to be spread on LB-agar plates containing the appropriate antibiotic. After 
overnight growth at 37ºC, a single colony was picked and resuspended in 5 ml 
(Miniprep) or 200 ml (Maxiprep) of LB medium to be grown overnight. 
2.2.2 Isolation of plasmidic DNA from bacteria 
2.2.2.1 Miniprep 
NocleoSpin® Plasmid kit (Macherey-Nagel) was used according to manufacturer’s 
instructions. 3 ml of bacterial culture were centrifuged (10.000 rpm, 5’, 4ºC). The 
supernatant was discarded and bacteria were resuspended in 300 μl of buffer S1 
containing RNase A. After addition of 300 μl of lysis buffer S2, the tubes were inverted 
6 times and incubated at room temperature for 5 minutes. 300 μl of buffer S3 were then 
added to neutralize the reaction. Following a centrifugation step to get rid of the 
precipitates, the supernatant was transferred and made run through a mini spin column, 
washed with buffer Wash and eluted with 30 μl Elution buffer in subsequent 
centrifugation steps at 13.000 rpm during 5 minutes at 4ºC.  
2.2.2.2 Maxiprep 
Nucleobond PC 500 kit was used following the manufacturer’s instructions. 200 ml of 
bacterial culture were spun (5.000 rpm, 15’, 4ºC) and resuspended in 12 ml of ice cold 
buffer S1. 12 ml of lysis buffer S2 were added and the lysate was incubated for 5 
minutes at room temperature. The reaction was then neutralized with 12 ml of ice cold 
buffer S3 and incubated for 10 minutes on ice. After a centrifugation step to get rid of 
the cell debris, the clarified lysate was applied to and run through a previously 
equilibrated Nucleobond 500 PC column and washed twice with washing buffer. Next, 
bacterial DNA was eluted with 15 ml of elution buffer and precipitated with 15 ml of 
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isopropanol. After centrifugation the pelleted DNA was washed one last time with 70% 
ethanol and air-dried. DNA was finally dissolved in 100 μl H2O for at least 2 hours at 
4ºC. 
2.2.2.3 DNA concentration and purity 
DNA concentration and purity were measured using a Nanophotometer (Implen) and 1 
μl of the DNA solution. The DNA concentration was quantified by measuring optical 
density (OD) at 260 nm. To determine the purity of the isolated DNA protein 
concentration was quantified by measuring OD at 280 nm. Purity was considered 
acceptable when the ratio OD260/OD280 resulted in a value between 1.8 and 2. 
2.2.3 Polymerase chain reaction (PCR) 
For each standard PCR reaction the following components were handled on ice and 
added into 0,2 ml tubes: 
Component Volume 
H2O 31 μl 
Phusion HF Buffer 5x 10 μl 
dNTP (10 mM stock) 1 μl 
Forward primer (10 μM 
predilution) 
2.5 μl 
Reverse primer (10 μM predilution) 2.5 μl 
Template DNA (10 ng/μl) 1 μl 
DMSO 1.5 μl 
Phusion Polymerase 0.5 μl 
 
The thermocycling program used was the following:  
 
 
5 μl of the obtained PCR products were loaded and run on a 1% agarose gel in order to 
monitor successful amplification. 
Step Temperature Duration 
1) Initial denaturation 98°C 30 sec 
2) Denaturation 98°C 10 sec 
3) Annealing 55°C 30 sec 
4) Elongation 72°C 1 min per kbp 
5) Final extension 72°C 7 min 
6) store  4°C 
30 x 
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2.2.4 Electrophoretic separation of DNA 
Separation DNA purification was achieved through electrophoresis in agarose gel. 3 μl 
of Midori Green were added to 50 ml of 1% agarose in TAE Buffer 1x (w/v). DNA 
samples were mixed with DNA Sample Buffer prior to being loaded onto the gel. Size 
was evaluated via comparison to 1 kb DNA Ladder which was, when possible, loaded 
in a central lane of the gel. Gels were run at 80 V for 30-40 minutes. DNA was then 
visualized under UV light. If needed, DNA fragments were excised by using a fresh 
scalpel and the DNA for their subsequent purification. 
2.2.5 PCR product and DNA purification 
Purification of PCR products as well as of agarose gel-embedded DNA was performed 
using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel) according to the 
manufacturer’s instructions. 50 μl of H20 were used for elution of DNA.    
2.2.6 DNA restriction 
Both for analytical and preparative restriction, DNA was digested with the appropriate 
restriction enzymes in the following proportions for a 25 μl reaction: 
Component  Volume 
Restriction enzyme A  1 μl 
Restriction enzyme B 1 μl 
DNA  1 μl 
CutSmart Buffer  2.5 μl 
Nuclease-free water  To 25 μl 
 
For analytical DNA restriction the reaction was incubated at 37ºC for 30 minutes. 
Incubation time was increased to a minimum of 60 minutes for preparative purposes and 
more restriction enzyme was added if necessary.  
2.2.7 Ligation  
In order to perform ligation, the digested and purified vector and insert were mixed in a 
way that a vector-to-insert molar ratio between 1:2 and 1:3 was achieved. 2 μl of 10x T4 
ligase buffer and 1 μl of T4 DNA ligase were added to the DNA mix and incubated for 
2h at room temperature before it was used for transformation of bacteria (see ). 
2.3 Cell biology Methods 
2.3.1 Cell line culture 
Cells were cultivated in the appropriate culture media at 37°C and 5% CO2, humidified 
atmosphere. Passage of adherent cells was carried out 2 to 3 times a week depending on 
the growth speed. For that purpose, cells were washed with PBS and trypsin/EDTA was 
added for detachment adjusting the volume so it would just cover the bottom of the 
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flask with a thin layer (1 ml for T75; 2 ml for T175). Detachment was monitored by 
eye. A 9x volume of complemented medium was added into the flask to inactivate 
trypsin and detachment was facilitated by pipetting medium on the still undetached 
cells. Splitting was carried out at 1:10 dilution (dependent on growth rate and 
experiment plans). Suspension cell lines were cultured at 0.3-1 x 106 cell/ml in their 
respective vulture media. Splitting was typically performed at 1:4 dilution every 2-3 
days, depending on growth rate and experiment plans. A3.01 cells were observed to 
show higher polarization rates after transfection when denser, so for polarity assay they 
were allowed to grow up to 2 x 106 cell/ml. 
2.3.2 Freezing and thawing of cells 
Cell line stocks storage was achieved by cryoconservation in liquid nitrogen. To that 
end, 1x107 cells were centrifuged at 1200 rpm for 5 minutes and the pellet was 
resuspended in 1 ml freezing media and transferred into a cryotube. Cells were frozen at 
-80°C either in freezing containers for 24 hours before they were taken to a liquid 
nitrogen-containing tank for long term storage. Thawing of cells was carried by 
submerging the bottom of the tube in the water-bath at 37°C. Thawed cells were rapidly 
transferred to 15 ml falcon tubes containing 10 ml of pre-warmed medium and spun 
down. Cell pellets were resuspended in the appropriate media (see ) and cultured 
initially in low volumes (3-5 ml) which were progressively increased once cells had 
recovered from freezing-thawing stress. HUVECs were frozen the same gradual way in 
Cryo-SFM medium (PromoCell) in a concentration of 10 x 106 cell/ml. When thawed, 
they were directly added onto supplemented ECGM. 
2.3.3 Cell transfection 
2.3.3.1 Electroporation 
Transient transfection of plasmidic DNA was achieved by electroporation using a Gene 
Pulser Xcell (Bio-Rad). To that end, the appropriate number of cells was resuspended in 
non-supplemented medium, since the presence of FCS is known to diminish 
transfection efficiency. For A3.01 cells, 18 μg of plasmidic DNA were used and 1 x 107 
cells were pulsed at 350 V and 950 μF. For CCR7 cells, 60 μg of plasmidic DNA were 
used and 1 x 107 cells were pulsed at 250 V and 950 μF.  Immediately after pulsing, 
cells were transferred into 6-well plates containing 3 or 5 ml pre-warmed supplemented 
medium (for polarity assay or all other assays, respectively). Cells were then culture at 
37ºC and 5% CO2 until they were used for the subsequent assay.  
2.3.3.2 Cationic polymer transfection using Pei 
HEK293T cells were seeded 24 hours earlier in 15-cm culture dishes (5x106 cells/dish). 
DNA and Pei were mixed in a 1:3 in 7.5 ml Optimem/culture dish. The transfection mix 
incubated for 60 min at room temperature and added then dropwise to the cell culture. 
This type of transfection was used for HIV-1 or lentiviral particle production (see 2.3.8 
and 2.3.9). 
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2.3.4 Treatment with pharmacological inhibitors 
The impact of pharmacological inhibition of NAKC members in T cell polarity was 
evaluated on A3.01 transfected cells. To that end, 2 hours pot-transfection cells were 
harvested, resuspended in 4 ml of supplemented RPMI, split into two and transferred 
into p24-well plates. The appropriate volume of each inhibitor was then pipetted onto 
the culture and, after gentle shacking of the plate, cells were cultured for another 6 
hours until being subjected to polarity assay (see ).  
2.3.5 Isolation of human PBMCs 
Human peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation in 
Ficoll gradient from buffy coats of healthy individuals provided by the Blood Bank of 
Heidelberg University Hospital. Buffy coats were diluted 1:1 with sterile 1x PBS and 34 ml 
of the mix were used to overlay 15 ml of Ficoll. The two-phase obtained solution was 
centrifuged at room temperature at 2000 rpm without break for 30 min. PBMCs 
accumulated at the interphase were collected and washed with sterile 1x PBS and 
centrifuged at 1600 rpm for 7 min. Typically the obtained pellets were red, so lysis of 
erythrocytes was performed by resuspending the pellet in 5 ml ACK lysis buffer for 5 min, 
mixing the cell suspension every 1 minute. Next, an excess of 1x PBS was added and cell 
suspension centrifuged at 1400 rpm for 7 min. After one last wash and centrifugation step 
(1200 rpm, 7 min), monocyte depletion was performed by incubating 2 x 108 cells in 20 ml 
of supplemented RPMI on a T175 flask in horizontal position for 2 hours. The supernatant 
was collected and cells were resuspended in fresh RPMI++ containing 10 ng/ml of IL2 at a 
concentration of 3 x 103 cell/ml. Cells were then activated for their subsequent infection 
(see 2.3.6 and 2.3.7). 
2.3.6 Standard lymphocyte activation 
For standard activation, 10 ng/ml of IL-2 and 2 μg/ml of PHA-p were added to the 
supplemented RPMI medium of isolated PBMSs and they were incubated for 72 hours. 
2.3.7 Activating surface: anti-CD3/anti-CD28 activation 
In order to activate EV-producer A3.01 human T lymphocytes, activating surfaces were 
used; i.e. anti-CD3 and anti-CD28 antibody-coated surfaces. Goat anti-mouse IgG, Fc 
Fragment (Jackson Immunoresearch) antibody was diluted in carbonate/bicarbonate 
buffer solution at a concentration of 0.5 mg/ml and applied on to the surface to be 
coated. After 2h incubation at room temperature, the antibody solution was sucked 
away and the surface was washed 3 times with 1x PBS containing 0.5% FCS. Then a 
carbonate/bicarbonate tampon buffer based solution containing anti-CD3 and anti-CD28 
antibody (both at 0.5 mg/ml) was applied to the surface. Following three final washings, 
cells were added onto the surface (flask or culture plate) and incubated overnight at 
37ºC and 5% CO2.  
2.3.8 3 x 3 lymphocyte activation 
This protocol was developed by Dr. Andrea Imle in order to optimize infection with 
pNL43 IRES.pDisplay.YFP sortable HIV-1 virus. Tissue culture flasks were coated 
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with anti-CD3 antibodies contained in OKT3 hybridoma supernatant overnight at room 
temperature with mild shaking 24 hours prior PBMC isolation. PBMC from three 
donors were isolated as detailed in 2.3.4 and, following CD8+ T cell-depletion by 
magnetic isolation according to the manufacturer’s protocol with an autoMACS pro 
separator (Miltenyi Biotec), cells from the three donor were pooled and subjected to 
activation in parallel with 0.5 μg/ml PHA (low PHA), 5 μg/ml PHA (high PHA) or 
activating (anti-CD3 coated) surfaces for 72 h at 3x106 cells/ml. Cells activated by the 
three different methods were pooled and infected (see ). 
2.3.9 HIV-1 production 
HEK293T cells 6 x 106/15-cm culture dish cells were seeded at one day before 
transfection. For each 15-cm plate, 25 μg of proviral DNA were added in 1.5 ml of 
Optimem containing 75 μl Pei (1 mg/ml) and mixed by inverting the tube once or twice. 
The mix was incubated for 60 min at room temperature and added gently dropwise to 
each culture dish. Supernatants were harvested two and three days after transfection, 
filtered using 0.45 μm pore size filters. Typically virus was subjected to concentration 
by ultracentrifugation of the cleared supernatant through a 20% sucrose cushion (24.000 
rpm, 1.5-2 h). The pelleted virus was resuspended in supplemented RPMI medium, 
aliquoted and stored at -80°C. Virus titers were evaluated by p24 ELISA or SG-PERT 
(see 2.3.17 and 2.) and infectivity was determined by Blue cell assay (see 2.3.19). Half 
of the cells on a 15 cm culture dish were lysed in 2x sample buffer and protein 
expression was analyzed by Western Blot.  
2.3.10 p24 ELISA 
Mouse-anti-CA 183 antibody was used to coat Maxisorb 96-well plates overnight at room 
temperature in a humidified atmosphere. Following three washing steps with PBS-T, plates 
were blocked with 200 μl 10% FCS/PBS for 2 h at 37°C. Viral supernatants were 
inactivated by mixing them with 10% Triton at a 1:10 ratio. 100 μl of these samples and of 
p24 standard were pipetted into each well of the plate in duplicates. Seven 1:1 serial 
dilutions of the latter were prepared in PBS-T resulting in concentrations ranging between 
50 ng and 0.78 ng p24. A negative PBS-T control was also included. Virus samples were 
diluted 1:20, 1:200, 1:2000 and 1:20000. The plates were incubated overnight in a wet 
chamber at room temperature. The next day and after 3 washing steps with PBS-T, plates 
were incubated with polyclonal rabbit-anti-CA serum for 1 h at 37°C. Plates were washed 
again prior addition of a peroxidase-conjugated goat-anti-rabbit antibody for 1 h at 37°C. 
After one last washing step, 100 μl of peroxidase substrate were added to each well. 
Development of blue color was facilitated by gentle shaking and the reaction was stopped 
2-5 min later by the addition of 50 μl of 0.5M H2SO4 to each well inducing a color change 
to yellow. p24 concentration was finally correlated to photometric measurements performed 
using a Multiskan EX photometer by interpolation in the linear range of the standard curve. 
2.3.11 SG-PERT 
Quantification of HIV-1 particles in cell culture supernatant was performed by the 
SYBR Green-I product-enhanced reverse transcriptase (SG-PERT) assay (Pizzato et al., 
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2009; Vermeire et al., 2012). To that end, serial 1:10 dilutions of standard virus 
supernatant with known reverse transcriptase activity and plane dilution buffer as 
negative control were used. 5μl of virus supernatant samples or standard were lysed 
with 5μl of 2x SG-PERT lysis buffer containing RNase inhibitor (RiboLock). After 10 
minutes incubation at room temperature, 90 μl of 1x SG PERT PCR buffer were added. 
10 μl of lysed virus samples and standards were transferred to PCR tubes and 10 μl of 
2x SG-PERT reaction buffer containing GoTaq Hotstart Polymerase (1 μl polymerase 
for 100 μl 2x reaction buffer) were added. Accumulation SYBR Green signal was 
detected by RT-PCR using the following thermocycling program: 
Step Temperature Duration 
RT reaction 42°C 20 min 
Taq Activation 95°C 2 min 
Denaturation 95°C 5 sec 
Annealing 60°C 5 sec 
Extension 72°C 15 sec 
Acquisition 80°C 7 sec 
Concentration of RT activity per μl was assessed according to the standard curve using 
CFX Manager software. 
2.3.12 Infectivity assay: blue cell assay 
As a way to characterize the infectivity of HIV-1 virus after its production a HeLa based 
reporter system was used, the so called blue cell assay. The target cells for this assay, 
TZMbl cells, stably express two reporter genes under the HIV promoter, namely 
luciferase and β-galactosidase. One day prior to being infected, 5 x 103 TZMbl cells 
were seeded in each well of a 96-well plate and they were cultured at 37ºC and 5% CO2. 
The following day, serial dilutions of the concentrated virus were added on the cells 
starting with a 1:102 dilution and diluting it further to 1:106 and the plate was placed in 
the incubator for another 48 hours. After this time, supernatant was sucked away, cells 
were washed with PBS and they were fixed in ice cold 1:1 (v/v) acetone/methanol 
mixture. Following incubation at -20ºC, 100 μl of the reaction substrate, β-Gal 
supplemented with 200 μg/ml X-Gal, were added onto each well and the plate was 
incubated for 3 hours at 37ºC. After this incubation time the number of infected cells 
was evaluated by eye due to the blue coloration derived from the β-galactosidase 
activity and the processing of the substrate and subsequent oxidation of the subproduct. 
2 x 104 blue cell units of virus were used to infect 2 x 105 target cells (see 2.3.9). 
2.3.13 HIV-1 infection 
Infection of primary lymphocytes was carried out by standard spin infection. The format 
chosen for infection was a U-bottom, 96-well plate containing 2 x 105 PBMCs (CD8+ T 
cell-depleted or not) and an amount of virus to yield at least 2 x 104 blue cell units 
(MOI=1 or more, being never higher than 3) with a total volume of 100 μl/well. To 
achieve the mentioned conditions, concentrated virus and activated cells were 
30 x 
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resuspended in the required amount of supplemented RPMI medium containing 4 μg/ml 
of Polybrene. The plates were then centrifuged at 2000 rpm for 90 minutes at 37ºC and 
incubated 4-6 h at 37ºC and 5% CO2 prior to medium change to avoid toxicity by 
polybrene. Cells were cultured in supplemented RPMI containing 10 ng/ml of IL2. 72 h 
later, cells were either subjected to polarity assay or purified by magnetic sorting (see ). 
2.3.14 Sorting of pNL4.3 IRES pDisplay.YFP infected cells  
Following 3x3 stimulation (see ) and infection with pNL4.3 IRES.pDisplay.YFP, CD8+ 
depleted lymphocytes were sorted and enriched. Magnetic sorting is only successful if 
more than 2% of lymphocytes are infected, as determined by the number of YFP 
positive cells detected by FACS. 1x107 total cells were resuspended in 97 μl of ice cold 
MACS buffer and 3 μl anti-GFP beads (Miltenyi Biotec) were added (for 2% infected 
cells) or a higher volume depending on the percentage of infected cells. After mixing 
and 15 minutes incubation at 4ºC, a washing step with MACS buffer was performed to 
get rid of the non-bound beads and cell were pelleted down. Cells were the resuspended 
in 500 μl of MACS buffer and applied to pre-equilibrated LS columns placed on an 
OctoMACS magnet. 4 washing steps with 500 μl MACS buffer were carried out and 
elution of YFP positive cells took place as columns were removed from the magnet in 1 
ml MACS buffer. Eluted cells were subjected to a second round of magnetic selection 
by being applied to a second pre-equilibrated LS column. After the second elution step, 
isolation efficiency was determined by flow cytometry and also samples collected 
during the complete process. As a result of this process YFP positive, infected cells 
were enriched to 90-96%. 
2.3.15 Production of lentiviral vectors 
As a way to deliver exogenous DNA into A3.01 cells for expression of GFP, Nef.GFP 
or Vpu.GFP, lentiviral vectors were used. To that end, 6 x 106 HEK293T cells were 
seeded per 15 cm tissue culture dish. One day later, cells were transfected using 711 μl 
of Pei and 112.5 μg of the pWPI expression vector including the gfp, nef and gfp or vpu 
and gfp genes, 73 μg of pPax2 vector containing all structural lentiviral genes for 
packaging and the protease gen, 40 μg of VSV-G vector for pseudotyping of the 
lentiviral particles favoring fusion to most cell types and 11.5 μg of pAdvantage for 
enhancement of expression. The described amounts of DNA and Pei were added to 7.5 
ml optimem medium and the transfection mix was added gently to the cell culture 
dropwise after 60 minutes incubation at room temperature. Cell supernatant was 
collected 72 hours later, clarified by filtration through 45 μm pore-size filters and 
subjected to concentration by 20% sucrose cushion ultracentrifugation (24000 rpm, 1.5-
2 h). Pellets were then resuspended in supplemented RPMI, aliquoted (typically 100 μl) 
and stored at -80ºC.    
2.3.16 Transduction of A3.01 cells 
One aliquot of the produced lentiviral vectors was used for titration. Different volumes 
of lentiviral particles (typically 60, 30 and 10 μl) were added onto 2 x 106 A3.01 cells 
contained in a total volume of 400 μl/well of a 24-well plate. Cells were centrifuged at 
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2000 rpm for 90 minutes and incubated for 48 hours at 37ºC and 5% CO2. After this 
time, transduction efficiency was analyzed by measuring the expression of by FACS 
using untransduced cells as negative control for establishing the gating. Once 
determined the optimal volume for transduction, A3.01 cells were transduced following 
the same protocol used for the prior titration. 
2.3.17  Lck retargeting assay 
One day after transfection, 5 x 105 A3.01 cells contained in 50 μl of supplemented 
RPMI were seeded onto coverslips previously coated with 0.01% Poly-L-Lysin. After 
incubation 10 minutes incubation at 37ºC, cells were fixed using 3% PFA in PBS (v/v) 
and incubated for another 15-30 minutes at room temperature, permeabilized with 0.1% 
Triton-X100 for 2 minutes and blocked in 1% BSA in PBS (v/v) for 30 minutes at room 
temperature. After washing with 1x PBS, mouse anti-human Lck antibody (1:50, in 1% 
BSA in PBS, Santa Cruz) was added and incubated for 2 h at room temperature. 
Coverslips were washed 3 times with 1x PBS and incubation with the secondary goat 
anti-mouse antibody coupled to Alexa-568 (1:2000, in 1x PBS, Invitrogen) was carried 
out for 1 h at room temperature protected from light. After 3 washing steps with 1x 
PBS, coverslips were mounted on microscopy slides using Linmount, let dry for 2 h at 
room temperature protected from light and stored at 4ºC until analyzed by microscopy. 
When cotransfected for ectopic expression of Lck.RFP, cells were directly mounted 
after fixation.  
2.3.18 Polarity assay 
6 hours post-transfection/post-inhibitor treatment or 72 hours post-infection, 3-5 x 105 
A3.01 cells or monocyte depleted, standard activated PBMCs respectively, contained in 
100 μl of supplemented RPMI were seeded onto Fibronectin-coated coverslips (30 
μg/μl, 1 hour at room temperature) and placed in the incubator for 2 hours. After this 
time, they were taken out of the incubator very gently to avoid shaking and they were 
fixed using 3% PFA in PBS (v/v) and incubated for another 15-30 minutes at room 
temperature. Cells were then permeabilized with 0.1% Triton-X100 for 2 minutes and 
blocked in 1% BSA in PBS (v/v) for 30 minutes at room temperature. Following 
washing with 1x PBS, mouse anti- CD44 antibody (1:800, in 1% BSA in PBS, 
Biolegend) was added and incubated for 2 h at room temperature. Coverslips were 
washed 3 times with 1x PBS and incubation with the secondary goat anti-mouse 
antibody coupled to Alexa-568 (1:2000, in 1x PBS, Invitrogen) was carried out for 1 h 
at room temperature protected from light. After washing with 1x PBS, coverslips were 
mounted using Mowiol, let dry for 2 h at room temperature protected from light and 
stored at 4ºC until analyzed by microscopy. 
2.3.19 Immunofluorescence 
Cell phenotype frequencies were quantified using an epifluorescence microscope (Olympus 
IX81 S1F-3). At least 100 transfected cells or 30 infected cells were evaluated for their 
phenotype as compared to untransfected or uninfected neighboring. Lck retargeting 
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confocal images were acquired using a spinning disc confocal microscope (Perkin Elmer 
Ultra-View ERS-6). All other images were acquired using the epifluorescence microscope. 
2.3.20 Flow Cytometry 
This technique was used to assess infection efficiency by determination of the 
percentage of p24-CA positive cells (72 hours post-infection), transfection efficiency by 
determination of the percentage of GFP or RFP positive cells (typically 48 hours post-
transfection), the effect of the expression of Vpu and Nef and their mutants on the 
expression of cell surface proteins, namely CD4, MHC-I, CD317 and Tetraspanins (48 
hours post-transfection), and to quantify the proportion of migrated cells in chemotaxis 
assay. To this end, cells were inactivated with 10% Triton at a 1:10 ratio for 90 minutes 
(only for infected cells), washed with PBS and transferred to a suitable format (1.5 ml 
reaction tubes, 1.2 ml FACS tubes or V-bottom 96-well plate). Following a 
centrifugation step at 1200 rpm for 5 minutes, cells were resuspended in 100 μl PBS or 
a 1:20 dilution of the appropriate antibody and incubated on ice in the dark for 60 
minutes. After washing with PBS supplemented with 0.5% FCS, cells were taken up in 
200 μl PBS 0.5% FBS for flow cytometry analysis using the BD FACS Calibur or the 
BD FACS Verse. 10,000 events were typically acquired and analyzed using the 
Cyflogic or FlowJo software. 
2.3.21 Chemotaxis assay 
24 hours post-transfection, Jurkat CCR7 cells were starved in DMEM medium 
containing 0.5% FCS for 2-4 hours at 37ºC and 5% CO2. Meanwhile, 450 μl starvation 
medium containing 10 ng/ml SDF-1α or not were added to the wells of a 24-well plate. 
Next, transwells (5 μm pore size, Corning)  pre-equilibrated with the same starvation 
medium were applied onto the wells and simultaneously 100 μl starvation medium 
containing 1 x 106 cells were pipetted into the transwell. Following 2 hours incubation 
at 37ºC and 5% CO2, cells were harvested and total GFP-expressing cells cell numbers 
of the input and of the chemoattracted cells were quantified by flow cytometry. Nef 
Inhibitory effects were evaluated as the ratio of the percentage of migrated GFP-
expressing cells and transfection efficiency relative to GFP controls, which were 
arbitrarily set to 100%. 
2.3.22 Extracellular vesicle isolation 
EV-producer cells were cultured in supplemented RPMI medium containing 10% 
exosome/EV-deprived FCS. The latter was obtained by ultracentrifugation of the 
normally used, inactivated FCS at 28000 rpm for 16 hours. Two different methods were 
used to isolate EVs from cell culture supernatant: the standard differential 
ultracentrifugation method and a commercial isolation reagent. 
The standard differential ultracentrifugation method was performed as previously 
established (Thery et al., 2006). Cell supernatants were harvested, sequentially clarified 
by centrifugation for 20 minutes at 4ºC at 2000 x g first (JA20 rotor, 5000 rpm) and at 
then at 10000 x g (JA20 rotor, 11300 rpm) and filtered using 0.45 μm pore size filter 
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(Merck Millipore). Cleared supernatant was then transferred to ultracentrifugation tubes 
and run at 100000 x g at 4ºC for 70 minutes to ensure 60 minutes at maximum speed. 
Extremely carefully to not disturb the pellet and leaving about 100 μl, supernatant was 
transferred into a fresh tube and run again at the same speed and temperature and for the 
same time. Even more carefully than before, supernatant was removed and pellet was 
resuspended in 30-50 μl of KEB lysis buffer.  
Alternatively, the Total Exosome Isolation (form cell culture media) reagent 
(Invitrogen) was used. In this case, cleared supernatants were mixed with the reagent in 
a 2:1 (v/v) ratio. The mixture was incubated at 4ºC overnight and centrifuged at 10000 x 
g for 1 hour at 4ºC. Supernatant was extremely carefully removed and pellet was 
resuspended in 30-50 μl of KEB lysis buffer.   
Protein quantification was measured directly after EV isolation using the BCA or the 
microBCA protein assay kits according to manufacturer’s instructions and samples were 
analyzed by SDS-PAGE and Western Blotting. 
2.3.23 Transendothelial migration assay  
At day one, 50-mm μ-dishes (Ibidi) were coated with Matrigel (BD/Corning) at a 
concentration of 0.225 mg/ml. To that end a silicone ring with the size of a 96-well 
plate well was placed into the dish to delimitate the cell culture area and Matrigel 
(handled on ice) was added and incubated for 1 hour at room temperature. Freshly 
acquired, dense HUVECs were detached using the Detach Kit for Endothelial Cells 
(PromoCell) according to manufacturer’s instructions, stained with trypan blue and 
counted. 2-4 x 104 cells contained in 100 μl of ECGM were added into the silicone 
rings. Four hours later, the medium was replaced for fresh medium containing 200 U/ml 
of TNF-α and incubated overnight (between16 and 18 hours). The following day, 
HUVECs were activated by addition of Sdf-1α to a final concentration of 1 μM. CD8+ 
depleted T lymphocytes stained or not with Cell Tracker dyes (Thermo Fisher) were 
diluted in MAM (preferentially) or binding medium migration media at a concentration 
of 2 x 106 cell/ml. Flow movie chamber was assembled and connected to a syringe 
plugged onto a Syringe Pump (Harvard Apparatus) through the output tube. The input 
tube was submerged into the lymphocyte solution. Flow movies were acquired using an 
inverse light microscope (10 or 20 x objective, Nikon Ti-E) and a withdrawing program 
with shear flow values of 0.1 dyn/cm2 (0.028 ml/min) for the accumulation phase and 5 
dyn/cm2 (1.390 ml/min). 
2.3.24 Software and statistical analysis 
Data analysis and statistical calculations were performed using Microsoft Excel and 
GraphPad Prism. Image editing was carried out using Adobe Photoshop and Illustrator 
CS4. Video editing was performed with ImageJ. Lck accumulation was assed using a 
free-hand tool to define the boundary and the pixel intensity measuring tool of ImageJ. 
Analysis of DNA sequences and cloning strategies were performed and defined using 
Ape and Snapgene software and NCBI Basic Local Alignment Set Tool (BLAST) and 
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Expasy Translate free online tools. Statistical significance was calculated by Mann-
Whitney-U-test analysis (***, p<0.001; **, p<0.01; *, p<0.05; n.s., not significant). 
2.4 Biochemistry methods 
2.4.1 Cell and extracellular vesicle lysis 
A3.01 (or other cell lines) EV-producing cells and EV preparations were lysed in ice 
cold KEB lysis buffer. Typically the cell pellet obtained in the first step of EV isolation 
(see ) was lysed in 100 μl of KEB buffer and the EV pellet obtained at the end of the 
isolation process was resuspended in 10-20 μl of the same buffer. Cell lysates and EV 
preparations were handled on ice and stored at -80ºC following protein quantification 
and to SDS-PAGE analysis. 293T virus-producer cells were lysed in 500 μl 6x sample 
buffer for half a 15-cm culture dish. 
2.4.2 Protein quantification  
In order to measure cell lysate and EV sample protein content and to be able to 
normalize loading for SDS-PAGE, the Pierce BCA protein assay and the Pierce 
microBCA Pierce assay were used according to manufacturer’s instructions. 
2.4.3 SDS-PAGE 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) was used for 
qualitatitive and quantitative protein detection. To this end, the electrophoresis system 
2-D (Hoefer) was used. Preparation of 10% separating and stacking gels was conducted 
as detailed in the materials section (see ). Samples in 6x sample buffer were boiled at 
95ºC for 10 minutes. EV-producer cell lysates were mixed with 3x non-reducing sample 
buffer as well as EV preparations, adjusting the volume of sample buffer for the latter so 
the desired amount could fit in the gel wells when loading. Volumes corresponding to 
106 cells of cell lysate-3x sample buffer mix and EV-sample volumes containing equal 
amounts of protein also mixed with 3x sample buffer were boiled as described above. 
Gels were mounted on the running chamber containing SDS running buffer. After 5 
minutes wait for cooling, samples were loaded onto the gel and run at 30 mA/gel for 
about 1 hour. ColorPlus prestained protein marker was used as a protein size standard. 
2.4.4 Western blot 
Following SDS-PAGE, the resolved protein content of the samples was transferred onto 
nitrocellulose membranes using a semi-dry blotting apparatus (Cti). To this end, 
Whatman paper was dipped in blotting buffer and used to make a sandwich containing 
the SDS polyacrylamide gel and the membrane. Blotting was achieved after 60 minutes 
at 100 mA/gel. Membranes were then blocked for 1 hour in 5% milk in PBS-T, washed 
3 times with PBS-T, cut (if necessary) and incubated overnight with the primary 
antibodies at 4ºV. After 3-6 10-minute-long washes with PBS-T, the membranes were 
incubated with hoseradish peroxidase-coupled secondary antibodies for 60 minutes. 
Following 4 10-minute-long washes, the enhance chemoluminiscence (ECL) substrate 
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was added homogenously on the membrane surface and wiped off after one minute. 
Film exposure times were variable depending on the sample.   
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3 RESULTS: OVERLAPPING FUNCTIONS BETWEEN NEF 
AND VPU 
As it has been already reviewed in the introduction, redundant functions between the 
HIV-1 pathogenicity factors Nef and Vpu have been previously reported. All of these 
are related to the ability of these two proteins to reduce surface expression levels of a 
short list of receptors, such as CD4, MHC-I, CD1d, or PVR (Chen et al., 2006; Galaski 
et al., 2015; Garcia and Miller, 1991; Kerkau et al., 1997; Matusali et al., 2012; Moll et 
al., 2010; Schwartz et al., 1996; Willey et al., 1992a). We have further studied Nef and 
Vpu overlapping functions which resulted in an expanded list of host cell membrane 
receptors targeted by both viral proteins, as well as describing the shared abilities to 
internalize the host kinase Lck to intracellular compartments and to modify extracellular 
vesicle (EV) secretion (Haller et al., 2014). 
3.1 Both Nef and Vpu are able to downmodulate a broad spectrum of cell 
surface host receptors  
One of the most described effects of the HIV-1 accessory proteins Nef and Vpu is the 
modulation of surface levels of host cell receptors. To analyze the breadth of this effect 
and to identify the target specificity of the viral factors, we studied by flow cytometry 
the susceptibility of a panel of receptors after expression of the viral proteins. A3.01 
human T lymphocytes were transiently transfected for the expression of HIV-1 
Nef.GFP, HIV-1 Vpu.GFP or SIVMac239 Nef.YFP. The expression of these proteins was 
only slightly lower to that obtained after infection in this cell system (Fig. 3.0B). The 
reduction in surface expression of the analyzed cell receptors was calculated as the ratio 
between the mean fluorescence intensity (MFI) values obtained for GFP/YFP positive 
cells (transfected) and for negative cells (untransfected) from the same sample (Fig. 
3.1A, R3 gate vs R2 gate) (Haller et al., 2014). This methodology proved to be suitable 
for determining the effect of isolated expression of the accessory proteins on the levels 
of individual cell surface receptors (Fig. 3.0A, primary data shows efficient 
downregulation or no effect on CD4 and CD49a, respectively, by the expression of 
HIV-1 Nef, HIV-1 Vpu and SIVMac239 Nef). A panel of 105 receptors was analyzed this 
way (Fig. 3.0D and E). The results show that a number of receptors were unaffected by 
the expression of the viral factors, proving the specificity of the surface level 
modulation mediated by them. Receptor upregulation was a rare event (that took place 
only for CD69 in the presence of Nef). Nef was observed to downmodulate a 
considerable number of these receptors: 36 out of 105 showed reduction in their plasma 
membrane level to an extent of <65%, including previously but also newly identified 
Nef targets with an interesting relation to HIV Virology, such as CD37 (Fig. 3.1A), 
Lamp-1 (CD107a), Lamp-2 (CD107b), ICAM-1 (CD102), or gamma interferon receptor 
(CD119). Interestingly, there was a significant overlap between receptors that were 
downregulated by HIV-1 Nef and HIV-1 Vpu. 32 receptors were identified to have 
diminished levels in the presence of the latter accessory protein to an extent of at least 
80%, being all of them targeted as well by Nef. No significant receptor upregulation 
was observed in this case. Overall, the effect mediated by Vpu was less pronounced 
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than that of Nef, except for CD164, CD71 and CD317 (data not shown). Taken 
together, this results show there is a vast but specific overlap in the set of cell surface 
receptors targeted by both viral proteins. 
Upon analysis of the characteristics of the newly identified targets of Nef and Vpu, we 
detected amongst the studied host cell receptors several belonging to the tetraspanin 
(TSPAN) superfamily of proteins. HIV-1 Nef and Vpu lowered the levels of all TSPAN 
proteins included in the study (CD37 [also referred to as TSPAN-26], CD53 [TSPAN-
25], CD63 [TSPAN-30], CD81 [TSPAN-28], CD151 [TSPAN-24], and CD231 
[TSPAN-7]). Furthermore, the effect of Nef on CD37 and CD81 was the strongest seen 
in the complete study. Also in this case, Vpu affected the surface expression levels of all 
these proteins to a lesser extent than Nef (Fig. 3.0C).   
3.2 Downregulation of TSPANs from cell surface by HIV-1 Nef and Vpu is the 
result of a specific activity    
Given the observed specificity of Nef and Vpu for members of the TSPAN family of 
transmembrane proteins, we next wondered if the observed downregulation could be the 
result of an artifact caused by unspecific effects on membrane trafficking due to 
membrane association and insertion, respectively. To study this, we utilized transfected 
A3.01 human T cells (over)expressing Nef.GFP or Vpu.GFP and compared them to 
cells (over)expressing N18-src.GFP, the N-terminal domain of the src protein fused to 
GFP, and pDisplay.YFP. The reason why the latter two proteins were chosen as controls 
is that they are targeted to the cell membranous system (preferably to the plasma 
membrane) by the same mechanism as the viral proteins. N18-src.GFP contains a SH4 
domain susceptible to myristoylation that favors anchoring at the inner leaflet of 
membrane (Geist et al., 2014; Haller et al., 2014; Pan et al., 2013b), as in the case of 
Nef. pDisplay.YFP consists of the transmembrane domain of CD4 spanning the 
membrane similarly to the Vpu protein (Haller et al., 2014). Forty eight hours after 
transfection, cells were stained with antibodies targeting CD4 and several TSPANs and 
analyzed by Flow Cytometry. The relative remaining surface expression of the receptors 
was calculated as the ratio between the MFI of intermediate-high expressing cells and 
that of GFP-negative from the same sample (Fig. 3.1A, gates R3 vs R2). Expression of 
Nef.GFP and Vpu.GFP resulted in diminished levels of the five studied TSPAN 
members, CD27 (data not shown), CD37, CD53, CD63, and CD81. The reduction was 
in all cases less pronounced than that seen for the control receptor CD4 (Chaudhuri et 
al., 2007; daSilva et al., 2009; Garcia and Miller, 1991; Ren et al., 2014) (First set of 
Fig. 3.1B). The unrelated control proteins N18src.GFP and pDisplay.YFP did not cause 
significant downregulation of any of the transmembrane proteins. Thus, HIV-1 Nef and 
Vpu target proteins from the TSPANs superfamily for downregulation in a specific 
manner. 
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Fig. 3.1 HIV‐1 Nef and Vpu  target cell surface TSPANs  for downregulation  in a specific manner. A3.01 human T 
lymphocytes were transfected with expression plasmids for Nef.GFP, Vpu.GFP, the N‐terminus domain of Src fused 
to GFP (SrcN18.GFP), pDisplay.YFP or GFP as a control. 48 hours  later, cells were stained with antibodies targeting 
different TSPANs or CD4 to study surface expression levels by flow cytometry. (A) Representative flow cytometry dot 
plots of  the CD4  levels of gated  living cells. Mean Fluorescence  Intensity  (MFI, YGeoMean) of untransfected  (gate 
R2) and medium‐  to high‐GFP‐expressing  (gate R3)  cells  is  shown  in  red  for each of  the different  conditions.  (B)  
Depicted  protein  levels  were  calculated  and  plotted  using  the  MFI  of  GFP  positive  cells  relative  to  that  of 
untransfected  cells  from  the  same  sample. Displayed  are  the  arithmetic means  and  standard  deviation  of  three 
independent experiments. For  reference, dotted  line corresponds  to no downregulation  (100%  remaining surface 
expression). 
 
3.3 Different motifs of Nef and Vpu are important for TSPAN proteins 
downregulation from the cell surface   
As the next step in this study, we wanted to define the molecular determinants by which 
Nef and Vpu mediate downregulation of TSPANs. To this end, A3.01 human T cells 
were transfected with expression plasmids encoding GFP fusions of Nef, Vpu, or well-
characterized mutants of the viral proteins. CD4 and tetherin, two well described 
downregulation targets of the accessory proteins (Bolduan et al., 2013; Chaudhuri et al., 
2007; daSilva et al., 2009; Garcia and Miller, 1991; Goffinet et al., 2009; Neil et al., 
2008; Schmidt et al., 2011; Tervo et al., 2011), were analyzed as controls. 
Immunostaining of these cells was performed 48 hours later and plasma membrane 
levels of stained receptors were analyzed by flow cytometry as the ratio between the 
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MFI values of intermediate-high GFP-expressing and untransfected cells from the same 
sample (as shown in Fig.3.1A, R3 vs R2).  
Motif Relevance/loss of interaction Mutant 
MGxxxS(1–6) Membrane association G2A 
S(6) Phosphorylation by nPKC S6A 
M(20) MHC-I downregulation M20A 
N-t amphipatic helix NAKC formation Δ12-39 
EEEE(66–69) MHC-I downregulation E4A4 
VGF(71–73) MHC-I downregulation VGFAAA (VGF) 
PxxP(80–83) MHC-I downregulation AxxA 
ExxxLL(164–169) AP-2 binding , CD4 downregulation LLAA 
ED(178,179) CD4 downregulation EDAA 
F(195) Pak2 association F195A 
Table 3.1 HIV-1 SF2 Nef mutants used in this study. 
Transient expression of Nef.GFP causes a pronounced reduction of CD4 levels on the 
cell surface of A3.01 T cells (from 90.1% of GFP control cells to 6.2% of Nef.GFP-
expressing cells). Expectedly, mutations in the acidic stretch (EEEE66-69; E4A4), 
needed for interaction with PACS adaptor involved in receptor downregulation (Piguet 
et al., 2000), the VGF motif (VGFAAA), involved in SH3-domain interactions between 
Nef and host cell proteins (Meuwissen et al., 2012), the PxxP motif (AxxA), central 
structure of the SH3 domain interaction surface in Nef (Collette et al., 1996; Saksela et 
al., 1995), and the hydrophobic patch (F195A), essential for the interaction with PAK2, 
resulted in marginal or no effects on the extent of Nef-mediated CD4 downregulation 
(see table 1.3).  The Nef mutant unable to become myristoylated (G2A), deficient for 
most described functions of the accessory protein, and the 12-39 deletion mutant of Nef 
(Δ12-39), which lacks an amphipathic alpha-helix needed for the interaction with a 
multi-molecular complex consisting of at least two cellular adaptor proteins and four 
kinases, NAKC (Baur et al., 1997), were largely deficient for this activity. As expected, 
modifications targeting the C-terminal flexible loop, LL168/169 and ED178/179 
residues (LLAA and EDAA), interacting with the endocytic machinery, abrogated this 
Nef activity (Chaudhuri et al., 2007; Fackler et al., 2006; Keppler et al., 2006). 
Surprisingly, the downregulation Nef mutant-profile differed for the individual TSPANs 
and none of the analyzed molecular determinants emerged as essential for any of the 
studied host proteins. Despite the unspecific G2A mutant, the acidic stretch and the 
VGF and proline-rich motifs also accounted for a discrete partial loss of function in 3 
out of 4 TSPANs studied (all but CD37). In the case of CD37, along with the G2 
mutation only mutation in the dileucine motif led to partial inhibition of downregulation 
as compared to wt Vpu. Also, no similarities to CD4-downregulation profile (or that of 
MHC-I or CXCR4, differing to the CD4 one and described elsewhere (Mangasarian et 
al., 1999; Meuwissen et al., 2012; Venzke et al., 2006)) were observed.  
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Fig.  3.2  Alteration  of  individual  TSPANs  cell  surface  levels  by  Nef  and  Vpu  depends  on  distinct  molecular 
determinants. A3.01 T lymphocytes were transfected with expression plasmids for various Nef.GFP (A) and Vpu.GFP 
(B) proteins or GFP control. After 48 hours, cells were harvested and immunostained for flow cytometry analysis of 
surface  receptor  levels. The graphs  show  relative protein  levels as  the MFI  ratio of gated GFP positive  cells and 
untransfected cells within the same sample (R3 vs R2, as in figure 1). The arithmetic mean and standard deviation of 
the means from three experiments (two in the cases of Nef.G2A, Δ12‐39, and VGFAAA) in triplicates are plotted.     
 
Vpu expression also caused an important reduction in CD4 surface expression levels, 
although less pronounced as that induced by Nef (from 99.7% of GFP control cells to 
39.2% of Vpu.GFP-expressing cells). Conversely, Vpu caused a more potent 
downregulation on exposed levels of tetherin (from 101.4% to 35.6%). Modification of 
the diserine motif necessary for the interaction with beta-transducin repeat-continuing 
protein (β-TrCP) (S52/56A) caused a loss of Vpu-mediated downregulation of both 
CD4 and tetherin (see table 1.4). The same result was observed when the 
transmembrane (TM) domain was replaced by that of the vesicular stomatitis virus G 
protein (TM VSVG) (Magadan et al., 2010). While all other mutations tested did not 
affect Vpu-mediated downregulation of tetherin, changes were observed for CD4. 
Mutations targeting a Vpu motif essential for lipid raft association (V25Y29G) (Fritz et 
al., 2012) or that needed for interaction through the transmembrane domain 
(A14LW22A) (Vigan and Neil, 2010) resulted in disruption of CD4 downmodulation. 
Mutations in a motif necessary for the natural localization of Vpu at the trans-Golgi 
network (TGN) (R30A,K31A) (Dube et al., 2009) did not affect downregulation. 
Regarding effects of Vpu mutants on TSPAN surface levels, mutations at the diserine 
motif or the TM domain of Vpu showed a partial loss of the effect. All the other 
mutants affected only slightly, if at all, the surface levels of TSPANs as compared to 
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those in presence of wt Vpu. Of note, in the case of Vpu-mediated downregulation, the 
tested mutants generated a comparable profile for each of the proteins.  
Motif Relevance/loss of interaction Mutants 
DS(52)GNES(56)  β-TrCP-dependent degradation S52/56A 
AxxxAxxxW(14–22) Tetherin downregulation A14LW22A 
R(30)K(31)  TGN localization R30K31A 
V(25)Y(29)  Lipid raft association V25GY29G 
TMD CD4 downregulation  TM VSVG (TMD replaced by VSVG TMD) 
Table 3.2 HIV-1 NL4.3 Vpu mutants used in this study. 
Overall, these results show that the determinants of Nef and Vpu relevant for 
downregulation of proteins of the TSPAN superfamily are different to those previously 
described for other target proteins of these viral factors. Furthermore, distinct 
mechanisms might explain Nef-mediated downregulation of individual TSPANs.     
3.4 Nef and Vpu target Lck for relocalization to an intracellular compartment 
A consequence of the Nef-mediated modification of intracellular trafficking is the 
relocalization of the Src kinase and peripheral membrane protein Lck from the plasma 
membrane to recycling endosomes and trans-Golgi network (RE/TGN) to fine tune 
TCR signaling and favor viral replication (Pan et al., 2013b; Pan et al., 2012). Since Nef 
and Vpu share specificity for downregulation of a number of receptors as described 
above, we wanted to study whether Vpu can as well exert another well characterized 
Nef activity such as rerouting of the TCR signaling master switch Lck. A3.01 cells were 
therefore transfected with expression vectors for GFP versions of both accessory 
proteins or the empty GFP-expressing plasmid as control. Under these three conditions, 
cells were analyzed by immunofluorescence for the localization of endogenous or 
overexpressed Lck. The latter was achieved by cotransfecting the cells with a plasmid 
expressing the RFP-labeled kinase (Fig 3.3B). The frequency of Nef-expressing cells 
displaying retargeted endogenous Lck to intracellular compartments was close to 100%. 
Only a marginal fraction of Vpu-expressing cells showed this cytoplasmic accumulation 
when compared to GFP control cells, which showed no detectable cytoplasmic Lck 
signal (Fig 3.3C; 91.7 +/- 3.8% of Nef.GFP-expressing cells showing accumulation, 
18.7 +/- 5.6% of Vpu.GFP-expressing cells and 0% of GFP-expressing cells). The 
magnitude of the accumulation in single cells was determined as the ratio between 
accumulated and total Lck signals (i.e. pixel quantification of cytoplasmic vs total Lck 
signal). Accordingly, the extent of the relative accumulation per individual cell studied 
was in average significantly higher also in the case of Nef-expressing cells than in the 
case of Vpu-expressing cells. The obtained value was significantly higher for cells 
expressing either of the viral proteins when compared to GFP control cells (Fig 3.3E; 
6.4 +/- 4.8% of the total per cell Lck signal at intracellular compartments in GFP-
expressing cells, 57.2 +/- 14.3% in Nef.GFP-expressing cells and 27.4 +/- 11.2% in 
Vpu.GFP-expressing cells).  
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Fig.3.3  Nef  and  Vpu  affect  the  subcellular  localization  of  Lck.  A3.01  T  lymphocytes  were  transfected  with 
expression  vectors  for GFP, Nef.GFP or Vpu.GFP  alone  (A, C  and  E)  (endogenous  Lck) or  co‐transfected with  an 
expression vector for Lck.RFP (B, D and F). 24 hours later, cells were fixed on poly‐L‐lysine‐coated cover glasses and 
analyzed by confocal microscopy. To study endogenous Lck, an intermediate step was required in which cells were 
immunostained. Representative micrographs in (A and B) show the relocalization of Lck mediated by both accessory 
proteins compared  to GFP control cells. Scale bars = 10 μm.  (C and D) Frequency cells showing Lck accumulation 
(recycling endosomes/trans‐Golgi network). GFP‐high‐expressing cells were evaluated for their Lck localization and 
classified  into  two  groups:  showing  Lck  intracellular  accumulation  or  with  Lck  at  its  usual  plasma  membrane 
localization. Depicted  are mean  values  and  standard  deviation  of  data  from  three  independent  experiments  in 
which 100 cells were considered per condition. (E and F) Single‐cell analysis of the relative Lck accumulation. Signal 
intensity was evaluated as the pixel quantification of the cytoplasmic compartment or of the whole cells. Shown is 
the  intracellular  Lck  signal  as  a  percentage  of  the  total  Lck  signal  for  each  of  the  cells  analyzed.  Each  symbol 
corresponds to the value obtained for an individual cell. Bars indicate mean values of 25 cells studied per condition. 
Statistical analysis was performed by the Mann‐Whitney U test (***, P < 0.0001). 
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When Lck.RFP was overexpressed, no changes were observed in the frequency of Lck 
cytoplasmic accumulation and its extent per single cell when compared to endogenous 
Lck in Nef-expressing cells (Fig. 3.3C vs D and E vs F) (Fig. 3.3D and F; 89.7 +/- 6.4% 
frequency of cells showing accumulation and 55.4 +/- 10.9% relative accumulation per 
single cell, respectively). In Vpu-expressing cells co-transfected with Lck.RFP, 
however, the frequency of accumulation increased to 72.7 +/- 5.8% (Fig. 3.3D). Single 
cell analysis, however, did not reveal important differences to what was observed for 
single-cell endogenous Lck relative accumulation in the same cells (Fig. 3.3E vs F) 
(Fig. 3.3F; 35.2 +/- 8.3% relative accumulation per single cell in Vpu.GFP-expressing 
cells). Altogether, these results show that, as it was already described for Nef, Vpu can 
affect the localization of peripheral membrane proteins like Lck. Nevertheless, as 
observed for the downregulation of TSPANs and most of the studied membrane 
receptors, the extent of Vpu-mediated effect on Lck retargeting to RE/TGN is less 
potent as compared to that mediated by Nef. Also, Vpu seems to block anterograde 
transport of Lck molecules directly after their synthesis but, unlike Nef, it has no effect 
on those that already reached their steady-state distribution.    
3.5 Extracellular vesicles (EV) can be purified from human T cells culture 
supernatant   
EVs are shed by most cell types (Thery et al., 2002; Yanez-Mo et al., 2015). Thought to 
be cellular waste, they remained out of the scope of research until they were discovered 
to contain enriched proteins and microRNAs (Ratajczak et al., 2006a; Valadi et al., 
2007). Today, EVs have been shown to play an important role in many physiological 
processes in complex organisms and to be key pathological and disease factors (Schorey 
et al., 2015; Yanez-Mo et al., 2015). Among the proteins which are actively sorted into 
EVs, proteins of the TSPAN superfamily are some of the best characterized, serving 
therefore as EV detection markers (Thery et al., 2002). HIV-1 Nef has been described to 
boost EV release in cells transiently expressing the protein but also in the context of 
infection. It also has been shown to induce its own inclusion in EVs from these cells to 
potentially alter metabolism and intracellular signaling in bystander cells favoring 
pathogenesis and disease progression (Lenassi et al., 2010; Muratori et al., 2009). We 
thereby hypothesized the release of TSPAN proteins on EV as a potential mechanism of 
downregulation by Nef and, presumably, also by Vpu. Furthermore, we aimed at 
understanding this process in a physiologically relevant system in the context of HIV-1 
disease, namely HIV-1 target cells. In order to set up a system to study the effects of 
both HIV-1 accessory proteins on the production and composition of EV, we analyzed 
the capacity of different human T cell lines to release EV under different conditions. 
Initially we checked E6 Jurkat cells (Fig. 3.4A). After an overnight starvation, they 
were cultured in control or stimulation RPMI++ media, containing 20 μg/ml of 
phytoemagglutin (PHA). The FCS added to this medium was previously depleted form 
EVs by ultracentrifugation (UC). EV isolation was then performed by the differential 
UC method (Thery et al., 2006). To analyze the results, we used as output the Western 
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Blot (WB) signal of TSPANs as exosomal markers (Lotvall et al., 2014). TSPAN WB 
needed to be performed in non-reducing conditions as described elsewhere (Thery et al., 
2006). Cells responded to PHA stimulus by increasing EV release in comparison to 
control cells, as observed by the increase in the WB signal of both TSPANs used as 
detection markers CD63 and CD81. Intrigued by the decrease in (and even absence of) 
signal seen for later time points, known that EV should have high stability and therefore 
long half-life (Kalra et al., 2013), we added two other human T cell lines to the next pre-
experiment: A3.01 and JTag cells. Cells were culture for 16 hours in EV-depleted FCS-
containing medium under control or stimulating conditions (PHA). Supernatants were 
cleared, ultracentrifuged and EV preparations were analyzed by Western Blot. As noted 
before, EVs derived from Jurkat E6 cells were unstable over time and TSPAN marker 
detection was not stably achieved (Fig. 3.4B). A3.01 cells- and JTag cells-derived EV 
detection, however, worked efficiently and cells responded to stimulus by a boost 
release of EVs inferred from stronger WB signals, as expected. Unlike what was 
observed for E6 cells, the signal for both TSPANs obtained from cell lysates (CLs) with 
equal protein amounts to that of corresponding EV preparations (equivalent to 106 cells) 
was lower. This effect was strongly marked for CD63, in particular in A3.01 cells. 
Given the strong signal obtained from EV preparations for both markers, CD63 and 
CD81, in the case of A3.01 cells, we utilized these as EV source thereon.   
In order to find a more potent, T cell-specific stimulus which could be used as positive 
control in future experiment if needed, we analyzed the effect of culturing cells on 
activating surfaces or, in other words, anti-CD3 and anti-CD28 antibody coated 
surfaces. This way we should trigger a more specific signaling by direct cross-linking of 
TCR. Following overnight starvation, A3.01 T cells were stimulated with PHA or TCR-
specific antibodies in EV-depleted FCS-containing medium. Unstimulated cells were 
used as control. After 5 days in culture, SNs were cleared and EVs were isolated by UC. 
The WB signal obtained by TCR-specific stimulation with antibodies was stronger as 
that obtained by stimulating with PHA for both CD63 and CD81 from the EV 
preparations (Fig. 3.4C). Of note, both stimulation methods were efficient in enhancing 
shedding of EV when compared to unstimulated control cells whose EV prep showed 
very low signal for CD81 and CD63 at the displayed exposure time. Surprisingly and 
unlike what was observed in the previous experiment (Fig. 3.4B), the CD63 signal from 
CLs was much more intense in all cases as compared to the corresponding EV preps. 
Moreover, the CD63 signal from CLs increased in response to the antibody stimulus. In 
contrast, the CD81 signal from the CL samples was undetectable except in the control 
cells-derived sample. Altogether, the TCR-specific antibody treatment resulted in an 
increased EV release as compared to stimulation with PHA (Fig. 3.4C). 
Finally we compared two EV isolation methods, ultracentrifugation vs a commercial 
lipophilic reagent. A3.01 cells were starved overnight, cultured under control or 
stimulating conditions and harvested after 16 hours. The FCS in the culture media had 
been previously depleted of EVs. Supernatants were then cleared and either subjected to 
successive centrifugation and UC steps or incubated overnight with the Exosome 
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Isolation Reagent (Invitrogen, Carlsbad CA) and pelleted down by centrifugation. EVs 
obtained with the reagent generated considerably more TSPAN signal as those obtained 
by ultracentrifugation (Fig. 3.4D). Of note, the CD63 WB signal from CL of the reagent 
samples and from the CL obtained by UC was so intense that higher exposure times 
were not possible to achieve. As a consequence CD81 bands are faint (reagent samples) 
or not visible (UC samples). However, given the very low specificity of the isolation 
mechanism and the high risk of impurity in the final preparation, we decided to use the 
standard sequential UC as the EV isolation method thereon.    
Fig. 3.4 Setting up extracellular vesicle  (EV)  isolation and detection  in T  lymphocytes.  (A) 5 x 107  Jurkat E6 cells 
were cultured in exosome deprived medium (EDM) in the absence or presence of 20 μg/ml PHA during 30 minutes, 
2 hours or 16 hours. PHA addition was coordinated timewise to collect the respective supernatants simultaneously. 
EV  from  the  cleared  supernatants were  isolated by differential ultracentrifugation and analyzed by non‐reducing 
SDS‐PAGE. Volumes of EV preparation corresponding  to 1 x 106 cells were  loaded.  (B) Three different T cell  lines 
were tested  for their capacity to respond to a general stimulus that elevates extracellular vesicle release. 5 x 107 
cells were cultured as in A after a 24‐hour starvation step in 0.5% FCS containing medium. After 16 hours, EVs were 
isolated by differential ultracentrifugation. Volumes corresponding to 1 x 106 cells from the cell lysates were loaded 
as well as equal amounts of protein of the EV samples. (C) 10 x 106 serum‐starved cells were stimulated either by 
addition PHA  to a concentration of 20  μg/ml or by cultivation on anti‐CD3/anti‐CD28 pre‐coated bottles. After 5 
days,  EV were  isolated  and  analyzed  as  in  B.  (D)  Experiment  performed  as  in  C  but  comparing  EV  isolation  by 
ultracentrifugation vs Exosome Isolation Reagent (Invitrogen).  
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3.6 HIV-1 Nef stimulates extracellular vesicle release and its own export to the 
extracellular space by this mechanism 
As mentioned above, previous reports showed that, when expressed by cells, HIV-1 Nef 
boosts EV release and induces its own inclusion in EVs with subsequent effects on 
bystander cells (Lenassi et al., 2010; Muratori et al., 2009). In order to reconfirm the 
published information at our laboratory, we used pre-starved A3.01 human T 
lymphocytes transiently expressing Nef.GFP fusion protein or GFP as a control. Cell 
numbers were normalized so that an equal number of GFP-expressing cells were 
contained in the culture for each condition. Cells were cultured in EV-depleted FCS-
containing medium. 3 days post-transfection, cell cultures were harvested, cleared and 
ultracentrifuged. After lysis, the protein concentration of EVs and CLs was measured. 
Interestingly, the amount of total protein was close to 2-fold higher in the Nef-
expressing cell-derived EV preparation than in GFP-expressing cell-derived EV 
preparation (Fig. 3.5C). However, protein levels in cell lysates from both conditions did 
not differ (Fig. 3.5B). This increase in protein might be due to a boosted EV secretion 
mediated by Nef. Consistent with these results, WB analysis of both preparations under 
non-reducing conditions showed an increase in total EV release as interpreted form the 
higher CD63 and CD81 signal obtained for the Nef-derived sample as compared to the 
GFP-derived sample (Fig. 3.5A). In this case, TSPAN WB signals form EV samples 
were more intense than those from the corresponding CLs. Nef.GFP could be detected 
in EVs shed by cells transiently expressing this protein when proving with an anti-GFP 
antibody (Fig. 3A, upper panel). Notably, the Nef-specific antibody was not able to 
detect this (Fig. 3A, second panel from the top). That might reflect the low 
concentration of Nef on EVs despite of its strong presence in the CL and the higher 
sensitivity of the anti-GFP antibody. The heat-shock cognate 70 kDa protein (Hsp70), 
another described exosomal marker (Escola et al., 1998; Raposo et al., 1996; Thery et 
al., 1999), did not show significant enrichment in EVs as compared to CL nor for Nef-
samples neither for GFP-samples. Expectedly, calnexin, and ER marker used as a 
negative control (Lotvall et al., 2014), was present in CL but not in EVs. Thus, with 
these results we have been able to reproduce and confirm the previously published 
information which defines HIV-1 Nef as able to potentiate the secretion of EV and to 
use these shed EV vesicles to deliver itself to the extracellular compartment. 
   Results: Overlapping functions between Nef and Vpu 
 
81 
 
Fig. 3.5 HIV‐1 Nef promotes EV production and is incorporated in EVs. (A) 6 x 108 cells per condition were starved 
during 24 hours in 0.5% FCS‐containing medium and transfected with expression vectors for GFP or Nef.GFP. 3 days 
later, cell culture medium was harvested and EVs were  isolated by ultracentrifugation. Samples were analyzed by 
Western Blotting for different exosomal markers and control markers. Detection of CD63 and CD81 was achieved 
under non reducing conditions (absence of 2‐mercaptoethanol). Proteins levels were measured by the BCA assay in 
the case of cell lysates (B) and micro‐BCA assay for EV (C). 
 
3.7 HIV-1 Nef and Vpu boost secretion and stimulate their own export into EV 
HIV-1 Nef interferes with migration of T cells both in vitro and in vivo (Choe et al., 
2002; Hrecka et al., 2005; Janardhan et al., 2004; Lee et al., 2008; Park and He, 2009). 
Nef exerts this effect by altering the actin dynamics of the cell.  The molecular 
mechanism governing this relies on the interaction between Nef and the cellular kinase 
PAK2 through the viral factor’s hydrophobic patch (Stolp et al., 2010; Stolp et al., 
2012; Stolp et al., 2009). The interaction of both proteins is very transient (Imle et al., 
2015) but, upon dissociation of the complex, leads to a substrate specificity switch 
toward phosphorylation of the actin severing factor Cofilin. Hyper-phosphorylation of 
Cofilin results in its inactivation and, thereby, in a reduction in actin turnover affecting 
chemokine-induced actin cytoskeleton rearrangements that cause an arrest of migration. 
In a more recent study, our laboratory described the Nef-mediated interference with T 
cell homing in vivo and transendothelial migration (TEM) in vitro (Stolp et al., 2012). 
Both effects were dependent on the PAK2 interacting motif of Nef and, thereby, on the 
disruption of actin dynamics. However, a more detailed analysis into the multi-step 
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TEM process uncovered a lack of dependency on the integrity of that motif for 
diapedesis, the central step of this intricate process. Furthermore, Nef was also observed 
to affect the morphological polarization of the cells upon attachment to the endothelium, 
a prerequisite for efficient migration performance. Given the need for an extreme 
polarization of cells for transmigration through the endothelium, we hypothesized that a 
deep understanding of the mechanism of Nef-mediated polarization disruption would 
shed some light onto how the viral protein alters the TEM process. In this work we 
aimed at unraveling the molecular determinants of Nef involved both in polarization and 
TEM interference in the context of infection of primary human T lymphocytes.  
Fig. 3.6 HIV‐1 Vpu  is able  to boost EV  release and  is  incorporated  in EVs.  (A) 3  x 108  cells per  condition were 
transduced using lentiviral expression vectors for GFP, Nef.GFP and Vpu.GFP. After 36 hours, transduction efficiency 
was evaluated by flow cytometry and equal amounts of GFP‐positive cells were starved for 24 hours  in 0.5% FCS‐
containing medium. 72 hours  later, EV were  isolated by ultracentrifugation and analyzed by Western Blotting  for 
different exosomal and  control markers.  (B and C) Protein  levels measured by  the BCA assay  in  the  case of  cell 
lysates (B) or micro‐BCA assay for EV (C). 
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4 RESULTS: HIV-1 NEF INTERFERES WITH T CELL 
POLARIZATION AND TEM 
HIV-1 Nef interferes with migration of T cells both in vitro and in vivo (Choe et al., 
2002; Hrecka et al., 2005; Janardhan et al., 2004; Lee et al., 2008; Nobile et al., 2010; 
Park and He, 2009). Nef exerts this effect by altering actin dynamics in the cell.  The 
molecular mechanism governing this was described by our laboratory and it relies on 
the interaction between Nef and the cellular kinase PAK2 through the viral factor’s 
hydrophobic patch (Stolp et al., 2010; Stolp et al., 2009). The interaction of both 
proteins is very transient (Imle et al., 2015) but, upon dissociation of the complex, it 
results in activation of the kinase and leads to a substrate specificity switch toward 
phosphorylation of the actin severing factor Cofilin. Hyper-phosphorylation of Cofilin 
results in its inactivation and, thereby, in a reduction in actin turnover affecting not only 
migration but also chemokine-induced actin cytoskeleton rearrangements following 
TCR cross linking. In a more recent study, our laboratory described the Nef-mediated 
interference with T cell homing in vivo and transendothelial migration (TEM) in vitro 
(Stolp et al., 2012). Both effects were dependent on the hydrophobic interacting surface 
of Nef required for its association with PAK2 and, thereby, on the disruption of actin 
dynamics. However, a more detailed analysis into the multi-step TEM process 
uncovered a lack of dependency on the integrity of that motif for diapedesis, the central 
step of this intricate process. Furthermore, Nef was also observed to affect the 
morphological polarization of the cells upon attachment to the endothelium, a 
prerequisite for efficient migration performance. Given the need for an extreme 
polarization of cells in order to perform transmigration through the endothelium, we 
hypothesized that a deep understanding of the mechanism of Nef-mediated polarization 
disruption would shed some light onto how the viral protein alters the TEM process. In 
this work we aimed at unraveling other molecular determinants of Nef involved both in 
polarization and TEM interference in the context of infection of primary human T 
lymphocytes.  
4.1 Uninfected primary human T cells polarize in a simple 2D in vitro system 
In order to determine the conditions under which we could study polarization of primary 
human T lymphocytes in vitro we isolated these cells from Buffy coats with blood of 
healthy donors. After 72-hours activation with interleukin-2 (IL-2) and phytoemagglutin 
(PHA), the cells were incubated on Fibronectin (FN)-coated surfaces for 15 minutes and 
fixed. A chemokine, SDF1-α, was used to stimulate polarization (data not shown), 
however integrin signaling triggered by crosslinking of FN proved to be sufficient for 
this. Cells were fixed and stained for the visualization of polarity markers. Well 
described markers were chosen to this purpose (Fig. 4.1A) (Freeley et al., 2012; 
Samstag et al., 2003; Stolp et al., 2012; Vicente-Manzanares and Sanchez-Madrid, 
2004). Staining of the leading edge markers Talin and PKC-ζ did not provide conclusive 
information in terms of protein localization since they appeared at the uropod or at the 
leading edge depending on the individual cell studied. Moreover, immunofluorescence 
signal for these two markers was in general rather low. Conversely, staining of the 
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uropod markers Ezrin and CD44 was more robust resulting in a strong signal for the 
cells mainly at the plasma membrane which was polarized to the rear of the cell if it was 
morphologically polarized or elongated. The frequency of morphologically polarized 
cells under these conditions ranged between 30 and 45% depending on the donor. 
Parallel analysis of uropod marker polarization resulted in frequencies around 70% (Fig. 
4.1B). Acquisition of expertise with this experimental set up as well as optimization of 
the immunofluorescence staining led to an increase in detection of cell polarization 
based on morphology as well as markers, achieving lymphocyte polarization 
frequencies ranging from 50 to 70%. In addition, CD44 was chosen as the best polarity 
marker given the stronger immunofluorescence signal and the lower background. 
Analysis of cell polarization over time did not reveal strong differences between the 
various time-points analyzed; however for two of the studied donors polarity 
frequencies increased until 2 hours and dropped after that, so we decided to fix cell after 
2 hours incubation on FN-coated cover glasses in subsequent experiments (Fig 4.1C). 
 
Fig. 4.1 Establishing timing and markers of polarization of Human Peripheral Blood Mononuclear Cells (PBMCs). 
Human PBMCs were  seeded onto Fibronectin  (FN)‐coated  cover glasses and  let attach at 37ºC  for various  time 
periods, fixed and stained for known polarity markers. Samples were then analyzed by epifluorescence microscopy. 
(A) Representative epi‐fluorescence micrographs showing polarization of the leading edge markers Talin and PKC‐ζ 
and of the uropod markers Ezrin and CD44 2 hours post‐seeding. Scale bar = 5 µm. (B) Quantification of polarized 
cells  from  three healthy donors. Cells were  incubated on FN‐coated surface  for 15 minutes. A  total of 100 cells 
were  analyzed  for  morphological  polarization  (black  bars)  and,  among  morphologically  polarized  cells,  the 
frequency  of  polarization  of  Ezrin  (dark  grey  bars)  and  CD44  (light  grey  bars)  markers  was  evaluated.  (C) 
Morphological polarization of PBMCs from three healthy donors. Different timepoints after seeding were studied.
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4.2 HIV-1 Nef interferes with polarization of infected primary human T cells 
HIV-1 Nef’s effects on T lymphocyte polarization are largely unstudied. Only two 
reports described that Nef can affect T cell polarity but did not study the mechanism or 
relevance of this phenomenon (Park and He, 2009; Stolp et al., 2012). Park and He 
(Park and He, 2009) described a Nef-mediated polarity loss on Jurkat T cell lines 
inducible for the expression of Nef.GFP or GFP-tagged Nef mutants using crosslink of 
LFA-1 as polarization stimulus. They, however, did not study the phenotype in the 
context of infection. Dr. Bettina Stolp-Rastätter from our laboratory (Stolp et al., 2012) 
observed a defect in polarization of murine T cells transduced for isolated expression of 
SF2 Nef.GFP and the PAK2-interaction deficient mutant, SF2 F195A Nef , both when 
seeded on FN-coated cover glasses in the presence of SDF1-α and after attachment to 
the endothelium in vitro. In the present work, we addressed the question from a more 
physiologically relevant point of view by using PBMCs from healthy donors which 
were infected in vitro with a laboratory strain of HIV-1. Activation is required to render 
primary human lymphocytes susceptible to productive infection by HIV-1 (Stevenson et 
al., 1990). After the standard activation with IL-2 and PHA for 72 hours, cells were 
infected with NL4.3 HIV-1 viruses expressing or lacking expression of the Nef protein. 
72 hours post-infection, cells were harvested, seeded on FN-coated cover slips and 
incubated for 2 hours at 37ºC before being fixed with 3% PFA/PBS. Under these 
conditions, non-infected cells were established to polarize at least to a frequency of 
50%. To visualize cells from these samples we stained them with antibodies recognizing 
CD44 and p24/CA, as markers of polarization and infection, respectively. In order to 
exclude dead cells from the analysis, they were stained with the 7-amino-4-
chloromethylcoumarin (CMAC) cell tracker dye (Invitrogen, Carlsbad CA) and 
discriminated from viable cells by the characteristic loss of the dye (Fig. 4.2A, intense 
blue epifluorescent signal vs dim blue epifluorescent signal, respectively; only for cells 
from donors 5 to 7). Quantification of polarized cells in these samples illustrates the 
negative effect caused by the wt HIV-1 infection in relation to the values for uninfected 
cells from the same samples (Fig. 4.2B, black bar and first white bar of each data set, 
respectively). Frequency of polarization of infected PBMCs was largely decreased 
(from 47.3% polarization of uninfected to 3.3% polarization of wt HIV-1 infected for 
donor 1; from 53.6% to 6.7% for donor 2; from 63.2% to 26.7% for donor 3; from 
45.3% to 16.7% for donor 4; from 70.0% to 8.3% for donor 5; from 54.0% to 6.7% for 
donor 6; from 59.0% to 15.0% for donor 7). This reduction of polarization frequency 
was less pronounced or not observable, depending on the donor, when cells were 
infected with the ΔNef virus (grey bars as compared to black bars in the same figure; 
13.33% polarization of ΔNef HIV-1 infected for donor 1; 33.3% for donor 2; 50.0% for 
donor 3; 53.3% for donor 4; 28.3% for donor 5; 18.3% for donor 6; 36.7% for donor 7). 
The differences become more obvious when these results are shown as relative to values 
of non-infected cells from the same sample (Fig. 4.2C; from 7.1% relative polarization 
of wt HIV-1 to 27.5% relative polarization of ΔNef HIV-1 infected for donor 1; from 
12.4% to 52.7% for donor 2; from 42.2% to 88.8% for donor 3; from 36.8% to 103.9% 
for donor 4; from 11.9% to 41.1% for donor 5; from 12.4% to 36.7% for donor 6; from 
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25.4% to 52.4% for donor 7). It is appreciable in all cases that polarity values increase 
in the absence of Nef, even reaching levels of control uninfected cells for two donors. 
For these two donors Nef was sufficient to inhibit T cell polarization while other factors 
may contribute to this effect in the other donors. From these results we conclude that 
HIV-1 infection disrupts polarization of human primary T lymphocytes in vitro and that 
Nef plays a critical role in this polarity disruption.  
 
Fig. 4.2 HIV‐1 Nef impairs polarity of primary infected human T cells. Human PBMCs were activated for 72 hours 
with 2 μg/ml PHA and 10 μg/ml  IL‐2 and spin‐infected with wt and ΔNef versions of NL4.3 SF2 Nef HIV‐1  in  the 
presence of 4 μg/ml polybrene. After 72 hours, cells were seeded on FN‐coated cover glasses, incubated for 2h at 
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37ºC and fixed. Cells were stained for CD44 and HIV‐1 p24‐Capsid, as polarity and infection markers, respectively. 
For donors 5  to 7, CellTracker™ Blue CMAC viability dye was used  to discriminate dead cells.  (A) Representative 
epi‐fluorescence micrographs of  the studied morphotypes: polarized  (upper  row) or not polarized  (middle  row). 
Dead cells (lower row) were not considered.  Scale bar = 5 µm.  (B) Histogram of the polarization values observed 
for HIV‐1 wt‐infected (black) and ΔNef‐infected (grey) cells. Polarization values of non‐infected cells (white) from 
the same cover glass are shown as controls. At least 30 cells were counted per condition. (C) Relative frequency of 
polarization was calculated as the ratio between polarity frequency values of infected cells (p24 CA positive, black 
and grey bars in B) and those of non‐infected control cells from the same cover glass (p24 CA negative, white bars 
in B). 
 
4.3 HIV-1 Vpu is dispensable for disruption of T cell polarity   
As addressed by Haller et al. (Haller et al., 2014) and extended in the first part of this 
doctoral thesis, HIV-1 Nef and Vpu share several activities such as downregulation of a 
multitude of host cell surface receptors, rerouting the cellular kinase Lck form the 
plasma membrane to cytoplasmic compartments and induction of EV secretion. Since 
polarization frequencies did not reach levels of uninfected control cells for several of 
the donors studied when their cells were infected with the nef deleted HIV-1 virus, we 
wondered whether Vpu could act synergistically with Nef. To answer this question we 
included the Vpu deficient as well as the double deficient (lacking expression of both 
Nef and Vpu) counterparts of the NL4.3 virus used in the previous experiment. After 
cell fixation and immunostaining for CD44 and p24-Capsid (Figure 4.3A), cell polarity 
was quantified. As we had observed before, HIV-1 ΔNef induced a weaker reduction in 
polarization frequency than HIV-1 wt (Fig. 4.3B and C; from 23.3% polarization of wt 
HIV-1 infected to 46.7% polarization of ΔNef HIV-1 infected for donor 8; from 33.3% 
to 43.3% for donor 9; from 23.3% to 50.0% for donor 10; from 59.7% polarization 
relative to non-infected of wt HIV-1 to 97.3% polarization relative to non-infected of 
ΔNef HIV-1 infected for donor 8; from 66.6% to 92.1% for donor 9; from 44.0% to 
100.0% for donor 10). In the case of the three donors studied here, polarization 
frequencies completely equaled those of uninfected control cells. No significant 
differences were observed, however, between the polarization levels of cells infected 
with the ΔVpu virus and the wt virus (16.7% polarization of ΔVpu HIV-1 infected for 
donor 8; 23.3% for donor 9; 16.7% for donor 10; 40.7% polarization relative to non-
infected of ΔNef HIV-1 infected cells for donor 8; 47.6% for donor 9; 39.8% for donor 
10). The effect of the double deficiency in Nef and Vpu expression did not adjust to a 
clear trend and the donor variability in polarity frequency was high. Thus, the Vpu 
protein of HIV-1 does not affect polarity of human T lymphocytes in the context of 
infection. Taken together with the results presented in 4.3, for 5 out of ten donors, the 
absence of Nef completely prevented disruption of polarization in HIV-1 infected cells. 
For the other 5 donors, the observed partial effect accounted for more than a two-fold 
increase in polarization as compared to wt HIV-1 infected cells. Together with result 
from 4.3, the results shown here support the idea that HIV-1 Nef is the major player in 
disruption of polarity of infected human T cells. Therefore, we focused on studying Nef 
as the key factor in T cell polarity impairment from here on. 
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Fig. 4.3 HIV‐1 Vpu does not affect polarity of primary human T cells. Pre‐activated human PBMCs  (2 μg/ml PHA 
and 10 μg/ml IL‐2 for 72 hours) were spin‐infected with HIV‐1 wt NL4.3 SF2 Nef and its ΔNef, ΔVpu and ΔNefΔVpu 
derivatives  in  the presence of 4 μg/ml polybrene. Another 72 hours  later, cells were seeded on FN‐coated cover 
glasses,  incubated  for 2h at 37ºC, and  fixed. Staining  for HIV‐1 p24‐Capsid and CD44 was performed. Dead  cells 
were  identified  by  loss  of  the  live‐cell  dye  CellTracker™  Blue  CMAC  in  all  samples.  (A)  Representative  epi‐
fluorescence micrographs. Scale bar = 5 µm. (B) Polarity quantification. Coloured bars indicate polarization levels of 
infected  cells  in  comparison with  the polarization  levels of uninfected  cells  from  the  same  cover  glasses  (white 
bars). 100 cells were counted per condition. (C) Relative frequency of polarization of infected cells from donors 10 
to 12 (p24 CA positive, coloured bars in B) as compared to non‐infected control cells (p24 CA negative, white bars in 
B) from the same cover glass. 
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4.4 Establishment of an experimental system to study Nef-mediated effects on T 
cell polarity 
To further understand Nef’s effects on polarity we wanted to search for molecular 
determinants involved in the phenotype as well as to evaluate the prevalence of this 
phenotype in lentiviral evolution. For that we needed a cellular system in which we 
could express various Nef mutants and alleles. To that end, we tested nucleofection as 
delivery method of an expression vector for GFP into PBMCs using the AMAXA kit 
(Lonza, Basel, Switzerland) and evaluated polarization of these cells. This resulted in 
frequencies of polarization as low as 2% for GFP-expressing cells (Fig. 4.4A and B). 
Values were only slightly higher for GFP-negative cells from the same coverslip or 
mock control cells; however they did not exceed 21%. Under these circumstances, the 
dynamic range needed to see the consequences of Nef expression would not be 
achieved. Moreover, polarization frequency values of control (untransfected) cells were 
importantly reduced respect to the usual values observed for control (uninfected) 
PBMCs (Figures 4.1C, 4.2B and 4.3B vs ). Therefore we can conclude that the process 
of nucleofection itself negatively affected the capacity of cells to polarize. Thereby 
nucleofection was ruled out as a gene delivery method for subsequent experiments. As a 
next attempt, A3.01 cells were tested for polarity. These cells showed a frequency of 
polarization of around 50% for all the timepoints studied (Figure 4.4C). When 
transfected for the expression of GFP or Nef.GFP, polarity values dropped marginally 
for GFP-expressing control cells but expression of Nef caused a 2-fold reduction in cell 
polarization. In such situation, the dynamic range of Nef’s effect on polarity was broad 
enough to make possible the molecular studies we wanted to pursue (Figure 4.4 D and 
E). Thus, A3.01 cells turned out to be a suitable system for subsequent molecular 
studies to further enlarge our understanding of Nef-mediated effect on T cell-polarity. 
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Fig. 4.4 A3.01 T  lymphocytes are a suitable system for  in vitro polarity studies. (A and B) Pre‐activated (2 μg/ml 
PHA and  IL‐2 10 μg/ml  for 72 hours) human PBMCs  isolated  from two healthy donors were nucleofected with an 
expression vector for GFP. Polarity assays were performed 28 hours later and cells were fixed at various timepoints.  
Histogram bars depict frequency of polarization of GFP‐positive cells (black bar) compared to those of GFP‐negative 
cells  from  the  same  coverslip  (dark  grey  bar)  or mock  control  cells  (light  grey)  from  a  different  coverslip.  (C) 
Polarization  values of human A3.01 T  lymphocytes  subjected  to polarity assay. Cells were  fixed at  the  indicated 
timepoints. n = 100 cells. (D) Representative epi‐fluorescent micrographs of A3.01 cells transfected with expression 
plasmids  for GFP  or  SF2 Nef.GFP.  6  hours  post‐transfection,  cells were  subjected  to  polarity  assay  and  fixed  at 
different  timepoints. Shown are cells  fixed 1 hour post‐transfection. Scale bar = 5 µm.  (E) Quantification of cells 
shown in (D). n = 100 cells. 
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4.5 T cell polarity disruption is an evolutionarily conserved effect of lentiviral 
Nef proteins 
Primate lentiviruses, including human pathogenic viruses HIV-1 and HIV-2 as well as 
SIVs, have in common, among other features, the accessory nef gen. Functions of the 
viral gene products important for HIV-1 biology are conserved and conserved 
throughout evolution. This is the case for most of the described functions of Nef. 
However, some functional differences have been also reported as the ability of HIV-2 
Nef to downregulate CD3 from the plasma membrane which cannot be performed by 
HIV-1. Lack of this activity correlates to high T cell activation levels observed in 
infected subjects and with virus pathogenicity displaying (faster) progression towards 
AIDS (Munch et al., 2002; Rudolph et al., 2009; Schindler et al., 2006). According to 
the capacity to downmodulate CD3, Nef alleles can be categorized into two groups: 
Group 1, containing Nef alleles of HIV-1 and SIVcpz, unable to downmodulate CD3, 
and Group 2, including Nef alleles of less- or non-pathogenic viruses HIV-2 and SIV 
that downregulate CD3. Differences between Nef alleles can help determining at which 
point in lentiviral evolution a specific activity was developed. All previously shown 
results were obtained with the HIV-1 SF2 Nef allele, the standard allele used for in vitro 
studies in our laboratory. To study the evolutionary relevance of Nef-mediated polarity 
disruption we transfected A3.01 human T lymphocytes with expression plasmids for 
GFP, HIV-1 SF2 Nef.GFP and a panel of YFP-tagged Nef alleles from HIV-1 (NL4.3, 
NA7, 8161K9, YBF30), HIV-2 (Ben, Cbl23), and SIV (Cpz Gab2, Cpz Tan3, gsn, mon 
Val, mac239, blue, smm Fwr 1, smm Ffm 1, agm Sab 1, agm Tan 1, sykes 51). Six 
hours after transfection, cells were incubated at 37ºC on FN-coated coverslips for 1 
hour, fixed and stained for the visualization of the polarity marker CD44 (Figure 4.5A). 
All alleles tested reduced the frequency of polarization when expressed by A3.01 cells 
ranging from 9.7 +/- 3.8% for SIV Nef mac239 to 40.7 +/- 9.3% for HIV-1 YBF30 as 
compared to GFP-expressing control cells, with 46.8 +/- 7.1%. In addition, all of them 
showed no statistical differences when compared to the effect caused by HIV-1 SF2 Nef 
except two Nef alleles, HIV-1 YBF30 Nef and SIV cpz Tan 3 Nef (Figure 4.5B; p 
values of 0.0315 and 0.0400, respectively; p value for SIV Nef Gab 2 of 0.0625). These 
two Nef alleles were totally or partially deficient for many other studied Nef functions, 
including Lck relocalization, TCR-induced actin dynamics or induction of tyrosine 
phosphorylation (Rudolph et al., 2009). A comparative analysis of the polarity values of 
Nef alleles categorized into group 1 or group 2 evidenced a statistically significant 
difference between them, suggesting Nef’s effects on polarity may be linked to the CD3 
downregulation capacity of these alleles (Figure 4.5C; p value < 0.0001). To address 
whether CD3 downmodulation is indeed coupled to the Nef-mediated disruption of 
polarity, we made use of a panel of SIV Blue Nef mutants with specific defects in 
downregulating surface receptors (Rudolph et al., 2009). Modification of the ExxxL 
motif of SIV Blue Nef generates a mutant which specifically downregulates CD3 but 
not other receptors (E181A/L185A; ELLA). R129/130A (RRAA) and R129A mutations 
result in CD3 downmodulation deficient mutants. Surprisingly, ELLA mutant turned 
out to be deficient in T cell polarity impairment while RRAA and R129A performed as 
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efficiently as SIV Blue Nef wt (Figure 4.5D; 19.0 +/- 2.3% for SIV wt Blue; 24.1 +/- 
0.8% for RRAA; 14.2 +/- 6.3% for R129A; 42.7 +/- 10.4%). However, comparison of 
cell polarization frequencies for HIV-1 SF2 Nef, unable to downregulate CD3, with 
those of SIV ELLA Blue Nef, selectively targeting CD3 for downregulation, allows us 
to rule out a CD3 downregulation dependency for the observed Nef-mediated disruption 
of T cell polarity. 
 
Fig.  4.5 Polarity disruption  is  an  evolutionarily  conserved  activity of Nef proteins. A3.01  T  lymphocytes were 
transiently  transfected with expression plasmids  for GFP, SF2 Nef.GFP or YFP versions of various SIV, HIV‐1 and 
HIV‐2 Nef alleles. 6 hours post‐transfection, cells were seeded on FN‐coated cover glasses and incubated for 1h at 
37ºC,  fixed  and  stained  for  CD44.  At  least  100  cells were  counted  for  each  condition.  (A)  Representative  epi‐
fluorescence micrographs of  transfected cells. Scale bar = 5 µm.  (B) Histogram bars depict polarization  levels of 
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transfected cells. Nef alleles were categorized into tow group: group 1, or Nef alleles able to downregulate the CD3 
surface receptor, and group 2, or Nef alleles unable to downregulate CD3. Shown are arithmetic mean values and 
standard errors  from  three  independent experiments. Statistical significance as assessed by  the Man‐Whitney U 
test is indicated (*, P < 0.05). (C) Batch comparison of the two groups of Nef alleles. Bars indicate mean values for 
each group. Statistical analysis was performed by  the Man‐Whitney U  test  (***, P < 0.05).  (D) A3.01 cells were 
transfected with expression vectors for GFP, SF2 Nef.GFP or YFP versions of SIV Blue Nef and three of its mutants. 
Polarity  assay  was  performed  as  described  above  and  polarization  quantification  was  carried  out.  Arithmetic 
means and standard errors are plotted.  
 
4.6 The NAKC interacting surface of Nef is important for T cell polarity 
impairment 
As described above (see section 4), the molecular determinant/s of Nef that mediate the 
impairment of transendothelial migration and polarization are unknown. To identify 
these determinants, we transfected A3.01 human T cells with expression plasmids for 
GFP, Nef.GFP or mutants thereof. After 6 hours, cells were incubated at 37ºC on FN-
coated coverslips for 1 hour, fixed and stained for the polarity marker CD44 (Figure 
4.6A). Frequency of polarization was quantified for transfected cells. As observed 
previously, the isolated expression of Nef resulted in an approximate 2-fold decrease in 
polarization frequency as compared to GFP-expressing control cells (Figure 4.6B; 24.7 
+/- 2.4% for SF2 wt Nef and 48.4 +/- 3.7% for GFP). As expected, the PAK2-
interacting deficient mutant, F195A Nef.GFP (Stolp et al., 2010; Stolp et al., 2009), did 
not cause impairment and displayed polarization levels comparable to those of control 
cells, 48.2 +/- 4.0%. Expression of G2A Nef mutant, unable to anchor into membranes 
due to lack of the myristoyl-acceptor glycine 2 and, therefore, largely deficient in all 
Nef functions (Fackler et al., 2006; Geyer et al., 1999), also resulted in a frequency of 
polarization similar to that of GFP-expressing control cells, 44.2 +/- 12.4%. On the 
other hand, mutations of serine at position 6, the phosphorylation site by novel PKC 
(nPKC)  required for efficient viral transcription and infectivity (Wolf et al., 2008), and 
of methionine at position 20, needed for downmodulation of HLA-I (Tomiyama et al., 
2002), did not show relevance for T cell polarity impairment (polarization frequencies 
of 28.2 +/- 7.2% and 23.2 +/- 1.4%, respectively). The same was observed for sequence 
modifications targeting the motifs LL168/169 and ED178/179 at the C-terminal flexible 
loop, essential for CD4 downregulation through the interaction with the endocytic 
machinery (adaptor complex and V-ATPase, respectively) (Bresnahan et al., 1998; 
Craig et al., 1998; Lu et al., 1998), (polarization frequencies of 23.4 +/- 6.7% and 28.9 
+/- 6.4%, respectively). Mutations at the acidic stretch (EEEE66-69), needed for 
interaction with PACS adaptor involved in receptor downregulation (Piguet et al., 
2000), the VGF motif, the integrity of which is needed for SH3-domain interactions 
between Nef and host proteins (Meuwissen et al., 2012), or the Proline rich motif 
(PxxP), part of the SH3 domain interaction surface in Nef (Collette et al., 1996; Saksela 
et al., 1995), resulted in intermediate reduction in polarity as compared to the 
expression of SF2 wt Nef and GFP (35.7 +/- 2.2%, 31.9 +/- 4.8%, 4.6 +/- 4.4%, 
respectively). Interestingly, expression of a Nef version lacking an amphipathic alpha-
helix necessary for the interaction with a multi-molecular complex consisting of at least 
two adaptor proteins and four kinases, NAKC (Baur et al., 1997), did not affect cell 
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polarization levels as compared to GFP-expressing control cells, displaying a frequency 
of polarization of 50.8 +/- 8.2%. Thus, the interacting surface of Nef implicated in the 
formation of the NAKC is required for inhibition of polarity by Nef. This suggests the 
implication of one or more of the factors and/or kinases involved in the complex in the 
molecular mechanism governing this effect. 
Fig.  4.6 Mapping  the  phenotype:  correct NAKC  formation  necessary  for  T  cell  polarity.  A3.01  cells were  transfected with 
expression plasmids for GFP, SF2 Nef.GFP or various mutants. 6 hours after transfection, cells were incubated at 37ºC for 1 hour 
on  FN‐pre‐coated  cover  glasses,  fixed  and  immunostained  for  CD44.  (A)  Representative  epi‐fluorescence  micrographs  of 
transfected cells. Scale bar = 5µm. (B) Histogram showing polarization levels of cells transfected with the indicated mutants. Bars 
correspond to the arithmetic mean and standard error of three  independent experiments. At  least 100 cells were counted for 
each condition. (C) Cells from the same source as those used in (A) and (B) were stained in parallel with APC‐coupled antibodies 
targeting CD4 to evaluate by  flow cytometry the downregulation capacity of each of the mutants studied. Representative dot 
plots of gated  living cells  transfected with GFP, wt Nef.GFP or LLAA Nef.GFP are shown. MFI values are shown  in  red  for  the 
gated populations. (D) Histogram depicts the remaining surface CD4 levels obtained by dividing the MFI of transfected cells by 
that  of  untransfected  cells  (R3  gate  vs  R2  gate,  respectively).  All  values were  normalized  to  that  of  GFP  transfected  cells, 
arbitrarily set to 100.     
 
To make sure of the functionality of the constructs used in the previous mapping 
experiment, we evaluated CD4 surface expression levels of cells from the same source. 
Cells were harvested 8 hours post-transfection and stained them with an APC-coupled 
antibody recognizing CD4 for subsequent analysis by flow cytometry. Membrane 
exposed CD4 levels were calculated as the ratio between the MFI values of 
intermediate/high-GFP-expressing cells and those of untransfected cells (GFP-negative) 
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form the same sample (Figure 4.6C, gate R3 vs gate R2). As expected, modifications in 
Methionine at position 20, the acidic stretch (EEEE66-69), the VGF motif, the PxxP 
motif and the hydrophobic patch (F195) had little to no effect in the expression of CD4 
(Collette et al., 1996; Fackler et al., 2006; Meuwissen et al., 2012; Piguet et al., 2000; 
Saksela, 2011; Saksela et al., 1995). The non-myristoylatable mutant of Nef displayed a 
two-fold reduction in CD4 expression at host cell plasma membrane (Fackler et al., 
2006; Geyer et al., 2001; Giese et al., 2006). As expected, structural changes in the C-
terminal flexible loop, and more specifically at LL168/169 and ED178/179 residues, 
abrogated this Nef activity (Chaudhuri et al., 2007; Fackler et al., 2006; Keppler et al., 
2006). Finally and also expectedly, deletion of the 12-39 region of Nef caused also no 
significant difference in remaining CD4 expression when comparing to that of GFP-
expressing control cells, or, in other words, this mutant was deficient for CD4 
downregulation (Figure 4.6D) (Fackler et al., 2006). 
Taken together, the in vitro mapping allowed to define a protein determinant previously 
unrelated to migration phenotypes, namely the NAKC interaction surface (12-39), as 
essential for Nef-mediated T cell polarity disruption together with the PAK2-interacting 
surface.  
4.7 NAKC interaction surface of Nef is required for disruption of T cell 
polarity in the context of HIV-1 infection 
We next wanted to validate the results from the mapping experiment in a more 
physiologically relevant set up. We utilized the experimental design used in the 
beginning of this work (see 4.1 and 4.2) in which we infected pre-activated primary 
PBMCs from healthy donors and subjected them to our polarity assay 72 hours later. In 
this case, together with NL4.3 HIV-1 wt SF2 Nef and its Nef-deficient version we 
included viruses bearing F195I and Δ12-39 Nef mutants. CD44 and p24-Capsid were 
used as polarity and infection markers, respectively (Figure 4.7A). Evaluation of 
polarization frequencies once more showed a strong reduction in polarity of HIV-1 wt 
infected cells as compared to non infected cells from the same sample (Figure 4.7B; 
from 66.4% polarization of uninfected to 14.6% polarization of wt HIV-1 infected for 
donor 11; from 56.1% to 19.7% for donor 12; from 69.9% to 32.2% for donor 13). This 
difference became less pronounced or even not observable for cells infected with the 
ΔNef virus (from 71.7% polarization of uninfected to 44.4% polarization of ΔNef HIV-1 
infected for donor 11; from 45.1% to 62.0% for donor 12; from 68.1% to 73.5% for 
donor 13). Of note, polarization levels of cells infected with both Nef-mutant viruses 
also resulted in polarization frequencies similar to those of uninfected cells and ΔNef-
infected cells for all three donors studied (polarization frequency of 52.1, 49.2 and 
67.6%, for cells from donors 11 to 13 infected with Δ12-39 Nef HIV-1, respectively; 
52.2, 50.8 and 67.1% for cells from donors 11 to 13 infected with F195I HIV-1 virus, 
respectively). Thus, the amphipathic alpha-helix at the N-terminal region of Nef 
responsible for the formation of a protein/kinase complex is also required for the 
interference with polarization processes in T cells. 
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Fig. 4.7 The NAKC‐interaction surface of Nef is also relevant in the context of infection. Pre‐activated (PHA 2 μg/ml 
and 10 μg/ml IL‐2 for 72 hours) human PBMCs from healthy donors were spininfected  in the presence of 4 μg/ml 
polybrene. Cells were then incubated on FN‐coated coverslips at 37ºC for 2 hours, fixed and stained for CD44 and 
HIV‐1 p24‐Capsid.  (A) Representative  images of  infected cells acquired with an epifluorescence microscope. Scale 
bar = 5 µm. (B) Histogram of the polarization levels of cells infected with HIV‐1 wt (black) and or its ΔNef, F195I Nef, 
Δ12‐39 Nef derivatives (three tones of grey: dark to light, respectively) compared to uninfected cells from the same 
coverslip (white). At least 100 cells were counted for each condition. 
 
4.8 Pharmacological inhibition of NAKC members unravels implication of 
PKC as part of the Nef-mediated polarity disruption mechanism  
In order to search for host cell factors which could potentially be implicated in the 
molecular mechanism of the impairment of T cell polarity by Nef, we targeted members 
of NAKC by pharmacological inhibition. First of all the potential cytotoxicity of this 
drugs was studied by evaluating viability rates of A3.01 cells pot-treatment at different 
timepoints by exclusion of 7AAD dye. After the corresponding adjustment of 
concentration, none of the inhibitors caused cytotoxic effects on target cells (data not 
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shown). A3.01 cells were transfected with expression plasmids for GFP or Nef.GFP 
followed by addition of inhibitors or DMSO to the culture 1 hour later and cells were 
cultured for 6 hours in the presence of the inhibitors (see Table). After harvesting, cells 
were seeded on FN-coated coverslips, incubated for 1 hour at 37ºC, fixed and stained 
for CD44 (Figure 4.8A). Addition of DMSO did not change frequencies of polarization 
of GFP- and Nef-GFP transfected cells as compared to the same DMSO-untreated cells. 
Treatment of GFP-transfected cells with the inhibitors caused no significant change in 
the frequency o polarization as compared to control and DMSO-treated cells. The only 
exception was observed for the addition of rottlerin, a PKC inhibitor targeting 
preferentially PKC-δ and less efficiently all the other PKC isoforms as well as other cell 
proteins including MAPK. This inhibitor induced a decrease in the frequency of 
polarization to the levels seen for untreated and DMSO-treated Nef.GFP-transfected 
cells. On the other hand, treatment of Nef-expressing cells with the inhibitors resulted in 
no significant increase in the frequency of polarization excluding Gö6983, a pan protein 
kinase C (PKC) inhibitor which targets all PKC isoforms except PKC μ (Figure 4.8B; 
35.8 +/- 6.8% as compared to 20.0 +/- 6.2% of Nef.GFP-expressing DMSO-treated 
cells) (He et al., 2014; Lin et al., 2014; Prgomet et al., 2015; Young et al., 2005). The 
drug caused a recovery in the frequency of polarization to that observed for control and 
DMSO-treated GFP-transfected cells. Of note, no difference was observed for GFP-
expressing cells cultured in the presence of Gö6983 as compared to untreated and 
DMSO-treated GFP-expressing control cells (Figure 4.8C; 4.4 +/- 2.9% and 43.2 +/- 
4.4%, respectively), providing evidence that the observed recovery in polarity levels is 
Nef-specific. Importantly, treatment with Rottlerin resulted in an even stronger 
reduction in the polarization frequency levels of Nef.GFP-transfected cells as compared 
to the Nef.GFP control and DMSO-treated cells. Since this drug showed a low target 
selectivity affecting indistinctly GFP- and Nef-GFP expressing cells, we concluded that 
Rottlerin treatment results in an unspecific reduction in the frequency of polarization 
which does not relate to Nef expression. Thus, from the Nef-specific effect on of 
polarization levels observed after treatment with a PKC inhibitor, we presume PKC 
plays a key role as a host cellular Nef partner in mediating disruption of T lymphocyte 
polarity. 
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Fig.  4.8  Pharmacological  inhibition  of  NAKC  members  discloses  involvement  of  PKC  in  the  Nef‐mediated 
impairment of T  cell polarity. A3.01  cells were  transfected with GFP or Nef.GFP. One hour  later,  the  inhibitors 
were added to the culture (see working concentrations  in Table) and cells were  incubated for another six hours. 
DMSO was used as the internal control. Cells were then incubated for one hour on FN‐coated coverslips, fixed and 
stained  for  CD44.  (A)  Representative  epi‐fluorescence micrographs  of  transfected  control  and  Gö6983‐treated 
cells.  Scale  bar  =  5µm.  (B)  Polarization  frequency  values  of  inhibitor‐treated  Nef.GFP  transfected  cells  (grey) 
compared to GFP and Nef.GFP untreated and DMSO‐treated controls (black). At  least 100 cells were counted for 
each condition. Depicted are the arithmetic means and standard deviation from three  independent experiments. 
(C) Frequency of polarization of inhibitor‐treated GFP‐transfected cells compared to the same controls as in (B). At 
least  100  cells  counted  per  condition.  Arithmetic  means  and  standard  deviation  from  three  independent 
experiments are shown. Statistical significance as assessed by the Man‐Whitney U test is indicated (*, P < 0.05). 
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4.9 The NAKC interaction surface of Nef is not involved in chemotaxis 
inhibition toward SDF-1α in vitro 
A well described activity impaired by Nef is T lymphocyte chemotaxis toward the 
cytokine SDF-1α through a porous filter system (Choe et al., 2002; Lee et al., 2008; 
Park and He, 2009; Stolp et al., 2010; Stolp et al., 2009). With a pore size sufficiently 
small, this artificial system can resemble in a not very physiological manner the central 
steps of TEM diapedesis. In order to see if the defect in T cell polarization described 
here accounts for the previously observed disruption in diapedesis (Stolp et al., 2012), 
we wanted to test the 12-39 deleted Nef mutant in this assay and compare it to Nef wt 
and the rest of the relevant mutants. To that end, we transfected CCR7 T lymphocytes 
for the expression of GFP, Nef.GFP and various Nef mutants as GFP fusions. 24 hours 
after transfection, cells were starved in 0.5% FCS-containing medium in order to boost 
response to the chemokine. Cells were seeded onto transwell inserts of 5 μm pore size 
and placed on 50 μg/ml SDF-1α-containing media. Migration of GFP-positive cells was 
evaluated by flow cytometry after culturing the cells at 37ºC and 5% CO2 for 2 hours 
(Figure 4.9A). The proportion of migrated cells was calculated as the ratio between the 
percentages of GFP-positive cells from the cells migrated through the filter (total 
migrated cells at the lower chamber) and the cells added initially on the filter (input). 
The obtained value is then normalized to those obtained for GFP-transfected control 
cells arbitrarily set to 100%. Expression of Nef abrogated almost completely migration 
as compared to GFP-expressing control cells (Figure 4.9B; 4.4 +/- 2.3% migrated cells 
expressing Nef.GFP). Mutation in the flexible loop (ED178/179), responsible for the 
interaction with the endocytosis machinery, did not induce any changes to the 
proportion of wt Nef-expressing cells (4.9 +/- 1.8% migrated cells). As described 
previously, by mutating the Phenylalanine residue from the hydrophobic patch (F195) 
responsible of the interaction with PAK2 the Nef-mediated inhibition of migration was 
significantly reduced in comparison to the wild type protein (Stolp et al., 2009). 
However, this effect did not reach GFP-expressing control levels (43.5 +/- 5.0% F195A 
Nef-expressing migrated cells). This underlines the importance of the actin cytoskeleton 
dynamics for T cell migration toward chemotactic stimulus. Deletion of the amphipathic 
helix forming the interaction surface with NAKC caused only a marginal reduction in 
the inhibition of migration caused by wt Nef (12.9 +/- 5.0% migrated cells). We 
wondered then whether simultaneous disorganization of the hydrophobic patch and 
deletion of NAKC-interaction surface could completely inhibit Nef function. The effect 
of the double mutation on chemotaxis in vitro did not provide further loss of Nef-
mediated inhibition of migration as compared to F195A mutation (46.4 +/- 6.8% 
migrated Δ12-39.F195A Nef.GFP-expressing cells), indicating that the effect mediated 
by this double mutant was exclusively due to disorganization of the hydrophobic patch. 
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Fig.  4.9  NAKC‐interacting  surface  of  Nef  does  not  play  a  role  in  an  in  vitro  chemotaxis  assay.  CCR7  human 
lymphocytes were transfected with expression plasmids encoding GFP, Nef.GFP or four Nef mutants. After 24 hours, 
cells were starved in 0.5% FCS‐containing medium for 2‐4 hours and their ability to migrate through a transwell (5 
µm pore  size)  toward 50 ng/ml SDF‐1α was  studied over 2h.  (A) Representative dot blots of  the  INPUT and  the 
migrated  fractions.  (B)  Histogram  depicts  the  proportion  of migrated  cells  calculated  as  the  ratio  between  the 
percentages  of GFP‐positive‐gated  cells  (Gate  R2)  of  total migrated  cells  and  INPUT  (Shown  in  red).  Arithmetic 
means with standard deviations from three independent experiments are shown. Values were normalized to those 
of GFP transfected cells, arbitrarily set to 100.  
 
4.10 Monitoring polarity of Nef-expressing T cells over time shows fundamental 
differences with control cells and cells expressing Nef mutants 
All the results shown so far had been obtained in a steady state, from infected or 
transfected human lymphocytes after attachment to FN-coated surfaces and fixation. 
That experimental set up provided information on how many cells could polarize at a 
certain timepoint, however it did not provide insight about the dynamics of this cellular 
process. Had GFP or Nef-GFP round-shaped cells been round over the whole incubation 
time until fixation (1 or 2 hours)? Or were they rather subjected to cycles of polarization 
and depolarization? In other words, is polarity a “yes or no” phenotype or is it subjected 
to temporal regulation? To address this, A3.01 human T cells were transfected with 
expression plasmids for GFP, Nef.GFP, and GFP fusions of the Nef mutants Δ12-39, 
F195A and the double mutant Δ12-39.F195A. 6 hours after transfection, cells were 
stained with PKH26 membrane dye and seeded on FN-coated MatTek microscopy 
plates. Time lapse microscopy videos were then acquired over 1 hour (Figure 4.10). 
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Fig. 4.10 Nef interferes with T cell polarity in a sustained manner over time and its mutants revert this effect. Still 
images from time lapse microscopy videos of A3.01 cell polarization in the presence of Nef. Cells were transfected 
with  expression  plasmids  encoding  SF2  Nef.GFP,  Δ12‐39  Nef.GFP,  F195A  Nef.GFP  or  the  double  mutant  Δ12‐
39.F195A Nef.GFP and 6 hours later they were stained with the PKH26 membrane dye (Sigma‐Aldrich, St. Louis, MO) 
and seeded on FN‐pre‐coated MatTek (four‐chambered petri dishes for live cell imaging). Acquisition of one frame 
every 1.5 minutes results  in time  lapse videos of approximately 1 hour  length. Confocal spinning disk microscope 
was handled by Nikolaos Tsopulidis 
 
Analysis of the videos revealed that polarization of GFP-expressing or untransfected 
control cells is a highly dynamic process in which cell shape cycles between elongated 
and round, with a tendency to rather long elongation periods as compared to those in 
which the cell remains round (Figure 4.11). Of note, when analyzed over 60 minutes, all 
of the studied control cells were able to polarize at least once during the observation 
period. On the other hand, Nef.GFP-expressing cells displayed an almost complete lack 
of polarization over the complete 1 hour. If occurring at all, polarization periods in this 
case were rare and with a clear tendency to be very short (for one single frame in most 
cases). For 9 out of 15 cells polarization events were inexistent during the acquisition 
time. Unlike wt SF2 Nef-expressing cells, expression of the three analyzed mutants 
resulted in much higher frequency of polarization over time.  These cells therefore 
showed a behavior more similar to that of GFP-expressing cells. However, some 
fundamental differences were observed in the effect these mutants exerted on T cell 
polarization. Firstly, polarization of all the studied cells was not observed for none of 
the three mutants. There were cells which did not polarize over the complete 1 hour, and 
the frequency of these cells was the highest for Δ12-39 Nef (4 cells out of 15), followed 
by F195A Nef (2 cells out of 15) and the double mutant Δ12-39.F195A Nef in the last 
place (1 cell out of 15). Furthermore, Δ12-39 Nef-transfected cells showed in general 
longer periods of no polarization as compared to the other two mutants or control cells. 
Conversely, F195A Nef-expressing cells had a higher tendency to remain polarized 
during the complete 1 hour of acquisition or to display shorter periods of no polarization 
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as compared to the other two mutants or control cells. The extent of the elongation of 
polarized cells differed also between the mutants and control cells. Cells expressing 
F195A Nef had a tendency to be very elongated. Δ12-39 Nef-expressing cells on the 
other hand generally polarized less keeping a round cell body with a rather short but 
well defined uropod. Δ12-39.F195A Nef-expressing cells and GFP-expressing and 
untransfected control cells kept also an easily recognizable round cell body but with a 
longer uropod in general. All in all, the double mutant resembled better the phenotype 
shown by GFP-expressing or untransfected control cells. 
Fig. 4.11 Nef interferes with T cell polarity in a sustained manner over time and its mutants revert this effect. Analysis 
of the polarity assay over time shown in Figure 10. Polarization (black) and no polarization (white) periods for individual 
cells are depicted over the acquisition time (in minutes). Fifteen cells where analyzed per condition. 
 
Analysis over time of the area covered by cells from the same videos was also 
performed as an evaluation of the polarization extent (Figure 4.12). As expected, 
Nef.GFP-expressing cells displayed an almost 2-fold reduction in the area covered over 
time as compared to GFP-expressing control cells (213.73 +/- 106.14 μm2/h vs 397.5 +/- 
75.9 μm2/h, respectively). Only a subtle change could be observed in the area covered 
over time for the Δ12-39 Nef mutant as compared to wt Nef (284.8 +/- 138.2 μm2/h). 
F195A and Δ12-39.F195A were defective for this Nef effect and did not cause a 
reduction in respect to GFP-expressing control cells (394.4 +/- 152.9 μm2/h and 462.4 
+/- 181.2 μm2/h, respectively) 
Taken together, the results shown so far describe a Nef-induced polarity defect in 
human PBMCs in the context of infection and identify the α-helical motif 12-39, 
required for the assembly of the NAKC, as a new determinant for this effect together 
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with F195, involved in the interaction with PAK2 and responsible for actin dynamics 
disruption. Further characterization of the requirement of these motifs, and thereby of T 
cell polarization, for TEM via an artificial chemotaxis in vitro assay led to no 
conclusive results. Therefore, the following presents the setting up of a more 
physiologically meaningful TEM experimental system intended to help us 
understanding the contribution of polarity impairment to the negative effects of Nef on 
T cell homing.   
Fig. 4.12 Nef interferes with T cell polarity in a sustained manner over time and its mutants revert this effect. (A) 
Time projection of videos analyzed in Figure 10 shown as temporal colour code. Scale bar = 5 µm. (B) Depicted is the 
single‐cell area coverage over one hour. Each symbol corresponds to the value obtained for an individual cell. Bars 
represent  the  arithmetic mean  and  standard  deviation  for  at  least  6  analyzed  cells. Analysis was  performed  by 
Nikolaos Tsopulidis using FIJI.  
 
4.11 Establishment of an in vitro system to study transendothelial migration of 
primary infected human T lymphocytes 
T lymphocytes constantly migrate between blood and secondary lymphoid organs. This 
is a hallmark of lymphocyte function that leads to their activation, antigen-specificity 
development and efficient immune surveillance. It also requires constant crossing of the 
vascular endothelium by the complex, multistep process of TEM (Ley et al., 2007; 
Nourshargh and Alon, 2014). Successful transmigration is typically followed by 
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subendothelial locomotion and penetration into the underlying tissue. The study of TEM 
using primary human lymphocytes and endothelial cells in vitro is something that has 
been already performed and established by others (Boscacci et al., 2010; Muller and 
Luscinskas, 2008; Stolp et al., 2012). Primary human umbilical vein endothelial cells 
(HUVECs) are typically used to that end. These cells are able to form continuous 
monolayers which impose some difficulties for the lymphocytes to migrate through 
them. This makes of it an active process which requires strong stretching or polarization 
of the transmigrating cells to push their cell bodies through, and more specially their 
voluminous nucleus. Our laboratory has previously described that Nef interferes with 
TEM and subendothelial tissue migration both in vivo and ex vivo imposing a defect on 
T cell homing. While the inhibition of subendothelial migration is mediated via the 
effects of Nef-PAK2 on actin dynamics, Nef effects on transmigration involve other, yet 
to be determined protein interactions. Notably, the inability to transmigrate of Nef-
expressing cells was paralleled by a marked reduction of cell polarization. Therefore, 
we hypothesized that the observed new polarity defining Nef determinant 12-39 may be 
required for hindering TEM.  
In order to study the effects of deletion of the 12-39 deletion of Nef in TEM we 
designed an experiment in which infected and sorted human PBMCs will then be tested 
for transmigration through a primary HUVEC monolayer under shear flow. This highly 
complex experimental set up needed to be first established in our lab. To achieve 
attachment of lymphocytes to the HUVECs monolayer, the endothelial cells have to be 
activated e.g. with tumor necrosis factor-α (TNF-α) which stimulates surface expression 
of key adhesion molecules involved in TEM such as E-selectin, intercellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and 
platelet/endothelial adhesion molecule-1 (PECAM-1) (Pober and Cotran, 1990; Pober 
and Sessa, 2007). TNF-α concentration is critical for the correct activation and if it is 
too high this can result in cell aggregation or death (Figure 4.13A). Evaluation of the 
formation of continuous monolayers requires monitoring over time. We did this by 
seeding cells simultaneously on cell culture plates suitable for microscopy and transwell 
inserts, both coated with matrigel. The first ones allowed us visualizing the monolayer 
and the second ones facilitated a system in which we could measure trans-endothelial 
electrical resistance (TEER), as a method to evaluate the integrity of the monolayer. We 
seeded cells in two different concentrations, 3.125 x 104 cell/cm2 (low cell 
concentration) or 1.25 x 105 cell/cm2 (high cell concentration) treated with TNF-α 4.3 
ng/ml (200 U/ml) or untreated. We then monitored over a period of 30h the formation 
and evolution of the HUVEC monolayers both visually and by TEER measurements. 
Despite of visually looking confluent, the monolayers were not completely sealed as 
inferred from the TEER measurements (Figure 4.13B and C, images of cells at low 
concentration not shown). No differences were detected at any studied timepoint 
between cells seeded at any concentration or treated with TNF-α when compared to 
empty matrigel-coated transwell inserts.  
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Fig.  4.13  A  system  to  study  transendothelial  migration  in  vitro:  Human  Umbilical  Venule  Endothelial  Cells 
(HUVECs). (A) White field micrographs showing the effects of a too high concentration of TNF‐α (25 ng/μl). Scale bar 
= 500 µm.    (B) HUVECs were  seeded at various concentrations on Matrigel‐coated cell culture dishes with cover 
glass‐like  bottom,  which  allow  microscopy  visualization.  White  field  micrographs  of  HUVECs  seeded  at  high 
concentration (1.25 x 105 cell/cm2) over 30 hours. (C) Cells from the same source as in B were seeded on Matrigel‐
coated transwells at concentrations of 3.125 x 104 cell/cm2 (Low cell concentration) or 1.25 x 105 cell/cm2 (High cell 
concentration) and  treated when  indicated with TNF‐α 4.3 ng/ml  (200 U/ml)  for 16 hours. Measurement of  the 
Trans Endothelial Electrical Resistance  (TEER) was performed as an evaluation of  the  integrity of  the monolayer. 
TEER values for empty transwells were used for comparison.  
 
Endothelial cells construct confluent monolayers by formation of tight junctions (TJ) 
between them (Beese et al., 2010). This provides structural anchoring between the cells 
keeping them at close distance. Therefore, we studied TJ formation by seeding 
HUVECs on matrigel-coated cell culture plates suitable for microscopy at a 
concentration of 1.25 x 105 cell/cm2 and treating them with 4.3 ng/ml TNF-α for 16 
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hours. Cells were fixed 30 hours after seeding with PFA, Methanol of 
Acetone/Methanol and stained for the TJ markers Claudin-1, E-Cadherin (data not 
shown), ZO-1 and Occludin (Figure 4.14). In line with the TEER measurements, no 
tight junctions were observed for any of the fixation conditions studied. To test why we 
did not observe TJ, we used hepatocarcinoma cell line Huh7 as a positive control. 
Staining of these cells resulted in the characteristic net pattern evidencing antibodies did 
efficiently and specifically stain their target proteins (Figure 4.14). 
Fig.  4.14  A  system  to  study  transendothelial  migration  in  vitro:  Human  Umbilical  Venule  Endothelial  Cells 
(HUVECs). HUVECs  seeded at a concentration of 1.25 x 105 cell/cm2 on Matrigel‐pre‐coated culture dishes were 
fixed using 3% PFA/PBS, Methanol or an Acetone/Methanol mix  (1:1) after 16 hours of treatment with 4.3 ng/ml 
(200 U/ml) TNF‐ α  (30 hours post‐seeding) and stained for the Tight Junction markers ZO‐1 and Claudin. Huh7 cells 
were used as a positive control. Epi‐fluorescence micrographs of fixed stained cells are shown. Scale bar = 10 μm.   
 
We next speculated that the matrix coating of the cell culture surface on which the 
HUVECs grow could be the limiting factor to achieve a confluent monolayer. Time and 
cell seeding concentration were also key factors to be assessed. We therefore tested 
other coatings namely FN, gelatin and collagen and compared them to matrigel. We 
seeded cells on coated-cell culture plates suitable for microscopy at three different 
densities, 9.375 x 104, 1.094 x 105 and 1.25 x 105 cell/cm2, and monitored TEER over a 
longer time period of 65 hours. At this late time-point bright field images were also 
acquired to visually evaluate the integrity of the endothelial monolayers. HUVECs grew 
on all four matrices (Figure 4.15A). However, cell-free areas were clearly visible on 
gelatin- and collagen- coated plates at all concentrations. Cells on collagen grew not 
only as a 2D culture but also formed 3D structures which mirrored those observed in 
angiogenesis reports (Klose et al., 2015; Martin et al., 2008). On the other hand, 
endothelial monolayers grown on FN and matrigel seemed to be rather confluent when 
analyzed by eye. A more careful analysis of HUVECs seeded on matrigel-coated plate 
evidenced the appearance of cell-free areas or holes (Figure 4.15B), which could 
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explain the previous lack of success when measuring TEER (Figure 4.13C). In line with 
the cell-free spaces observed in the bright field images of HUVECs cultured on 
matrigel-, gelatin- and collagen-coated cell culture plates, the TEER values obtained for 
these samples did not show a significant change as compared to those of control empty 
transwell inserts coated with the same matrices (Figure 4.15C). In spite of the promising 
appearance of the endothelial monolayers grown on FN, the TEER values for these 
samples did not significantly differ from those of control empty transwells either.  
We now believe that in order to form a continuous monolayer where HUVECs interact 
closely among them and form tight junctions, they need to be seeded at a lower 
concentration (not seeded to density) and proliferate. This way when they get to touch 
each other junctions will be developed resulting in a confluent monolayer. Increasing 
the content in growth factors and specially Vascular Endothelial Growth Factor (VEGF) 
allows better and faster proliferation of HUVECs. These difference in growth rate 
compared to the regular medium cannot be observed for early passage (Figure 4.15D), 
but it is very prominent for passages there on (passage 3 and beyond). 
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4.12 Human lymphocytes attach, crawl and perform TEM under shear flow 
Despite of not having achieved a continuous monolayer, we wanted to test whether our 
designed experimental set up can potentially work once endothelial cells handling is 
optimized. With this aim, we isolated PBMCs from Buffy coats of healthy donors 
followed by a CD4+ cell selection and activation with PHA and IL-2 for 72 hours. In 
parallel we seeded HUVECs on matrigel-coated culture plates and acquired an 
endothelial monolayer relatively high in confluence in certain areas as assessed by eye. 
Activation of the endothelial cells with was performed by adding TNF-α at a 
concentration of 4.3 ng/ml (200 U/ml) for 16 hours. Coating the monolayer with CCL-
21 shortly before the TEM assay is necessary for T cells to adhere and roll on it (Bao et 
al., 2010; Shamri et al., 2005; von Andrian and Mempel, 2003). CD4+ lymphocytes 
were then perfused on the HUVECs utilizing a handmade TEM flow chamber and a 
syringe pump that allows adjustment of the flow. At a constant shear flow of 1.5 
dyn/cm2, a high number of PBMCs successfully attached to the endothelial cells (Figure 
4.16A). Furthermore, they displayed a highly motile behavior with a clear preference to 
migrate on or specially underneath the endothelial cells. Lymphocytes crawling on cell-
free, matrigel-coated plastic were very rare. By the end of the video all cells appear to 
be underneath the endothelial cells.  
A closer look at the video in an area of highly confluent endothelium revealed a cell 
performing TEM (Figure 4.16B). The observed diapedesis event is easily detectable by 
the characteristic progressive darkening of the cell body as it migrates through the 
endothelial cell layer and the observable uropod tip which is the last part of the cell in 
becoming dark. 
Thus, from this preliminar experiment we conclude that the in vitro TEM assay we plan 
to perform with primary infected human T lymphocytes could potentially work since 
uninfected cells are able to adhere to and crawl on HUVECs, transmigrate and migrate 
subendothelially. 
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Fig.  4.16 Human primary  T  lymphocytes  adhere on  and  transmigrate  through  a HUVECs monolayer. Activated 
primary human CD4+ lymphocytes (PHA 2 μg/ml and 10 μg/ml IL‐2 for 72 hours) were applied to TNF‐α‐stimulated, 
CCL‐21‐coated primary HUVECs under shear flow (1.5dyn/cm2). (A) Still images of time lapse microscopy video of a 
representative TEM field of view. The black rectangle on the second frame corresponds to the enlarged area shown 
in  (B).  Scale bar = 50  μm.  (B)  Zoom  from  images  in  (A)  showing a  cell presumably undergoing diapedesis. Black 
arrows point to the specific cell before and after extravasation.  Scale bar = 10 μm. 
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4.13 Sorting of HIV-1 infected cells will allow studying effects of Nef on TEM in 
the context of infection    
HIV-1 infection efficiency of primary T lymphocytes in vitro is very low even with pre-
activation of the target lymphocytes. Working with a homogeneously infected 
population is essential in our case since the presence of non infected, and thereby no 
Nef-expressing cells for example would lead to an elevated number of transmigration 
events and therefore to an underestimation of the Nef effect. In order to achieve a 
homogeneously infected population, Dr. Andrea Imle developed in our laboratory a 
proviral plasmid which allows sorting of infected cells. This provirus originates from 
the NL4.3 HIV-1 backbone and it contains sorting cassette expressing YFP fused to the 
transmembrane domain of Platelet Derived Growth Factor Receptor (PDGFR) (Figure 
4.17A). Since infection efficiencies are even lower as with the parental NL4.3 HIV-1 
virus strain, an optimized activation method was also developed by Dr. Andrea Imle to 
achieve higher infection rates (up to 3-6%). After infection with such virus, incubation 
with anti-YFP antibody-coupled magnetic beads allows for positive selection of 
infected cells and achievement of a highly pure infected population (over 90% HIV-1 
infected cells) (Figure 4.17C). The original provirus generated by Dr. Andrea Imle 
contained NL4.3 nef. In order to be able to compare our previous results obtained by 
studying Nef-mediated effects on polarity, we needed to substitute this NL4.3 nef with 
the SF2 nef used previously. We also included Δ12-39 nef, F195A nef and AXXA nef 
genes to be able to evaluate whether Nef motifs important for T lymphocyte polarity 
disruption play a role as well in TEM as we hypothesize. Cloning of all nef versions was 
successful as judged from the SDS-PAGE and Western Blotting of virus producer 293T 
cell lysates (Figure 4.17B). Nef was detected at the right size (~27kDa) in all producer 
cell lysates except for those transfected with a ΔNef provirus, whose nef gene 
expression is blocked by an artificially included early stop codon. (second and third 
lanes). As expected the 12-39 deletion of Nef resulted in a slightly higher 
electrophoretic mobility (~22kDa). Unprocessed Gag p55, intermediate-processed Gag 
p41 and the capsid protein p24 CA were also detected for all producer cell lysates 
although in variable levels, which mirror differences in gel loading as concluded when 
comparing to the WB signal of a house keeping gene, e.g. transferring receptor (TfR). 
Further successful confirmation was obtained by sequencing the cloned proviral 
plasmids.  
Infected cell-sorting worked appropriately for cells infected with wt, ΔNef and Δ12-39 
Nef viruses (shown in Figure 17.C for wt infected cells). The yield of infected cells 
obtained ranged between 3 and 7%. This was sufficient (>2%) for cell-sorting. 
Taken together, this NL4.3-backbone based, sortable virus provides a perfect tool to 
study TEM allowing for purification of a heterogeneous population obtained after in 
vitro infection.   
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Fig. 4.17 Sortable viruses expressing Nef mutants relevant for polarity disruption as tools to study TEM of primary 
human  lymphocytes.  (A)  Schematic  diagram  of  the  modified,  NL4.3‐backbone‐based  HIV‐1  provirus  construct 
designed  and  generated  by  Dr.  Andrea  Imle  in  our  laboratory:  HIV  pNL4.3  IRES.pDisplay.YFP.  It  incorporates  a 
sorting cassette consisting on YFP followed by the transmembrane domain of PDGFR thus allowing purification of 
infected cells  form a virus exposed population using anti‐YFP‐antibody‐coupled magnetic beads.  (B) SDS‐PAGE of 
the lysates of 293T virus‐producer cells. The nef gene was substituted for those encoding Δ12‐39, F195I or AXXA Nef 
mutants and compared to the parental wt virus as well as a Nef deficient variant. (C) Representative dot blots of the 
wt virus‐infected population before and after sorting. Left plots, percentages of infected cells are stated in black on 
the upper right corner.   
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5 DISCUSSION 
5.1 Overlapping functions between HIV-1 Nef and Vpu 
The work shown in the section 3 of this dissertation is partly incorporated or related to a 
recent study of our laboratory which aimed at improving understanding the breadth of 
the Nef- and Vpu-mediated downmodulation of cell surface molecules and membrane 
receptors (Haller et al., 2014). In this study a parallel analysis of 105 host cell 
membrane proteins present in human A3.01 T cells was performed. One third of them 
were newly identified as targets of HIV-1 Nef-mediated downregulation (36/105). 
Interestingly, a number of cell membrane markers were shown to be affected by HIV-1 
Vpu expression (32/105), all of which were targeted as well by HIV-1 Nef. Overall, the 
effects mediated by HIV-1 Vpu (or SIVmac239 Nef) on the surface levels of the 
receptors were less marked than those seen for HIV-1 Nef. This likely mirrors the 
capacity of Nef to not only block the anterograde transport of newly synthesized 
receptor molecules but also to induce their internalization (Casartelli et al., 2006; Giolo 
et al., 2007; Laguette et al., 2010; Laguette et al., 2009; Matusali et al., 2012; Roeth and 
Collins, 2006; Wonderlich et al., 2011). Vpu however can only block anterograde 
transport without inducing internalization (Bolduan et al., 2013; Dube et al., 2011; 
Kerkau et al., 1997; Lindwasser et al., 2007; Pujol et al., 2016; Schmidt et al., 2011; 
Willey et al., 1992a). Therefore, the ultimate effect induced by Vpu will depend 
strongly on the degree of turnover, i.e. endocytic internalization and anterograde 
transport of the specific cargo molecule, and when these processes are slow, as for 
relatively stable membrane protein pools, Vpu will fail to achieve the downregulation 
extent facilitated by Nef.  
Of note, the surface levels of all members of the TSPAN superfamily of transmembrane 
proteins studied were affected by both HIV-1 Nef and Vpu, two of which appeared 
among the most strongly downregulated molecules in the screen. The Thali laboratory 
had previously observed that CD81 -a representative member of the TSPAN family also 
included in our study-, despite of being present at the assembly sites of HIV-1 
(Nydegger et al., 2006), is largely downregulated from the infected cell surface 
(Krementsov et al., 2009). As a confirmation of our findings, in a parallel, independent 
study they could describe Vpu as the responsible factor for TSPANs downregulation in 
the context of infection (Lambele et al., 2015). A third study by Matheson et al. also 
obtained results consistent to the ones we have shown (Matheson et al., 2015). They 
identified downregulation of TSPANs among many other molecules from the plasma 
membrane of CEM-T4 T cells infected with a VSV-g pseudotyped HIV-1 reporter 
virus. To that end, they used a systematic, not-candidate-based screening approach 
combining plasma membrane profiling (PMP; PM enrichment through selective 
aminooxy-byotinilation) with tandem mass tag (TMT) and stable isotope labeling by 
aminoacids in cell culture (SILAC)-based quantitative proteomics. With this technical 
set up, these authors have been able to quantitate a much larger panel of proteins (2320, 
among which 804 were already reported to locate at the plasma membrane) and thereby 
have identified a large number of downregulation targets upon HIV-1 infection. 
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Interestingly, their preoteomics approach correlated well with quantification by flow 
cytometry and together with TSPANs CD37/53/63/81/82 they identified other known 
downregulation targets such as CD28, CCR7 or NTB-A. Taken together, our results and 
the results obtained by others identify a new family of receptors as major target for 
downmodulation by HIV-1 accessory proteins.  
In this work, a first attempt towards understanding the mechanism by which the two 
lentiviral accessory proteins induce TSPANs surface level reduction has been carried 
out by studying the contribution of several well-described motifs of each of these 
proteins in downregulation. Despite of no clearly comparable downregulation profiles 
applying to all TSPANs studied, clear differences in the mechanisms by which each of 
the viral factors induce downregulation of these molecules can be glimpsed from the 
overall data by Haller et al. (Haller et al., 2014). Here, we also observed that the overlap 
in specificity between HIV-1 Nef and Vpu applies to other proteins different than 
membrane molecules and receptors. The host cell peripheral protein Lck was observed 
to be targeted by both lentiviral proteins to intracellular accumulation. The data again 
suggest that two different mechanisms converge in the same effect here. One last 
activity described for Nef which remained unexplored for Vpu is the enhancement of 
EV secretion. We describe here that this represents one more shared function between 
the two accessory proteins and that, unlike what we could see for surface receptor 
downregulation and Lck rerouting to intracellular compartments, Vpu shows more 
pronounced effects than Nef. 
5.1.1 Specific Nef- and Vpu-mediated TSPAN downregulation and determinants 
involved 
The fact that numerous surface receptors were unaffected by the expression of HIV-1 
Nef or Vpu (or SIV Nef) suggests that of those which were efficiently downregulated 
were selectively targeted by the viral proteins. We however wanted to strengthen 
experimentally this point. To that aim, we compared the effect mediated by the 
expression of Nef and Vpu on TSPANs surface levels to that of completely unrelated 
proteins with similar membrane anchoring mechanisms, namely N18src.GFP and 
pDisplay.YFP (Geist et al., 2014; Pan et al., 2013b). As expected, none of the unrelated 
proteins induced reduction in the levels of the TSPANs studied whereas the HIV-1 
accessory proteins caused a marked effect. This strategy provides thereby evidence that 
the effect induced by HIV-1 Nef and Vpu does not result from an artifact such as an 
unspecific disturbance of membrane transport associated to membrane association and 
insertion of the viral factors, respectively.       
In this study, we attempted for the first time to define molecular determinants in Nef 
and Vpu required for TSPAN downmodulation. We addressed this by analyzing the 
effect of mutations targeting motifs implicated in well-described functions or protein-
protein interactions of these proteins. Of note, our mutant screen did not identify a motif 
leading to loss of TSPAN downregulation function upon induction of sequence changes. 
The downregulation profile obtained for the mutants tested was however similar for the 
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TSPANs studied. In the case of Nef a partial effect was observed for all three mutants 
targeting motifs within the SH3-interacting domain (EEEE66-69 and the VGF and PxxP 
motifs), involved in a number of protein-protein interactions required for interference 
with intracellular trafficking and cell membrane receptor downregulation, e.g. 
trafficking of Lck or surface downregulation of MHC-I (Collette et al., 1996; 
Meuwissen et al., 2012; Piguet et al., 2000; Saksela et al., 1995). The only exception 
was CD37 for which a partial effect could be observed when the dileucine motif at the 
C-terminal flexible loop implicated in CD4 downregulation via endocytic components, 
was mutated (LL168/169) (Craig et al., 1998; Chaudhuri et al., 2007). Also, a slightly 
less pronounced effect on CD37 downregulation was observed for mutations at the 
flexible loop and the SH3-binding domain of Nef (ED178/179, and EEEE66-69 and 
VGF respectively). For Vpu-induced downregulation a partial effect was observed for 
mutations at the transmembrane motif and the diserine motif, required for the 
interaction with β-TrCP and tetherin, respectively. Neither for Nef nor for Vpu the 
downregulation profiles obtained in this mutant screen resembled that of receptors with 
already described mechanisms, like CD4 or tetherin (used as controls in this study) or 
MHC-I.  
HIV-1 Vpu has also been shown to induce the intracellular accumulation of and 
colocalize with TSPANs at a TGN marker-positive compartment when overexpressed 
(Haller et al., 2014) and also in the context of infection (Lambele et al., 2015). 
Importantly, robust coimmunoprecipitation with TSPANs has been shown by us (Haller 
et al., 2014) and direct interaction has been observed independently by Lambelé et al. 
between CD81 and Vpu using fluorescence resonance energy transfer (FRET) (Lambele 
et al., 2015). These authors have also shown that pharmacological inhibition of 
lysosomal and proteasomal degradation blocks the Vpu-induced decrease in total CD81 
content suggesting Vpu mediates surface downregulation of this TSPAN. Furthermore, 
we have observed that Vpu coimmunoprecipitated with TSPANs even after disruption 
of TEMs by harsher buffer conditions (unpublished data) (Haller et al., 2014). This 
argues against a model in which Vpu coassembles with TSPANs at specific membrane 
microdomains, but rather reflects a direct protein-protein interaction as part of the Vpu-
mediated TSPAN downregulation from the host cell surface, intracellular accumulation 
and degradation. Given the central role of Vpu for TSPAN cell surface downregulation 
upon HIV-1 infection, dissecting the mechanism of this interaction would likely bring 
some clarification as to how specific downregulation of TSPAN take place in the sole 
presence of Vpu and in the context of infection. Weak (Haller et al., 2014) or no 
interactions (Lambele et al., 2015) were described for HIV-1 Nef with TSPANs. 
Colocalization between Nef and TSPAN molecules at perinuclear compartments was 
also less marked as that seen for Vpu (Haller et al., 2014). These observations suggest 
that Nef may alter TSPAN intracellular transport indirectly as it has been described for 
the induced accumulation of Lck at RE/TGN for which association and colocalization 
with Nef are not required (Pan et al., 2013b; Pan et al., 2012). 
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Taken together, the results shown here and those reported by Haller et al. suggest that 
HIV-1 Nef and Vpu may affect trafficking of TSPANs, amongst a wide range of 
cellular cargo, by different mechanisms. Moreover, the downregulation of this large 
spectrum of target membrane proteins likely mirrors the alteration induced by Nef and 
Vpu of general transport routes of which the downregulated molecules are cargo and 
argues against the “direct connector model”, previously described for specific molecules 
like CD4 or MHC-I (Mangasarian et al., 1997).  
5.1.2 HIV-1 Nef and Vpu overlapping functions extend to peripheral membrane 
proteins such as Lck 
HIV-1 is known to utilize it accessory protein Nef to finely modify basal T cell 
activation levels and the responsiveness to TCR engagement (Abraham and Fackler, 
2012; Baur et al., 1994; Fackler and Baur, 2002; Simmons et al., 2001). The block in 
some TCR proximal signaling transduction events like the reorganization of the actin 
cytoskeleton, TCR signaling-related protein microcluster formation or tyrosine 
phosphorylation significantly contribute to reduce AICD and prolong the life of infected 
cells (Abraham et al., 2012; Haller et al., 2007; Haller et al., 2006; Schindler et al., 
2006; Thoulouze et al., 2006). Perturbances in distal signaling events such as the Nef-
dependent intensification of the Ras-Erk signaling contribute to promote replication 
(Pan et al., 2012; Schrager et al., 2002). Our laboratory showed recently that Nef-
induced manipulation of proximal and distal TCR signaling events rely on one the 
relocalization of the Src kinase master switch Lck to RE/TGN compartments (Pan et al., 
2012). This Nef effect is highly specific since the closely related Src family kinase Fyn 
cellular distribution remains unaltered. Whereas the Nef-induced retargeting of a central 
player in early TCR signal transmission such as Lck results in block of TCR signaling at 
initial steps, the intracellular pool of Lck is highly active and contributes to signaling 
specifically to the Ras-Erk cascade to promote viral replication (Pan et al., 2013a; Pan et 
al., 2012).  
In this work we have described for the first time that HIV-1 Vpu can also induce 
relocalization of Lck towards intracellular compartments. However, the magnitude of 
the intracellular accumulation as well as the frequency of cells showing accumulation 
was significantly lower than that seen in Nef-expressing cells. The Vpu-mediated effect 
became more pronounced when the analysis was restricted to newly synthesized Lck. 
Under these conditions Vpu (or Nef) and Lck were synthesized simultaneously and the 
amount of Vpu-expressing cells showing intracellular Lck accumulation was 
comparable to that in Nef-expressing cells. Nevertheless, the magnitude of the Vpu-
effect remained lower. As seen in the case of the downregulation effect caused by the 
two lentiviral proteins, the more pronounced effect observed for Nef than for Vpu might 
reflect the ability of Nef to retarget the whole cellular pool of Lck by altering transport 
to as well as from the plasma membrane. On the contrary, Vpu is only able to block 
anterograde transport of newly synthesized Lck molecules to the plasma membrane, 
being unable to target Lck molecules which have reached already their steady-state 
distribution. Our results show that HIV-1 Vpu can potentially retarget the peripheral 
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membrane protein Lck. However, the fact that the observed Vpu-mediated effect is 
exclusively significant when Lck is overexpressed is probably mirroring the lack of 
biological relevance of this process.   
5.1.3 Vpu, like Nef, enhances EV release and exploits this strategy to induce its 
own export 
Enhancement of EV release is another activity which has been described for Nef but 
remained unstudied for Vpu. HIV-1 Nef expressed alone or in the context of viral 
infection enhances EV release (Campbell et al., 2008; Lenassi et al., 2010; Muratori et 
al., 2009). Furthermore, it induces its self-incorporation into the EVs. This leads to the 
induction of intracellular signaling and transport changes in bystander cells upon uptake 
of the shed EVs generating a favorable environment for viral replication and spread. Of 
note, Nef-positive EVs have been reported not only to be present in cell culture but also 
in plasma of HIV-infected patients (Raymond et al., 2011) It has been described that the 
released EVs triggered cell death in recipient cells, thus providing a potential 
mechanism for the bystander CD4+ T loss which represents a hallmark of HIV infection 
(Lenassi et al., 2010). Consistent with these studies, we have been able to detect Nef in 
EVs derived from A3.01 human T cells upon isolated expression of the accessory 
protein in vitro. Furthermore, we could observe a marked Nef-induced enhancement of 
EVs release in these cells as concluded from the higher CD63 and CD81 WB signal 
obtained as well as a strong increase in total protein content in the EV preparation when 
compared to GFP-expressing cells-derived control EVs. Of note, the CD63 signal and 
the total proteins content of CLs from both Nef-expressing and control cells showed 
comparable levels. The CD81 signal from lysates of Nef-expressing was stronger as that 
seen for GFP-expressing control cells, however the difference was not as marked as that 
seen between the CD81 signal of EVs derived from both cell cultures. Viewing these 
results, we can conclude we have confirmed the induction of EV release by Nef 
previously reported by others. 
Importantly, here and for the first time we have observed that enhancement of EV 
release can also be observed upon isolated expression of HIV-1 Vpu. Moreover, we 
have seen that the effect mediated by Vpu, in contrast to what was observed for cell 
surface receptor downregulation or rerouting of Lck, was stronger than the effect 
mediated by Nef. Of note, this novel observation has set up the basis to identify the 
presence of Vpu in EVs in the plasma of HIV-infected patients in a subsequent study by 
our collaborators, thus highlighting the physiological relevance of Vpu incorporation 
into EVs (Lee et al., 2016). Interestingly, these authors observe abnormally high 
amounts of EVs in the plasma of infected patients and detect both accessory proteins in 
them. Also interesting is that the biochemical analysis of those EVs shows absence of 
CD81, unlike what has been seen in this work. This is a surprising finding knowing that 
CD81 is a prototypical exosomal marker present in exosomes from most cell types and 
it might reflect the proteome of the main producer cells. 
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Based on the Western Blot signal obtained and despite of being expressed at a 
comparable degree in producer cells, EVs contained lower levels of Vpu than of Nef. 
Interestingly, the amount of CD81 and CD63 present in EVs from Vpu-expressing cells 
was considerably higher than that in Nef-expressing cells suggesting a more potent 
boost in EV release induced in the former case. This is consistent with slightly higher 
total protein content in EVs derived from Vpu- than for Nef-expressing cells and no 
visible difference in the same parameter for CL from these cells. Importantly, both 
proteins enhance significantly exosome release as compared to  
It is important to point out that the results shown in Section 3.7 (and also in Section 3.6) 
of this work have been obtained only once and would need further repetition to make 
the data and the conclusions from this part more robust. Nevertheless, we believe that 
the validation of previously published observations regarding Nef-induced secretion 
enhancement and its own inclusion onto released EVs (Campbell et al., 2008; Lenassi et 
al., 2010; Muratori et al., 2009) represents a strong argument contributing to the 
credibility of the obtained Vpu results in regard to EV release.   
Amongst the aims of this part of this doctoral work there was testing the hypothetical 
mechanism of TSPAN downregulation by enrichment and export onto EVs. 
Understanding which motifs of Nef and Vpu are important for the described effect on 
EV release enhancement was also of our interest. Technical issues however kept us 
from going that far into mechanistic research. The main reason for that was the low 
amounts of EVs obtained from T cell line cultures. This forced us to scale up the 
experimental settings and to use very high amounts of plasmidic DNA for transfection 
(section 3.6) or of lentiviral vectors for transduction (section 3.7). In this context, testing 
Nef and Vpu mutants would have required extremely high volumes of cell culture 
(litters) and it would have been unfeasible concerning time and resources. A recent 
publication by Choudhuri et al. showed that T cell vesicle secretion occurs in a very 
polarized manner directed to the immunological synapse formed upon recognition of 
cognate antigen-MHC-I complexes (Choudhuri et al., 2014). This is consistent with the 
increase in EV release we observed upon stimulation of A3.01 T cells with activating 
surfaces coated with TCR triggering antibodies. Furthermore, it offers an explanation 
for the low secretion levels observed for T cells in culture.       
5.1.4 Evolutionary perspective and functional advantage of redundancy in 
biological activity between HIV-1 Nef and Vpu 
The appearance of the vpu gene in some SIV precursors and its inter-species 
transmission to HIV resulted in a duplication of the manipulative potential on the host 
cell physiology mediated by the accessory proteins Nef and Vpu. As we describe here, 
Nef and Vpu alter intracellular transport, endocytosis and exocytosis leading to 
modification of cell surface molecule exposure of a broad range of molecules like 
TSPANs, retargeting of peripheral membrane proteins like Lck and enhanced vesicle 
secretion. The fact that Nef and Vpu are expressed early and late in the replication 
cycle, respectively, ensures to achieve efficiently vesicular trafficking modification at 
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all time points of its life cycle. It also allows for adaptation to different cellular 
environments given the mechanistic divergence of Nef and Vpu for the activities studied 
in this work. Furthermore, it provides a safeguarding mechanism and preventing the 
loss of those activities by disrupting mutation acquisition or counteraction. 
In contrast to the redundancy of function observed in our work, HIV-1 Nef and Vpu still 
posses well differentiated, distinct activities that are not shared. Examples of this are the 
enhancement in viral infectivity and actin rearrangements disruption by Nef, and 
counteraction of tetherin and boost of viral release by Vpu. Altogether, the complexity 
of activities, shared or specific, carried out by the accessory proteins Nef and Vpu of 
HIV-1 might have been the consequence of a detailed adaptation of the virus to achieve 
efficient infection in humans. 
From the functional point of view, it is tempting to speculate about the benefits 
generated by the studied processes affected by both HIV-1 Nef and Vpu, which in some 
cases are already known: 
 TSPANs have been described to disrupt membrane fusion by a yet to be 
identified mechanism (Symeonides et al., 2014; Takeda et al., 2003). 
Additionally, these molecules are present in HIV virion envelopes and it has 
been described that assembly occurs preferentially at TEMs (REFERENCES). 
In this scenario, TSPANS inhibit cell-to-cell fusion by binding of Env 
expressed at the membrane of infected cells and CD4 of neighboring cells 
(Gordon-Alonso et al., 2006; Weng et al., 2009) probably at the hemifusion step 
(Symeonides et al., 2014). It is easy to hypothesize that the described increase 
in virus cell-to-cell transmission results, at least partially, from the Nef- and 
Vpu-mediated downregulation of TSPANs from the plasma membrane 
(Casartelli et al., 2010; Haller et al., 2011; Malbec et al., 2013). 
 As mentioned before, Nef-mediated Lck rerouting to RE/TGN results in the 
inhibition of proximal TCR signaling steps avoiding AICD while downstream 
signaling is favored by the highly active intracellular Lck pool increasing viral 
replication. The redundancy of this activity by the Vpu protein likely permits 
efficient Lck targeting also at late steps of the viral cycle and provides a backup 
preventing from loss of this relevant function. 
 The incorporation of HIV-1 Nef and Vpu onto EVs provides a potentially 
strong strategy to alter the physiology of bystander cells (Muratori et al., 2009). 
This could translate into higher infection rates by rendering neighboring cells 
more permissive to infection or even induce and explain bystander cell death 
(Lenassi et al., 2010), a hallmark of AIDS. 
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5.2  Effects of HIV-1 Nef on T cell polarity and TEM 
The negative impact of Nef on T cell motility has been extensively described by us and 
others (Choe et al., 2002; Hrecka et al., 2005; Janardhan et al., 2004; Lee et al., 2008; 
Nobile et al., 2010; Park and He, 2009; Stolp et al., 2010; Stolp et al., 2012; Stolp et al., 
2009). Expression of the viral factor compromises the ability of these cells to undergo 
actin cytoskeleton rearrangements essential for efficient directional migration and 
results in chemotaxis block (Nobile et al., 2010; Stolp et al., 2010; Stolp et al., 2009). 
Our laboratory described the molecular mechanism by which Nef interferes with T cell 
actin dynamics and thereby with the motility of these cells to be the consequence of the 
interaction between the accessory protein and the host cell kinase PAK2 (Stolp et al., 
2010; Stolp et al., 2009). The interaction results in a shift in the specificity of the kinase 
towards a non-natural target, the actin severing factor cofilin. In this scenario, the 
phosphorylation of cofilin leads to its inactivation and thereby to a reduced actin 
turnover in the cell (Stolp et al., 2009). A subsequent study also by our laboratory 
reported that isolated expression of Nef in murine CD4+ T lymphocytes inhibits homing 
to lymph nodes in vivo using a mouse model (Stolp et al., 2012). Detailed investigation 
showed that the main block takes place at the level of migration through the 
endothelium as well as subendothelial migration. The latter appeared to be dependent on 
the effects of Nef on cell actin dynamics. The former however relies on other, yet 
unknown Nef molecular determinant(s). Notably, the impairment in TEM was 
paralleled by a block in polarization of T cells expressing Nef both on the endothelium 
and on collagen-coated surfaces under chemotactic stimulus. Only Park et al. have also 
addressed the question of how does Nef affect T cell polarization (Park and He, 2009). 
These authors used a Nef-inducible Jurkat T cell line and anti-LFA-1 antibody-coated 
surfaces to stimulate polarization of these cells. Importantly, both mentioned studies 
described for the first time a Nef effect on T cell polarization in the context of 
migration. However, many open questions remained such as if the Nef-induced polarity 
block can be observed in the context of infection of human primary cells and what is the 
relevance of it. The mechanism governing this Nef activity was completely unexplored 
as well.  
Here, we used a fibronectin stimulus-based 2D system to describe for the first time that 
HIV-1 SF2 Nef can hinder polarization of human PBMCs in the context of infection 
and of A3.01 T cells expressing the viral factor alone. Taken together, the results shown 
in this doctoral dissertation demonstrate that Nef is necessary and sufficient to cause 
this effect. Furthermore, together with the PAK2-interacting motif of Nef we identified 
the α-helical 12-39 stretch, required for the assembly of a kinase complex necessary for 
viral replication and enhanced EV secretion, as important for this activity (Figure 5.1). 
Further experimental work suggests that the relevant host protein among those forming 
the complex implicated on the Nef-induced polarity block is PKC. Future experiments 
should aim at identifying the isoform(s) involved and improve our understanding of the 
underlying mechanism. Besides, we have also set the basis here for a complex 
experiment to study the effects of Nef on transmigration of T cells through the 
endothelium ex vivo in the context of infection. This experiment intends to test our 
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hypothesis that the TEM defect mediated by Nef is ultimately due to the polarization 
defect. 
5.2.1 Specific role of Nef on T cell polarization block in the context of infection        
As mentioned above previous studies targeting effects of Nef on T cell polarity where 
not performed with physiological HIV-1 target cells and used isolated expression of the 
lentiviral protein (Park and He, 2009; Stolp et al., 2012). Here we have studied primary 
human target cells of HIV-1 in the context of infection. According to our observations, 
the polarity loss occurs also as a result of infection. HIV-1 wt infection caused at least a 
two-fold decrease in the frequency of polarization in cells from all donors except for 
one case. In this scenario, preventing expression of Nef led to higher polarization 
frequencies in cell form all 13 donors studied. Thus Nef appears as the major player 
being necessary and often sufficient to mediate polarity disruption. The extent of the 
effect caused by Nef on T cell polarity was however subject to marked donor 
variability. Of note, cells from 7 out 13 donors analyzed showed polarization 
frequencies which equaled those of uninfected cells when infected with a virus lacking 
expression of Nef. Importantly, the impact of wt HIV-1 on polarization levels was not 
as strong as that seen for cells from the remaining 6 donors which did not recover 
polarization levels of uninfected cells when Nef was absent. While for the latter 6 
donors the frequencies of polarization upon HIV-1 wt infection ranged between 3.3 and 
15.0%, the values for the former 7 donors only ranged between 14.6 and 33.3%. Thus 
the stronger the effect of wt HIV-1 infection on the frequency of polarization of PBMCs 
is the lower are the probabilities to see a recovery to levels obtained for uninfected cells 
by subtracting Nef from the system.  
5.2.2 A system to study T cell polarization in vitro 
In order to study further study the effects of Nef on T cell polarity we needed to 
establish in our laboratory an experimental set up for that. Despite of unsuccessful 
efforts to nucleofect human PBMCs to study the observed polarity defect induced by 
Nef, we could finally find a much simpler and more versatile system. We thereby tested 
different human T cell lines on surfaces coated with different extracellular matrix 
molecules and under different conditions (data not shown). A3.01 human T cells proved 
to polarize on fibronectin-coated surfaces without the need for chemokine stimulation. 
Of note, these cells were able to polarize to similar levels of uninfected PBMCs even 
after transfection with a GFP expression vector. The fact that these cells can be easily 
transfected or transduced for delivery of expression plasmids makes of our fibronectin-
based 2D system a perfect set up for the study of T cell polarity under different 
conditions, e.g. after manipulation of our cells for expression of a variety of ectogenic 
proteins or following different pharmacological treatments.  
Notably, unlike in previous studies (Park and He, 2009; Stolp et al., 2012), chemokines 
were not utilized since fibronectin-integrin crosslinking was enough to induce 
polarization both of PBMCs and A3.01 cells in vitro. In this regard and consistent with 
this experimental set up, downregulation of LFA-1 has been reported as one of the 
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mechanisms for Nef-mediated interference with T cell adhesion to the endothelium and 
with polarization, thereby inhibiting TEM (Park and He, 2009).    
5.2.3 Conservation of Nef-mediated T cell polarization defect in evolution  
This study reveals that the observed impact on T cell polarization by Nef is highly 
conserved among lentiviral proteins from SIV, HIV-1 and HIV-2. 18 Nef alleles, as 
well as specific SIV Nef mutants lacking CD3-downregulation activity, were studied for 
their ability to inhibit polarity in A3.01 human T cells. Notably, the HIV-1 YBF30 and 
the SIVcpz Tan 3 alleles failed or caused an intermediate decrease in polarization 
frequency levels, respectively. However, these alleles were previously reported to 
induce intermediate effect or to fail, respectively, in several Nef activities, namely Lck 
accumulation, inhibition of immunological synapse formation and concomitant tyrosine 
phosphorylation events (Rudolph et al., 2009). Additionally, SIVcpz Tan 3 Nef was also 
shown to be unable to inhibit membrane ruffles upon chemokine stimulation, 
chemotaxis and cofilin hyperphosphorylation induction (Stolp et al., 2010). This may 
indicate a global lack of most general Nef functions and our finding is consistent to it. 
Despite of the total independency of CD3 stimulus in our experimental set up, our data 
suggested initially dependency on CD3-downregulation as the overall effect of Nef 
proteins form HIV-1 and SIV unable to downregulate CD3 seemed less active in 
blocking T cell polarity than those of HIV-2 and other SIV strains able to do so. In 
order to study this implication we tested a panel of SIVblue Nef mutants with altered 
membrane receptor downregulation capacities as compared to the corresponding wt 
protein. Altogether, using these SIV Nef mutants helped us drawing the conclusion that 
Nef-mediated inhibition of T cell polarity is independent of CD3-downregulation 
activity. However, to our surprise, the trend observed for these mutants reflected exactly 
the opposite to what we observed with the whole set of alleles studied. Unlike the initial 
results with all the alleles, this other experiment showed that the two mutants unable to 
downregulate CD3 (R129/130A and R129A) were able to block polarity of A3.01 cells 
while the mutant downregulating selectively CD3 was not (E181A/L185A). Since CD4 
downregulation is dispensable for the Nef effect on T cell polarity (see below), the only 
possible explanation for the lack of function of the ELAA mutant should be linked to 
CD28 downregulation, which seems unlikely, or to other undetermined consequences of 
the mutation at the ExxxL motif for this precise Nef allele.  
5.2.4 12-39 stretch of Nef is important for T cell polarization impairment 
In search for molecular determinants implicated in T cell polarity block mediated by 
Nef we tested a panel of HIV-1 SF2 Nef mutants in our 2D fibronectin-based 
experimental system. As expected, the generally defective G2A mutant unable to anchor 
into membranes was unable to block polarity of A3.01 cells (Fackler et al., 2006; Geyer 
et al., 1999). Consistent to that observed previously, the F195A mutant specifically 
unable to interact with PAK2 and thereby to interfere with actin dynamics was also 
incapable of interfere with T cell polarity (Stolp et al., 2012). Interestingly, the PxxP 
motif had an intermediate, yet pronounced effect in our mutant screen, the integrity of 
which was described to be important for the inhibition of T cell motility (Park and He, 
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2009). Importantly, our mutant screen defined a third region of Nef needed for polarity 
disruption, the 12-39 α-helical stretch which acts as a platform for the assembly of a 
multimolecular complex consisting of several host cell kinases and adaptor proteins. 
The formation of this complex has been reported to be necessary for viral replication 
(Witte et al., 2008), extracellular vesicular secretion induction (Muratori et al., 2009) 
and downregulation of CD4 form the plasma membrane (Fackler et al., 2006). Further 
confirmation of the implication of the 12-39 Nef stretch on T cell polarity disruption 
was achieved by infection experiments on human PBMCs were a HIV-1 virus bearing 
the deletion mutant showed polarization levels comparable to uninfected cells unlike wt 
HIV-1 infected cells which were strongly impaired for polarization. Here we describe 
for the first time the implication of this mutant in a migration-related phenotype. Since 
mutations at the flexible C-terminal loop involved in interaction with the endocytic 
machinery and thereby required for CD4 downregulation (Bresnahan et al., 1998; Craig 
et al., 1998; Lu et al., 1998) had no effect on T cell polarization and behaved like Nef wt 
we conclude CD4 downregulation is dispensable for polarity disruption and the 12-39 
stretch must be involved by a different mechanism.  
5.2.5 Possible mechanism of T cell polarity block via 12-39 motif, role of PKC 
In the absence of enzymatic activity, the HIV-1 Nef protein exerts its functions by 
interacting with other proteins and molecules in the host cell. The mechanism by which 
Nef interferes with T cell polarization via the 12-39 stretch remains elusive. Our data 
suggest however that Nef might carry out this activity via PKC signaling since 
pharmacological inhibition of the other NAKC components in A3.01 cells did not 
induce changes in the frequency of polarization when compared to Nef-expressing cells 
(Figure 5.1).  
Given that, besides the generally defective mutant of Nef G2A, the only two mutants of 
Nef relevant for T cell polarity disruption are F195A and Δ12-39, and knowing that the 
former hinders cellular actin rearrangements with high specificity, it is tempting to think 
that the latter acts also affecting the cytoskeletal organization. Interesting results were 
obtained from a large comparison of lentiviral Nef proteins for the conservation of 
PAK2-based hyperphosphorylation of cofilin as a strategy to hamper cell actin 
dynamics (Stolp et al., 2010). This study described a strong interaction between SIVcpz 
Tan 3 Nef and PAK2 but yet this Nef allele was unable to interfere with actin 
rearrangements. Thus, PAK2 association via the F195 (or equivalent residue) is 
necessary but not sufficient for the observed disruption in actin dynamics. Therefore, 
there might be other relevant motifs implicated in this Nef activity. On the other hand, a 
previous study by Haller and colleagues from our laboratory included an assay 
evaluating the inhibition of the F-actin ring formation at the immunological synapse, a 
structural scaffold to establish morphological and molecular polarity as well as directed 
secretion in this scenario. In that study it was reported that the Δ12-39 Nef mutant was 
partially dysfunctional as compared to Nef wt suggesting the implication of this Nef 
stretch in actin rearrangements inhibition (Haller et al., 2006). Additionally, a marked 
dependency on F-actin integrity has been reported for diapedesis as well as 
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subendothelial migration (Cinamon et al., 2001). In line with this, F-actin regulators 
control both T-lymphocyte polarization and crawling on the endothelium (Faroudi et al., 
2010; Gerard et al., 2009; Heasman et al., 2010; Nombela-Arrieta et al., 2007; Shulman 
et al., 2006). Interestingly, the role of PKC, a component of the NAKC, in the 
regulation of actin dynamics and its impact on cell polarization and migration has been 
extensively studied in T lymphocytes. In this context, it has been reported that PKCβI 
was required for human T cell polarization and migration in vitro upon LFA-1-
dependent stimulation. It also colocalized during migration on anti-LFA-1 or ICAM-1 
(the cognate ligand of LFA-1) with the MTOC and microtubules at the uropod what 
suggests a role for this kinase on microtubule cytoskeleton rearrangements (Volkov et 
al., 1998; Volkov et al., 2001). Colocalization with MTOC and microtubules at the 
uropod under similar experimental conditions has also been described for PKCδ and 
pharmacological inhibition of this kinase hampered migration in a 3D matrix model 
(Fanning et al., 2005; Volkov et al., 1998). This kinase was reported to phosphorylate 
cytoskeletal adaptor paxillin contributing to LFA-1 activation and leading to adhesion 
(Romanova et al., 2010). Furthermore, phosphorylation of PKCδ has been shown to 
occur upon chemokine stimulation (Cronshaw et al., 2006). PKCε interacts with and 
phosphorylates Rab5a at the centrosomal region upon chemokine or integrin stimulation 
and regulates vesicular trafficking to the leading edge in migrating T cells. These events 
have been shown to be necessary for Rac1 activation, actin reorganization and T cell 
migration (Ong et al., 2014). The most studied PKC isoform in T cells is PKCθ due to 
the fact that its expression is more restricted to cell from the immune lineages and 
because it polarizes to the contact area between lymphocytes and APC or immune 
synapse (Zhang et al., 2013). Moreover, this kinase is central in antigen-dependent T 
cell activation and proliferation and induces chemokine secretion via activation of NF-
κB, AP-1 and NFAT. Whereas PKCθ localizes at the uropod of murine cells following 
chemokine stimulation and it regulates distribution of MTOC and ERM proteins 
(Cannon et al., 2013), this protein appears to localize at the leading edge of chemokine-
stimulated human lymphocytes (Freeley et al., 2012). Pharmacological inhibition in 
vitro and ex vivo experiments with PKCθ-deficient cells from knock-down mice show a 
marked reduction in migration towards chemokines when compared to the untreated or 
control counterparts, respectively (Cannon et al., 2013; Shahabi et al., 2008). In vivo 
studies however suggest that the observed effect is not as relevant as it could be 
expected from in vitro experiments (Cannon et al., 2013). Also, it is still unclear 
whether the impact of inhibition or lack of expression of PKCθ on migration are in fact 
the consequence of deficient T cell activation and adhesion due to impeded signaling 
events downstream of TCR (Letschka et al., 2008). Ultimately, atypical PKCs are 
known to regulate permanent polarity of epithelial cells (Chen and Zhang, 2013). 
Similarly, chemical inhibition or the use of dominant negative mutants of atypical PKCs 
part of polarity complexes in T cells following chemokine and integrin signaling 
showed impairment in polarization, migration and crawling on the endothelium under 
shear flow (Chen et al., 2008; Gerard et al., 2007; Gerard et al., 2009; Real et al., 2007). 
Furthermore, the F-actin bundling protein L-plastin has been reported to colocalize at 
the leading edge with and to become phosphorylated by PKC leading to defects in the 
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activation of Rac1 and Akt phosphorylation upon chemokine stimulation. PKCζ is part 
of the Par3 complex, involved in the establishment of polarity in well-studied cell 
systems like the epithelium or neurons. The inhibition of this atypical PKC in T 
lymphocytes prevents CCL21-induced LFA-1 polarization (Giagulli et al., 2004). 
Furthermore, the polarization of this PKC isoform has been described during 
asymmetric division in T cells, a process strictly dependent on cell polarity (Chang et 
al., 2007). Ultimately, all this events led to inhibition of T cell polarization and 
migration on ICAM-1-coated surfaces in an LFA-1 activation- or adhesion-independent 
manner. Altogether, PKCs play key roles in T cell polarity and motility and this is 
mainly related to their function as cytoskeletal regulators and key signaling master 
molecules. Therefore, it seems reasonable that Nef could affect T cell polarity or even 
migration via the manipulation of PKC proteins.  
Fig 5.1 Final model: Nef interferes with T cell polarity via two different mechanisms involving either PAK‐2 or PKC 
being the latter potentially the missing pathway resulting in transendothelial migration. Previously reported Nef’s 
interaction with PAK‐2  leads to hyperphosphorylation and thus  inactivation of cofilin  interfering thereby with the 
actin cytoskeleton dynamics. Alternatively, Nef possesses another determinant, the 12‐39 α‐helical stretch, through 
which the viral protein  interacts with adaptor proteins of the NAKC. This complex  includes PKC which presumably 
acts as an effector of other  factors  involved  (A) or not  (B)  in actin regulation. As a consequence, T cell polarity  is 
disrupted.  Whether  the  exposed  hypothesis,  that  is  the  a  further  impairment  of  transendothelial  migration 
downstream  in  this pathway,  is  true will subsequently be examined using  the experimental system set up  in  this 
work.     
            
5.2.6 What do we learn from polarity monitoring by live microscopy?  
Live microscopy has worked efficiently in the present study to observe the dynamics of 
the process and how Nef modifies the behavior of A3.01 human T cells in this regard. 
One question we initially asked was “how does polarity take place”, “is it a transient 
mechanism that takes places frequently or in cycles or is it a rather a permanent process 
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after which the cell remains long term elongated”. Our data shows that control A3.01 
cells polarize and depolarize constantly. They cycle between a rounded shape and an 
elongated one and at least for this cell type there is no clear predominance of one over 
the other state. This observation is consistent with the polarization values we have 
quantified generally for control cells of around 50% (40-60%). Nef-expressing cells 
however do not polarize that frequently. They remain round and, if at all, they polarize 
only very short intervals and with very low frequency. Altogether, the fact that we can 
see some Nef-expressing cells which polarize means that Nef does not completely block 
polarization capacity but it makes it much less frequent. If a Nef-expressing cell is able 
to polarize or not is probably dependent on the basal activity of that specific cell. Unlike 
wt Nef, the studied Nef mutants are unable to cause this effect. The way cells 
expressing these mutants polarize however is different suggesting different intensity in 
the effect mediated by each of them. Interestingly, expression of a Nef combining the 
mutations Δ12-39 and F195A results a phenotype that more closely resembles that of 
GFP-control cells. Altogether, we have learnt that polarity is a cyclic mechanism with 
high frequency of elongation-rounding events and Nef is able to reduce the frequency of 
this process significantly spacing the elongation events.      
5.2.7 Possible implication of T cell polarity impairment in TEM and migration 
Previous work from our laboratory described a lack of dependency on the PAK-2 
interacting domain for diapedesis, the central step of TEM, and therefore we decided to 
search for another molecular determinant responsible of that (Stolp et al., 2012). Given 
the parallel block on T cell polarity observed while studying TEM, we decided to 
characterize that effect aiming at learning more about both processes. We now know 
that both the 12-39 amino acid stretch and the F195 residue are important for Nef-
mediated polarity disruption. Whether the 12-39 deletion plays a role in inhibition of 
diapedesis or not is something we can only learn by performing the TEM study which 
has been set up and established in the present work. However, unpublished in vivo work 
form Dr. Sheetal Kaw from our laboratory suggest an important role of the 12-39 motif 
in T cell homing. The expression of the 12-39-deleted Nef by murine CD4+ T cells is 
enough to restore the block in T cell homing, as it was noticed before for F195A Nef 
mutant (Stolp et al., 2012). The effect observed is stronger at early timepoints (4 hours 
post-transfer into the mice) than that seen for the latter mutant. The impact of the 
expression of both mutants becomes equally important at a later timepoint (24 hours 
post-transfer into the mice). These results suggest that these two mutations may act 
through two different mechanisms to affect T cell homing yet leading to a convergent 
effect. Also, 12-39 is essential to mediate block of T cell homing at early timepoints as 
compared to F195 which enhances the implication of two different molecular 
mechanisms with different kinetics but an equal final consequence (Figure 5.1).   
5.2.8 T cell migration inhibition upon HIV-1 infection: the big picture 
HIV-1 infection of T cells results in a reduction in the migration of these cells. Previous 
studies’ results together with the ones presented here have pinpointed Nef as the main 
negative regulator of lymphocyte motility in this context. They also suggest that Nef 
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disturbs T cell migration at multiple steps. Despite of the increasing amount of 
information on how Nef exerts this activity, the reason why inhibition of migration of T 
cells is beneficial for viral infection and spread remains a conundrum. Some authors 
think that by rendering infected cells static, the chances to meet other cells of the 
immune system and thereby being recognized and cleared are minimized (Park and He, 
2009).  It has been also suggested based on the inability of Nef-expressing cells to 
migrate towards the chemoattractant sphingosin-1-monophosphate S1P, involved in 
lymph node egress, that HIV-1 infected cells’ density in the lymph nodes can thereby 
increment resulting in a maximization of the cell-to-cell spread (Stolp et al., 2012). 
Given the capital role of migration for T cell function and immune surveillance, the 
deficiencies in polarity, migration and TEM observed for Nef-expressing cells may 
correlate with the incapacity of HIV-1 infected individuals to mount an efficient 
humoral response (Moir and Fauci, 2009). In contrast to this and other studies, in vivo 
data with humanized mice by Murooka et al. showed that most HIV-1 productively 
infected cells migrate actively likely promoting cell-to-cell spread through the formation 
of virological synapses and resulting in high viremia (Murooka et al., 2012). These 
discrepancies may reflect   
   Outlook 
 
128 
 
6 OUTLOOK 
In this work, some of the functions exerted by the accessory proteins of HIV-1, Nef and 
Vpu, have been investigated. Our data shows a redundancy of functions among the two 
viral proteins that includes downregulation of TSPANs form the expressing-cell plasma 
membrane, Lck retargeting to intracellular compartments or enhancement of EV vesicle 
release. Despite of providing interesting clues about the molecular determinants 
involved in the first of those functions, TSPANs downregulation, our data could not 
provide definitive information on this regard. None of our mutants led to a clear cut 
effect in this assay and, in the case of Nef, the profiles obtained for the different 
molecules studied were even different to each other suggesting that different 
determinants could be involved in downregulation of individual TSPANs. In order to 
address this question in the future, screening of a larger Nef and Vpu mutant panel 
should be pursued. Even combination of mutations could help shedding some light on 
this. Concerning EV release, the main limitation faced for performing mechanistic 
studies was the small amounts of vesicles obtained from T cell cultures. Increasing 
culture size provided only small help improving the detection of EV markers. 
Alternatively, other cells different than our T cell lines were tested. Primary monocyte-
derived macrophages did not release substantial amounts of EV upon transduction for 
expression of Nef.GFP or Vpu.GFP. No better results were obtained with HUH7 cells 
and the same delivery method. Other cell types/lines may be tested in the future in order 
to establish a suitable experimental set up that allows mechanistic studies.  
The data shown in the second part of this thesis defines Nef as the main negative 
regulator of T cell polarization upon HIV-1 infection. A new Nef determinant 
implicated in the formation of the NAKC has been identified as necessary for T cell 
polarity disruption, besides the already defined motif specifically interfering with F-
actin dynamics. We hypothesize that the polarity defect correlates to the Nef-mediate 
block on TEM since the central step of this intricate process, diapedesis, implies a 
strong polarization of the T cells to squeeze it cellular body and nucleus through the 
endothelium. Here, the experimental conditions for the TEM experiment have been 
established. Conducting this experiment will prove whether the hypothesis formulated 
above is correct and will provide valuable information about the mechanism by which 
Nef specifically interferes with TEM, i.e. diapedesis. In this line, it has been previously 
postulated that the Nef-mediated block in diapedesis may rely on the downregulation of 
key TEM molecules such as CCR7 and CD62L by the viral protein (Stolp et al., 2012). 
Since a new determinant involved in polarity disruption has been identified and with a 
potential relevance for diapedesis inhibition, it would be interesting to evaluate the 
downregulation capacity of these molecules. Investigating the importance of the 12-39 
stretch of Nef in the inhibition of F-actin sheet like protrusions would be of high interest 
as well since this has been shown to be required not only to achieve successful TEM but 
also for efficient migration in highly constrained environments, e.g. high density 
collagen. It would be of significance to address the LFA-1 downregulation behavior for 
the Δ12-39 mutant due to the implication of this molecule not only on the acquisition of 
   Outlook 
 
129 
 
polarity through fibronectin crosslinking but also in adhesion to the endothelium. A 
more long-term goal would be to explore the role of well-known polarity establishing 
factors like Par3 or Scribble described to be essential for other cell systems, i.e. neurons 
and epithelial cells, in the context Nef expression and HIV-1 infection of T cells.  
One last point would somewhat combine learnt lessons from the two parts of this 
dissertation. As mentioned above, by interfering with T cell migration HIV-1 may favor 
immune recognition escape of infected cells. However, the still functional, non infected 
surveillant CD4+ T cells are able to migrate and encounter them. By releasing 
extracellular vesicles loaded with viral signal in form of Nef and Vpu, it could be 
possible that infected cells affected the migration of those uninfected CD4+ T cells that 
escape apoptosis induction that has been described for Nef-expressing cell-derived EVs. 
This could be tested experimentally by exposing uninfected T cells to Nef- and Vpu-
loaded EVs previous to migration assay.  
Interference with migration is increasingly recognized as essential for HIV-1 
pathogenesis. A profound understanding of the mechanism that governs it will help 
developing new therapeutic targets and eventually shorten the distance towards a cure.     
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ABBREVIATIONS 
Abbreviation Decscription 
2D two dimensions 
3D three dimensions 
ADCC antibody-dependent cellular cytotoxicity 
ADP adenosinediphosphate 
AICD activation-induced cell death 
AIDS acquired immunodeficiency virus 
ALIX ALG-2-interacting protein X 
ALV avian leukosis virus 
AMP adenosinemonophosphate 
AP adaptor protein complex 
APC allophycocyanin 
APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 
ART antiretroviral therapy 
Arp 2/3 actin related proteins 2/3 
ATP adenosinetriphosphate 
bNAbs broadly neutralizing antibodies 
BSA bovine serum albumin 
BST bone marrow stromal antigen 
CA capsid 
cART combination antirretroviral therapy 
CCL chemokine (C-C motif) ligand 
CD cluster of differentiation 
CDC Center for Disease Control 
Cdc42 Cell division control protein 42 
CD4 T cell T cell positive for CD4 
CD8 T cell T cell positive for CD8 
cGAS cyclic GMP-AMP synthase  
cm2 square centimeter 
CMAC 7-amino-4-chloromethylcoumarin  
C-t, C-terminal Carboxy-terminal end 
DAG diacylglycerole 
CTL cytotoxic CD8 positive T lymphocyte 
DC-SIGN dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin 
DMEM Dulbecco's Modified Eagle Medium 
DMSO dimethylsulfoxide 
DN dominant negative 
DNA desoxiribinucleic acid  
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dNTP deoxynucleoside triphosphate 
EBV Epstein-Barr virus 
ECL enhanced chemiluminescence 
ECM extracellular matrix 
EGFR endothelial growth factor receptor 
ELISA enzyme linked immunosorbent assay 
Env envelope protein 
ER endoplasmic reticulum 
ESCRT endosomal sorting complexes required for transport 
EV extracellular vesicle 
EXOC exocyst 
FACS fluorescence-activated cell sorter 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FIV feline immunodeficiency virus  
FLV feline leukaemia virus 
FN fibronectin 
FRET Förster resonance energy transfer 
G guanine 
Gag group-specific antigen 
GAP GTPase activating proteins  
GDP guanosinediphosphate 
GFP green fluorescent protein 
GEF guanine nucleotide exchange factor 
GMP guanosinemonophosphate 
gp glycoprotein 
GPCR G-Protein coupled receptor 
GTP guanosinetriphosphate 
h hour 
HAART high activity antiretroviral therapy  
HCMV human cytomegalovirus 
HDAC histone deacetylase 
HFV human foamy virus 
HHV human herpes virus 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HTLV human T-cell lymphotrophic virus 
HUVEC human umbilical vein endothelial cell 
ICAM imtercellular adhesion molecule 
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IL interleukin 
IFN interferon 
IN  integrase 
IRES internal ribosomal entry site 
IS Immunological synapse 
ISG interferon stimulated genes 
kb kilobases 
kbp kilobasepairs 
kDa kiloDalton 
Lamp Lysosome-associated membrane glycoprotein 
LAT linker for the activation of T cells 
LB lysogeny broth 
Lck lymphocyte-specific protein tyrosine kinase 
LEDGF lens epithelium-derived growth factor 
LFA lymphocyte function-associated antigen 
LTNP long-term-non-progressor 
LTR  long terminal repeat 
MA matrix 
MAPK mitogen-activated protein kinase 
MC microclusters 
MFI mean fluorescence intensity  
MHC major histocompatibility complex 
ml  mililiter 
mM millimolar 
MLV murine leukaemia virus 
MMLV moloney murine leukaemia virus  
MMTV mouse mammary tumor virus 
MMP matrix metalloprotein 
MPMV Mason-Pfizer monkey virus  
mRNA messenger RNA 
NAKC Nef-associated kinase complex 
NC nucleocapsid 
Nef negative factor  
NF-AT nuclear factor of activated T cells 
NF-κB nuclear factor κB 
NGFR nerve growth factor receptor 
NK natural killer cell 
nm  nanometer 
NNRTI non-nucleoside reverse transcriptase inhibitor 
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nPKC novel protein kinase C 
NRTI nucleoside reverse transcriptase inhibitor 
N-t, N-terminal Amino-terminal end 
OD optical density 
ORF open reading frame 
PACS phosphofurin acidic cluster sorting protein 
PAGE polyacrylamide gel electrophoresis 
PAK p21 activated kinase 
PAMP pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cell 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PDGFR platelet derived growth factor receptor 
PECAM platelet/endothelial adhesion molecule 
PE phycoerythrin 
PFA paraformaldehyde 
PI3K phosphatidylinositol 3-kinase 
PIC pre-integration complex 
PIP2 phosphatidylinositol-bisphosphate 
PIP3 phosphatidylinositol-trisphosphate 
PHA phytoemagglutin 
PKC protein kinase C 
PM plasma membrane 
Pol polymerase 
PR protease 
PRR pattern-recognition receptor 
P-TEFb positive transcription elongation factor 
PVR poliovirus receptor 
RDV rous sarcoma virus 
RE recycling endosomes 
Rev regulator of expression of virion proteins 
RFP red fluorescent protein 
RNA ribonucleic acid 
ROCK Rho kinase  
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute Medium 
RRE Rev responsive element 
RT reverse transcriptase 
RTC reverse transcription complex 
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SAMHD1 SAM domain and HD domain-containing protein 1 
SD standard deviation 
SDF-1α stromal cell-derived factor 1α 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SERINC serine incorporator 
SFV simian foamy virus 
SG-PERT sybr green one step PCR-enhanced reverse transcriptase assays 
SH src homology (domain) 
SHIV simian-human immunodeficiency virus 
shRNA short hairpin RNA 
siRNA small interfering RNA 
SIV simian immunodeficiency virus 
S1P sphingosine-1-phosphate 
ß-TrCP beta-transducin repeat-continuing protein 
SU surface component of envelope 
t time 
TAR transactivation responsive region 
Tat trans-activator of transcription 
TCR T cell receptor 
TEER trans-endothelial electrical resistance 
TEM transendothelial migration  
TGN trans-Golgi network 
TJ tight junctions  
TLR toll-like-receptor 
TM transmembrane component of envelope 
TM transmembrane domain (of a protein) 
TNF-α tumor necrosis factor-α 
TRIM5α Tripartite motif-containing protein alpha 
TRITC Tetramethylrhodamineisothiocyanate 
TSPAN tetraspanin 
VCAM vascular cell adhesion molecule 
VEGF vascular endothelial growth factor  
Vif viral infectivity factor 
Vpu Viral protein U  
VSVG vesicular stomatitis virus glycoprotein protein 
WASP Wiskott-Aldrich syndrome protein 
wt wild type 
WDSV Walleye dermal sarcoma virus  
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WHO  World Health Organization 
YFP yellow fluorescent protein 
ZAP-70 Zeta-chain-associated protein kinase 70 
μg microgram 
μl microliter 
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